

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-K

- Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2025 or  
 Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission file number 1-8002

**THERMO FISHER SCIENTIFIC INC.**

(Exact name of Registrant as specified in its charter)

Delaware  
(State of incorporation)

04-2209186  
(I.R.S. Employer Identification No.)

168 Third Avenue  
Waltham, Massachusetts 02451  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (781) 622-1000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$1.00 par value	TMO	New York Stock Exchange
1.450% Notes due 2027	TMO 27	New York Stock Exchange
1.750% Notes due 2027	TMO 27B	New York Stock Exchange
Floating Rate Notes due 2027	TMO 27D	New York Stock Exchange
0.500% Notes due 2028	TMO 28A	New York Stock Exchange
1.375% Notes due 2028	TMO 28	New York Stock Exchange
1.950% Notes due 2029	TMO 29	New York Stock Exchange
0.875% Notes due 2031	TMO 31	New York Stock Exchange
2.375% Notes due 2032	TMO 32	New York Stock Exchange
3.650% Notes due 2034	TMO 34	New York Stock Exchange
3.628% Notes due 2035	TMO 35A	New York Stock Exchange
2.875% Notes due 2037	TMO 37	New York Stock Exchange
1.500% Notes due 2039	TMO 39	New York Stock Exchange
1.875% Notes due 2049	TMO 49	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  No

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months. Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of June 27, 2025, the aggregate market value of the voting stock held by nonaffiliates of the Registrant was approximately \$154,038,987,000 (based on the last reported sale of common stock on the New York Stock Exchange Composite Tape reporting system on June 27, 2025).

As of January 31, 2026, the Registrant had 371,484,244 shares of Common Stock outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

Sections of Thermo Fisher's definitive Proxy Statement for the 2026 Annual Meeting of Shareholders (the "Proxy Statement") are incorporated by reference into Part III of this report.

**THERMO FISHER SCIENTIFIC INC.**  
**ANNUAL REPORT ON FORM 10-K**  
**FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025**  
**TABLE OF CONTENTS**

	<u>Page</u>
<b>PART I</b>	
<a href="#"><u>Item 1. Business</u></a>	<a href="#"><u>3</u></a>
<a href="#"><u>Item 1A. Risk Factors</u></a>	<a href="#"><u>9</u></a>
<a href="#"><u>Item 1B. Unresolved Staff Comments</u></a>	<a href="#"><u>18</u></a>
<a href="#"><u>Item 1C. Cybersecurity</u></a>	<a href="#"><u>18</u></a>
<a href="#"><u>Item 2. Properties</u></a>	<a href="#"><u>19</u></a>
<a href="#"><u>Item 3. Legal Proceedings</u></a>	<a href="#"><u>19</u></a>
<a href="#"><u>Item 4. Mine Safety Disclosures</u></a>	<a href="#"><u>19</u></a>
<b>PART II</b>	
<a href="#"><u>Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u></a>	<a href="#"><u>19</u></a>
<a href="#"><u>Item 6. Reserved</u></a>	<a href="#"><u>19</u></a>
<a href="#"><u>Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u></a>	<a href="#"><u>19</u></a>
<a href="#"><u>Item 7A. Quantitative and Qualitative Disclosures About Market Risk</u></a>	<a href="#"><u>28</u></a>
<a href="#"><u>Item 8. Financial Statements and Supplementary Data</u></a>	<a href="#"><u>29</u></a>
<a href="#"><u>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u></a>	<a href="#"><u>76</u></a>
<a href="#"><u>Item 9A. Controls and Procedures</u></a>	<a href="#"><u>76</u></a>
<a href="#"><u>Item 9B. Other Information</u></a>	<a href="#"><u>76</u></a>
<a href="#"><u>Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</u></a>	<a href="#"><u>76</u></a>
<b>PART III</b>	
<a href="#"><u>Item 10. Directors, Executive Officers and Corporate Governance</u></a>	<a href="#"><u>77</u></a>
<a href="#"><u>Item 11. Executive Compensation</u></a>	<a href="#"><u>77</u></a>
<a href="#"><u>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u></a>	<a href="#"><u>77</u></a>
<a href="#"><u>Item 13. Certain Relationships and Related Transactions, and Director Independence</u></a>	<a href="#"><u>77</u></a>
<a href="#"><u>Item 14. Principal Accountant Fees and Services</u></a>	<a href="#"><u>77</u></a>
<b>PART IV</b>	
<a href="#"><u>Item 15. Exhibits and Financial Statement Schedules</u></a>	<a href="#"><u>77</u></a>
<a href="#"><u>Item 16. Form 10-K Summary</u></a>	<a href="#"><u>81</u></a>

PART I

**Forward-looking Statements**

This Annual Report on Form 10-K (this Annual Report) and our 2025 Annual Report to Shareholders contain “forward-looking statements”, within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, and are often identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” or similar expressions or words with similar meanings. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements.

Forward-looking statements in this Annual Report and our 2025 Annual Report to Shareholders include, among others, statements regarding:

- **financial expectations**, including projections of revenues, expenses, margins, earnings, cash flows, liquidity, capital allocation plans, and tax matters;
- **operational matters**, including business strategies, productivity initiatives, restructuring activities, cost-reduction programs, and new product or service developments;
- **market and competitive conditions**, including customer demand trends, industry dynamics, pricing, and competitive positioning;
- **strategic actions**, including planned acquisitions, divestitures, investments, and partnerships;
- **legal, regulatory, macroeconomic, geopolitical, public health, supply chain, technology, and cybersecurity developments** and their potential impacts on the company; and
- the **timing and outcomes** of any of the foregoing.

Each forward-looking statement contained in this Annual Report and our 2025 Annual Report to Shareholders is inherently uncertain and involves significant risks, assumptions, and factors that could cause actual results to differ materially from those expressed or implied. Important risks and uncertainties that could cause such differences are detailed under the heading, “[Risk Factors](#)” in Part I, Item 1A.

Forward-looking statements in this Annual Report and our 2025 Annual Report to Shareholders speak only as of the dates on which they are made. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, in the event of new information, future developments, or otherwise, except as required by law.

**Item 1. Business**

**Description of Business**

Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

We continuously increase our depth of capabilities across our broad portfolio of innovative products and services and leverage our extensive global channels to address our customers’ needs. We do this through organic investments in research and development, capacity and capabilities and through acquisitions. Our goal is to enable our customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work.

**Business Segments and Products**

We report our business in four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

***Life Sciences Solutions Segment***

Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Life Sciences Solutions includes three primary businesses: biosciences, genetic sciences, and bioproduction.

## THERMO FISHER SCIENTIFIC INC.

Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in areas such as molecular biology and protein biology, discover new drugs and vaccines, and enable the diagnosis of disease. Our genetic sciences business combines a wide variety of instruments and related reagents used to provide high-value genomic and proteomic solutions to assist customer decisions in the research, clinical, healthcare and applied markets. Our bioproduction business provides solutions for both the production of biologics and industrial manufacturing, and offers a comprehensive portfolio of premium solutions and services focused on upstream cell culture, downstream purification, analytics for detection, quantitation, filtration and separation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.

### ***Analytical Instruments Segment***

Through our Analytical Instruments segment, we provide a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. This segment includes three primary businesses: chromatography and mass spectrometry, chemical analysis, and electron microscopy.

Our chromatography and mass spectrometry business develops and provides analytical instrumentation for organic and inorganic sample analysis across both applied technologies and scientific research. Our chemical analysis products fall into three main categories: production, process and analytics; field and safety instruments; and environmental and process instruments. Our electron microscopy business serves customers in the life sciences, materials sciences, and semiconductor markets providing leading research tools; and also, in the semiconductor market provides integrated workflows that power research and development and production solutions.

### ***Specialty Diagnostics Segment***

Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. This segment has five primary businesses: clinical diagnostics, immunodiagnosics, microbiology, transplant diagnostics and our healthcare market channel.

Our clinical diagnostics products include a broad offering of liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments. Such products are used for, among other things, drugs-of-abuse testing, therapeutic drug monitoring, thyroid hormone testing, sepsis screening, serum toxicity, first trimester screening, tumor markers testing, and the diagnosis and monitoring of multiple myeloma. Our immunodiagnosics offerings include developing, manufacturing and marketing complete blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. Our microbiology offerings include dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products and associated products for the microbiology laboratory. Our transplant diagnostics products include human leukocyte antigen typing and testing for the organ transplant market. Our healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for hospitals, clinical laboratories, reference laboratories, physicians' offices and other clinical testing facilities.

### ***Laboratory Products and Biopharma Services Segment***

Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. We serve the pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory market through four key businesses: laboratory products, research and safety market channel, pharma services and clinical research.

Our laboratory products include lab consumables, equipment and chemicals that are used for life science research and drug discovery and development to advance the prevention and cure of diseases and enhance quality of life. Our research and safety market channel offers a mix of products that are manufactured by Thermo Fisher, by third parties for us on a private-label basis, and by third parties under their brands but offered for sale through us. Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals. Our clinical research business offers comprehensive, integrated clinical development and analytical services including all phases of development (i.e., Phases I-IV), peri- and post-approval and site and patient access services.

## **Sales and Marketing**

We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. Our global team delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

We have approximately 14,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-users. We also provide customers with product standardization and other supply-chain-management services to reduce procurement costs.

## **New Products and Research and Development**

Our business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will continue to make significant expenditures for research and development (R&D) as we seek to provide a continuing flow of innovative products to maintain and improve our competitive position. Our R&D efforts focus on developing new technologies, enhancing the performance and usability of existing offerings, and expanding the applications for which our products are used. These activities include internal development programs, initiatives leveraging licensed or acquired technologies, and collaborations with leading research institutions around the world. Our R&D programs are aligned with the needs of each major business and are critical to maintaining our competitive position and supporting our long-term growth strategy.

## **Resources**

### *Raw Materials*

Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.

Raw material and fuel prices are subject to fluctuations due to market conditions. We employ many strategies, including the use of alternative materials, to mitigate the effect of these fluctuations on our results.

### *Patents, Licenses and Trademarks*

Patents are important in many aspects of our business. No particular patent, or related group of patents, is so important, however, that its loss would significantly affect our operations as a whole. Where appropriate, we seek patent protection for inventions and developments made by our personnel that are incorporated into our products or otherwise fall within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always accrue exclusively to the company and may be limited by agreements or contracts.

We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with products. We also enter into license agreements with others to grant and/or receive rights to intellectual property. We own or license copyrights in or to copyrightable subject matter, including graphic images and software, used or referenced herein.

All trademarks, trade names, product names, slogans and logos of Thermo Fisher contained herein are trademarks or registered trademarks of Thermo Fisher or its subsidiaries, as applicable, in the United States and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report without the <sup>TM</sup> and © symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our rights to our trademarks. To the extent other trademarks appear in this Annual Report, they are the property of their respective owners.

## **Seasonal Influences**

Revenues in the fourth quarter are historically stronger than in other quarters due to the capital spending patterns of industrial, pharmaceutical and government customers. Sales of seasonal products, such as allergy and flu tests and related diagnostic products, vary quarter to quarter and year to year.

## **Competition**

The company encounters aggressive and able competition in virtually all of the markets we serve. Because of the diversity of our products and services, we face many different types of competitors and competition. Our competitors include a broad range of manufacturers, third-party distributors and service providers. Competitive climates in many of the markets we serve are characterized by changing technology and customer demands that require continuing research and development. Our success primarily depends on the following factors:

## THERMO FISHER SCIENTIFIC INC.

- technical performance and advances in technology (including artificial intelligence) that result in new products and services, and improved price/performance ratios;
- product and service differentiation, availability and reliability;
- the depth of our capabilities;
- our reputation among customers as a quality provider of products and services;
- customer service and support;
- active research and application-development programs; and
- relative prices of our products and services.

### **Government Regulation**

#### *Environmental Regulations*

We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act (CERCLA). We are also subject to regulation by the Occupational Safety and Health Administration (OSHA) concerning employee safety and health matters. The United States Environmental Protection Agency (USEPA), OSHA, and other federal agencies have the authority to promulgate regulations that have an effect on our operations.

In addition to these federal laws and regulations, various states have been delegated certain authority under the aforementioned federal statutes and have authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and regulations, some of which are similar to federal requirements.

A number of our operations involve the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies engaged in similar businesses.

Our expenses for environmental requirements are incurred generally for ongoing compliance and historical remediation matters. Based on current information, we believe that these compliance costs are not material. For historical remediation obligations, our expenditures relate primarily to the cost of permitting, installing, and operating and maintaining groundwater-treatment systems and other remedial measures.

Our Fair Lawn and Somerville, New Jersey facilities entered into administrative consent orders with the New Jersey Department of Environmental Protection in 1984 to maintain groundwater-remediation activities at these sites, and are currently under the State's Licensed Site Remediation Professional Program. As the owner of the Fair Lawn facility, we are listed as a potentially responsible party for remediation within an area called the Fair Lawn Wellfields Superfund Site, and, in 2008, the company and certain other parties entered into a consent order with the USEPA to complete a Remedial Investigation/Feasibility Study. In 2018, the USEPA issued a Record of Decision, setting forth the scope of required remediation work at the site, which includes upgrading a water treatment plant to address constituents such as chlorinated organic compounds, 1,4-dioxane, and perfluorooctanoic acid/perfluorooctane sulfonate (PFOA/PFOS). In 2020, the court approved a consent decree that requires the company and another responsible party to finance and perform the required remediation work with USEPA oversight. In 2023, the design of a groundwater treatment plant was fully approved by USEPA. Construction of the plant was completed in 2025 and following a 6-month testing and verification period, the Borough of Fair Lawn took ownership and operation and maintenance (O&M) of the plant in January 2026. Along with the other responsible party, the company will continue to finance the O&M and perform groundwater monitoring under USEPA oversight.

In 2011, our Life Technologies subsidiary entered into a consent decree with the USEPA and other responsible parties to implement a groundwater remedy at the former Davis Landfill Superfund site in Smithfield, Rhode Island. After years of additional study, in September, 2020, USEPA revised its cleanup plan by selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site conditions. Depending on the results of these treatment and monitoring activities over the next several years, USEPA anticipates selecting a final groundwater remedy for the site. In November 2021, the 2011 consent decree was amended to reflect the parties' obligations to implement USEPA's interim remedy, for which pre-design work was completed and approved by the agencies in 2025, and the remedial action is expected to commence in 2026.

We record accruals for environmental liabilities based on current interpretations of environmental laws and regulations when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. We calculate estimates based upon several factors, including reports prepared by environmental specialists and management's knowledge and experience with these environmental matters. We include in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. Accrued liabilities for environmental matters totaled \$86 million at December 31, 2025.

## THERMO FISHER SCIENTIFIC INC.

These environmental liabilities do not include third-party recoveries to which we may be entitled. We believe that our accrual is adequate for the environmental liabilities we currently expect to incur. As a result, we believe that our ultimate liability with respect to environmental matters will not have a material adverse effect on our financial position, results of operations or cash flows. However, we may be subject to remedial or compliance costs due to future events, such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes in the conduct of our operations, and the effect of changes in accounting rules, which could have a material adverse effect on our financial position, results of operations or cash flows. For a discussion of the environmental laws and regulations that the company's operations, products and services are subject to and other environmental contingencies, refer to Note 5 to our Consolidated Financial Statements.

### *Other Laws and Regulations*

Our operations, and some of the products and services we offer, are subject to a number of complex and stringent laws and regulations governing the development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and other similar products, including the operating and security standards of the Food and Drug Administration, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco, Firearms and Explosives, and various state boards of pharmacy as well as comparable state and foreign agencies. As Thermo Fisher's businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury. In addition, our logistics activities must comply with the rules and regulations of the Department of Transportation, the Federal Aviation Administration and similar foreign agencies. While we believe we are in compliance in all material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to provide competitive distribution services and thereby have an adverse effect on our financial condition. To date, no such laws or regulations have had a material impact on our operations.

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products and services to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could also result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

We are subject to a broad and evolving set of global requirements related to data privacy, cybersecurity and the responsible use of emerging technologies such as generative artificial intelligence (AI). These include comprehensive frameworks such as the EU's General Data Protection Regulation (GDPR), the EU's AI Act, U.S. federal and state privacy and security laws (including the Health Insurance Portability and Accountability Act of 1996 (HIPAA) for certain operations), and data-localization or cross-border transfer restrictions in various international markets. Governments in the EU, U.S. and other jurisdictions are also advancing new regulations that govern transparency, risk management and data practices associated with AI systems. As these regulatory regimes continue to develop, we maintain policies and controls designed to support compliance and protect the data entrusted to us.

For a discussion of risks related to changes in governmental regulations, refer to "[Risk Factors](#)" in Part I, Item 1A.

### **Human Capital**

The success of Thermo Fisher is fueled by colleagues who are highly engaged and feel empowered to achieve their goals. Everything we do starts with our Mission - to enable our customers to make the world healthier, cleaner and safer. Our colleagues understand the role they play in fulfilling that Mission and that inspires them to bring their best to work each day. Our Mission is not only a differentiator for us externally, but a motivator for us internally.

Our culture is a competitive advantage and is rooted in our 4i Values of Integrity, Intensity, Innovation and Involvement. Our values are woven into our ways of working, embedded in every stage of our colleague lifecycle - from recruiting to onboarding, training, development and longer-term career planning. Within this framework, we strive to create a safe, fair and positive working environment for our colleagues around the world. We want our teams to feel they have a stake in our success, a voice in our direction and to be empowered to make a difference for the key stakeholders we serve.

We also prioritize engagement, empowerment and continuous improvement to enable colleagues to contribute, collaborate and innovate. To advance this goal, we conduct an annual Employee Involvement Survey to solicit direct feedback from our colleagues on what we're doing well and where we need to improve. We then compile the feedback to measure our progress using three key indices: Leadership, Involvement and Inclusion. Our continued focus on enhancing our culture helps position our company to be an even better place to work.

## THERMO FISHER SCIENTIFIC INC.

We are committed to maintaining the strongest team in our industry, focusing on developing and retaining our colleagues, while leveraging our Mission and leadership brand to attract new colleagues to our company. As of December 31, 2025, we employed approximately 125,000 colleagues globally, with an approximate regional distribution as follows: 59,000 based in the Americas, 22,000 in the Asia-Pacific region, and 44,000 in Europe, the Middle East and Africa (EMEA).

In today's environment, we know talent is a key differentiator, and that building the strongest team in the industry is critical to our future. Our overarching goal from a talent perspective is to create opportunities for our colleagues to achieve their full potential and career aspirations here at Thermo Fisher. We encourage and support colleagues to enhance their skills, so they are in the best position to deliver on their goals and achieve their career objectives. From our colleague referral program, summer internships, university relations, to our Graduate Leadership Development Program, we continue to build strong internal and external talent channels.

Once on board, talent development at Thermo Fisher is a key organizational capability. We continue to make significant investments to support our colleagues along every step of their career journey. Our talent development framework incorporates a multi-faceted approach, including formal and self-paced training, networking opportunities, on-the-job stretch learning, coaching, mentoring and manager training utilizing contemporary technology solutions to support the broad needs of our workforce.

We provide multiple programs at all career levels, from online learning for all colleagues through Thermo Fisher University, to focused trainings for managers at various experience levels, to our Global Leadership Program for executives. We also support our colleagues' career advancement through our tuition reimbursement program.

In a company our size, we can also actively manage our talent through rotational opportunities across our businesses, functions and geographies that help our colleagues gain new experiences, share knowledge and broaden their skills. Our executives and leaders participate in frequent talent discussions as well as formal reviews, leveraging workforce data and predictive analytics to better anticipate the talent requirements of our business based on our growth opportunities and market demand.

Thermo Fisher is dedicated to talent development to meet our evolving business needs and to provide our colleagues with opportunities for long and fulfilling careers.

Further, our total rewards package is regularly evaluated and measured against established benchmarks to ensure its effectiveness in recruiting and retention, and to continue to position Thermo Fisher as an employer of choice. We deliver comprehensive rewards, including competitive base pay, and also provide a variety of incentive and equity programs that, by design, directly link the impact of colleague contributions to the company's overall success.

Our health and wellness programs provide competitive, flexible benefits that our global colleagues and their families can count on. For example, for U.S. colleagues, we offer a choice of comprehensive national medical, dental and vision plans; a wellness program, including valuable health incentive opportunities and tax-advantaged savings and spending accounts; as well as commuter support, employee assistance programs, optional group legal coverage, and company-paid disability, accident and life insurance. We also offer a company-paid proprietary program for cancer care called the Impact Program, which gives our colleagues and their families access to personalized support and direct lines of communication to experts in cancer genetics and genomics. Similar benefits are available in all countries around the world where we operate.

We also invest in our colleagues' financial health, helping them to grow and protect their savings, plan for the future and share in the success of the company they are helping to build.

### **Available Information**

The company files or furnishes all required reports with the Securities and Exchange Commission (SEC). The company is an electronic filer, and the SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of the SEC electronic filing website is <http://www.sec.gov>. The company also makes available, free of charge on its website, its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The website address for the company is <http://www.thermofisher.com> and SEC filings can be found in the "Investors" section of our website under the heading "SEC Filings." The company is providing its website address solely for the information of investors. The company does not intend the address to be an active link or to otherwise incorporate the contents of the website, including any reports that are noted in this Annual Report as being posted on the website, into this Annual Report. Investors and others should note that we may announce material information to our investors using our investor relations website, SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, our business and other issues. It is possible that the information that we post on these channels could be deemed to be material information. We therefore encourage investors to visit these websites from time to time.

## THERMO FISHER SCIENTIFIC INC.

### Information about Our Executive Officers

As of February 26, 2026, our executive officers were:

Name	Age	Present Title (Fiscal Year First Became Executive Officer)	Other Positions Held
Marc N. Casper	57	Chairman, President and Chief Executive Officer (2001)	President and Chief Executive Officer (2009-2020) Chief Operating Officer (2008-2009) Executive Vice President (2006-2009)
Stephen Williamson	59	Senior Vice President and Chief Financial Officer (2015)	Vice President, Financial Operations (2008-2015)
Michel Lagarde	52	Executive Vice President and Chief Operating Officer (2017)	Executive Vice President (2019-2021) Senior Vice President and President, Pharma Services (2017-2019) President and Chief Operating Officer, Patheon N.V. (2016-2017)
Frederick M. Lowery	55	Executive Vice President (2024)	Senior Vice President and President, Customer Channels (2021-2024) Senior Vice President and President, Life Sciences Solutions and Laboratory Products (2017-2021)
Gianluca Pettiti	47	Executive Vice President (2021)	Senior Vice President and President, Specialty Diagnostics (2019-2021) President, Biosciences (2018-2019) President, China (2015-2017)
Michael D. Shafer	57	Executive Vice President (2024)	Senior Vice President and President, Pharma Services (2019-2024) President, Materials and Structural Analysis (2016-2019)
Lisa P. Britt	57	Senior Vice President and Chief Human Resources Officer (2017)	
Thomas B. Shropshire	54	Senior Vice President and General Counsel (2025)	General Counsel and Company Secretary, Diageo plc (2021-May 2025) Partner, Global Head of U.S. Practice, Linklaters LLP (2000-2021)

### Item 1A. Risk Factors

Set forth below are the risks, some of which have occurred and any of which may occur in the future, that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements in [Item 1. Business](#) under the caption “Forward-looking Statements”.

#### *Industry and Economic Risks*

**Our growth would be impacted if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicity.** Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish demand for our products and services, which would adversely affect our financial statements. Certain of our businesses operate in industries that may experience periodic, cyclical downturns.

**Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate.** Our business is affected by general economic conditions, both inside and outside the U.S. Both domestic and international markets experienced significant inflationary pressures in 2025 and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, are unstable, that could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of:

- reducing demand for some of our products and services;
- increasing the rate of order cancellations or delays;
- increasing the risk of excess and obsolete inventories;
- increasing pressure on the prices for our products and services;
- causing supply interruptions, which could disrupt our ability to produce our products; and
- creating longer sales cycles, and greater difficulty in collecting sales proceeds and slower adoption of new technologies.

**Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.** International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (which we refer to as the functional currency). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In 2025, currency translation had a favorable effect of \$0.37 billion on revenues due to the weakening of the U.S. dollar relative to other currencies in which the company sells products and services.

Some emerging market countries may be particularly vulnerable to periods of global and local political, legal, regulatory and financial instability, including issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues, and may have a higher incidence of corruption and fraudulent business practices. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and growth rates in these markets may not be sustainable.

In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the U.S. Accordingly, our prior results have been and our future results could be harmed by a variety of factors, including:

- tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries, on certain U.S. goods (including volatility resulting from the imposition of (and changing policies around) tariffs and related countermeasures);
- interruption to transportation flows for delivery of raw materials or parts to us and finished goods to our customers;
- changes in a specific country's or region's political, economic, social or other conditions;
- changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes and sanctions and other trade barriers;
- the impact of public health emergencies, pandemics, epidemics or other health outbreaks on the global economy;
- uncertainties regarding the collectability of accounts receivable;
- Chinese regulations requiring the use of local suppliers, which compel companies that do business in China to partner with local companies to conduct business and provide incentives to government-backed local customers to buy from local suppliers;
- the imposition of governmental controls;
- diverse data privacy, protection and localization requirements;
- supply interruptions, which could disrupt our ability to produce our products;
- increases in materials, energy, labor or other manufacturing-related costs or higher supply chain logistics costs;
- negative consequences from changes in or interpretation of laws and regulations, including those related to tax and import/export;
- difficulty in staffing and managing widespread operations;
- differing labor regulations;
- differing protection of intellectual property;
- unexpected changes in regulatory requirements; and
- geopolitical uncertainty or turmoil, including terrorism and war.

**Demand for some of our products depends on capital spending policies of our customers and on government funding policies.** Our customers include pharmaceutical and biotechnology companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities such as national procurement initiatives, available resources, cost reimbursement policies, and product and economic cycles, have had and we expect to have a significant effect on the capital spending policies of these entities. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. In October 2025, the federal government entered a shutdown due to a lapse in appropriations, resulting from an inability by Congress to pass a budget or continuing resolution. A similar impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.

**We are subject to risks associated with public health emergencies, pandemics, epidemics, or other health outbreaks.** Our global operations expose us to risks associated with public health emergencies, epidemics, pandemics and other health outbreaks. These events have had an adverse impact on certain of our operations, supply chains and distribution systems in the past, and may again in the future, and we may experience unpredictable reductions in supply and demand for certain of our products and services. National, state and local governments may implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide. Our ability to continue to manufacture products is highly dependent on our ability to maintain the safety and health of our factory employees. The ability of our employees to work may be significantly impacted by future epidemics and pandemics, including their residual effects.

#### ***Business Risks***

**We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products and services by competitors and maintain quality to remain competitive.** Our growth strategy includes significant investment in and expenditures for product and service development. We sell our products and services in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, including the timely, responsible and effective adoption of emerging technologies (such as AI), price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers' requirements than we can, and may achieve cost or quality advantages that we cannot match. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenues and operating results would suffer.

Many of our existing products and services and those under development are technologically innovative and require significant planning, design, development and testing at the technological, safety, quality, product and manufacturing-process levels. Our customers use many of our products and services to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products and services in advance of the commercialization of our customers' products. For example, we are incorporating AI and machine learning technologies into our products, services and internal processes. Failure to keep pace with rapid developments in AI technologies could adversely affect our competitive position and results of operations. If we fail to adequately develop products or predict our customers' needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenues.

**It may be difficult for us to implement our strategies for improving internal growth.** Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:

- strengthening our presence in selected geographic markets;
- allocating research and development funding to products with higher growth prospects;
- developing new applications for our technologies;
- expanding our service offerings;
- continuing key customer initiatives;
- combining sales and marketing operations in appropriate markets to compete more effectively;
- finding new markets for our products and services; and
- continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.

We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.

**Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us.** Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.

**Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business.** Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals, as well as disputes or litigation. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.

Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily trade names) on our balance sheet, which amount to approximately \$49.36 billion and \$1.23 billion, respectively, as of December 31, 2025. In addition, we have definite-lived intangible assets totaling \$14.60 billion as of December 31, 2025. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.

#### ***Operational Risks***

**Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies.** Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties, or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability or increased cost of key raw materials or commodities, such as energy, and external events such as global economic downturns and macroeconomic trends, sanctions and trade restrictions, natural disasters, pandemic health issues, geopolitical developments, war, terrorist actions, cybersecurity incidents including but not limited to ransomware attacks, misuse of AI and machine learning technologies, governmental actions and legislative or regulatory changes. Any of these factors could result in production interruptions, delays, extended lead times and inefficiencies.

**A significant cyber-attack or other disruption in, or breach in security of, our information technology systems could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business.** We rely on information technology systems to process, transmit and store electronic information (including sensitive data such as confidential business information, medical information, financial data and personally identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical business processes and activities (such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making payments, shipping products, providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting business). We use a risk-based approach to implementing security controls, reviewing the security controls of certain key business partners and third-party service providers and conducting due diligence on companies we propose to acquire. Despite our efforts, any particular system we operate or use may be susceptible to compromise of a vulnerability or a privileged account, damage or interruption from natural disasters, power loss, telecommunication failures, data center failure, third party provider failures (including failures at cloud services), hardware and software failures, improper or unauthorized use of AI, human error or sabotage, terrorist attacks, geopolitical events, computer hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems and access our information.

We and our third-party providers experience cyber-attacks and other attempts to gain unauthorized access to our products, services, and systems and data on a regular basis, and we anticipate continuing to be subject to such attempts as cyber-attacks

become increasingly sophisticated and more difficult to predict and protect against, particularly with the advancement of AI. Despite our and our third-party providers' implementation of security measures, our products, services, and systems and data, are vulnerable to cyber-attacks, data breaches, malware, inadvertent error, disruptions, tampering or other theft or misuse, including by employees, contingent workers, malicious actors, or nation-states or their agents. Although most of our systems leverage data backups, our disaster recovery planning is not sufficient for every eventuality. In addition, our customers rely upon our products (i.e., instruments, etc.) within their environments, which may be at risk of compromise. Risks affecting our products may include those associated with remote access solutions, system vulnerabilities, or delay of security updates, which may require customers to take action such as network isolation, password change, or manual update.

Cyber-attacks, disruptions or other incidents described above, or breaches of security in our networks, in our customers' or third-party providers' networks, in third-party products we use, or in cloud-based services provided to us, regardless of whether the breach is attributable to a vulnerability in our products or services, a privileged account compromise, or a failure to maintain the digital security infrastructure or security tools that protect the integrity of our products, services, and systems and data, could materially interrupt our operations or our customer's operations, delay production and shipments, impact quality, result in theft of our and our customers' intellectual property and trade secrets, damage our reputation or key relationships, result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, in each case resulting in an adverse effect on our business and financial results.

**Our success is largely dependent upon our ability to attract and retain a highly qualified workforce, comprised of scientific, technical, clinical, and management talent.** We have in the past, and may in the future, have difficulty in attracting and retaining such talent. Our success in doing so is largely dependent upon various factors, including a highly competitive market, sought-after skills, management changes, competitor recruitment, and maintaining an attractive workplace culture (including where there is high demand for new products, services, and technologies, such as related to AI). Macroeconomic shifts such as increased competition for employees and wage inflation, have previously and could in the future affect our talent retention, turnover rates and operational costs. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the departure of any personnel will not have a material impact on our financial condition and results of operations.

**We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows.** Our primary commodity exposures are for fuel, petroleum-based resins and steel. The costs for these commodities, as well as the costs of transportation, construction and services necessary for the production and distribution of our products, continue to increase and be volatile. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.

**Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.** We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.

**Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend, and could impact customer spending.** We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. An earthquake or other natural disaster (including the effects of climate change such as sea level rise, drought, flooding, wildfires and more intense weather events), could disrupt our operations, including the ability to fulfill supply obligations to our customers, or impair our critical systems. Any of these disruptions or other events outside of our control, such as strikes or other labor unrest, could have an adverse effect on our results of operations. In addition, if any of our facilities, including our manufacturing or warehouse facilities, or the facilities of our suppliers, third-party service providers, or customers, is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, fires, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other events outside of our control, such as trade protectionism, strikes or other labor unrest, our results of operations could be adversely affected. Moreover, these types of events could negatively impact customer spending in the impacted regions or depending upon the severity, globally, which could also adversely impact our operating results.

**Increasing attention to sustainability matters may impact our business, financial results, stock price or reputation.** We face increasing scrutiny from stakeholders related to our sustainability practices and disclosures. Investor advocacy groups, certain institutional investors, lenders, investment funds and other influential investors are also increasingly focused on such practices and related disclosures and in recent years have placed increasing importance on the implications and social cost of their investments. In addition, government organizations are enhancing or advancing legal and regulatory requirements specific to these matters. The heightened stakeholder focus on sustainability issues related to our business requires the continuous monitoring of various and evolving laws, regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet evolving stakeholder expectations may result in noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract customers and an inability to attract and retain top talent. In addition, if legislation or regulations are enacted or promulgated in the U.S. or in any other jurisdiction in which we do business that impose more stringent restrictions and requirements than our current legal or regulatory obligations, we and companies in our supply chain may experience increased compliance burdens and costs to meet the regulatory obligations, which could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations. In addition, our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.

***Legal, Quality and Regulatory Risks***

**New governmental regulations or changes in existing governmental regulations may reduce demand for our products or increase our expenses.** We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations, such as the Inflation Reduction Act of 2022 (IRA), which contains drug price negotiation provisions, or change in the interpretation of existing regulations, could reduce demand for our products or increase our expenses. For example, we manufacture pharmaceuticals and many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration's (the FDA) regulation of the drug discovery and development process could have an adverse effect on the demand for these products, and increased FDA regulation of laboratory-developed tests could delay and add to the cost of commercialization of these products, as well as subject us to additional regulatory controls.

**We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenues associated with these customers.** We have agreements relating to the sale of our products and services to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

**Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer.** Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.

In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenues, reimbursement to customers for lost drug product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.

**A violation of data privacy or data protection laws could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business.** As a global organization, we are subject to data privacy and data protection laws, rules, and customer-imposed controls as a result of producing, collecting, processing, storing and transmitting confidential, personal and/or sensitive data in the course of our business. A significant number of countries where we operate have enacted privacy or data protection laws, rules and regulations, the majority of which have extraterritorial scope, creating significant compliance challenges as we seek to maintain our global reach, with significant penalties for non-compliance, based on total worldwide annual revenue from the preceding financial year. In some cases, there are restrictions on the transfer of personal data outside the home country. More recently, privacy and data protection regulators are paying special attention to emerging issues linked to new digital technologies, such as the use of AI, biometrics, and surveillance technologies, which pose unique challenges to existing privacy and data protection paradigms. For example, in the U.S., individual states regulate data breach and security requirements, and multiple governmental bodies assert authority over aspects of the protection of personal privacy. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the EU GDPR imposes significantly stricter requirements in how we collect and process personal data. Several countries, such as China, have passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Any actual or perceived noncompliance with these laws, rules and regulations, our internal policies and procedures or our contracts governing the processing of personal data could result in significant consequences, including, among other things, business interruption, sanctions and significant pecuniary fines, regulatory inquiries and investigations, adverse publicity, loss of competitive advantage and customer trust, as well as privacy litigation and civil lawsuits with damages, any of which may adversely affect our business, reputation and financial statements. The importance of privacy and data protection laws, rules and regulations for our industry specifically is constantly growing, as personal data is an integral part of doing business in our sectors, and the legal standards are evolving and becoming more complex worldwide.

**We are subject to product and other liability risks for which we may not have adequate insurance coverage.** We may be named as a defendant in product liability or errors and omissions lawsuits, which may allege that products or services we have provided have resulted or could result in an unsafe condition, property damage or injury to end users or financial loss for consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. In addition, patients involved in our clinical services trials conducted by our clinical development services business or taking drugs approved on the basis of those trials may also bring personal injury claims against us. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers' operators and the training of such operators.

Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities subject to insurance policy exclusions where insurance would not respond or in excess of our insurance coverage. Although we carry product liability and errors and omissions insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.

**We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies.** We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the FDA, the U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.

The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims

from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients or personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the handling, transportation and manufacture of substances that could be classified as hazardous, and we are required to comply with various import laws and export control and economic sanctions laws, which may affect our transactions with certain customers. In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt our supply of imported inventory. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.

**Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties.** We have internal controls and compliance systems to protect the company against acts committed by employees, agents or businesses that we acquire that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, money laundering and data privacy, but these controls and systems may not be sufficient to prevent every such wrongful act. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies which we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements. Improper or unauthorized use of AI by our employees or third parties working on our behalf could create additional risks, including exposure of confidential information, errors in output, or the generation of inaccurate, misleading or biased results, which could negatively impact our customers, stakeholders and reputation. In addition, any allegations of issues resulting from the misuse of our products could, even if untrue, adversely affect our reputation and our customers' willingness to purchase products from us. Any such allegations could cause us to lose customers and divert our resources from other tasks, which could materially and adversely affect our business and operating results.

**Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.** We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain, defend and enforce patent protection for our products both in the U.S. and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. The integration of AI, including generative AI, into our products, services or internal operations may expose us to increased risks of intellectual property infringement or misappropriation. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.

We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.

## THERMO FISHER SCIENTIFIC INC.

We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business. If we are unable to protect or preserve the value of our intellectual property rights for any reason, including our inability to successfully defend against counterfeit, knock offs, grey-market, infringing or otherwise unauthorized products, our brand and reputation could be damaged, and our business may be harmed.

Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.

### ***Risks Relating to Financial Profile***

**Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows.** As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes, the results of examinations and audits of our tax filings and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.

In December 2021, the Organization for Economic Cooperation and Development (“OECD”) published a proposal for the establishment of a global minimum tax rate of 15% (the “Pillar Two rule”). As of December 31, 2025, numerous countries where we operate have enacted legislation, or have indicated their intent to adopt legislation, to implement certain aspects of the Pillar Two rules. The OECD and implementing countries are expected to continue to make further revisions to their legislation and release additional guidance. We are closely monitoring developments of the Pillar Two rule and are currently evaluating the potential impacts in each of the countries in which we operate; however, we currently do not expect the Pillar Two rule to have a material impact on our effective tax rate.

**Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings.** As of December 31, 2025, we had approximately \$39.38 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to \$5.00 billion of unsecured multi-currency revolving credit (the Facility). We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.

Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.

Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.

Additionally, the agreements governing our debt require that we maintain a financial ratio, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities and create liens. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter.

Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as the impact of foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.

**Item 1B. Unresolved Staff Comments**

None.

**Item 1C. Cybersecurity**

**Cybersecurity Risk Management and Strategy**

As is the case for most large global companies, we are regularly subject to cyberattacks and other cybersecurity incidents and, therefore, we incorporate cybersecurity into our overall risk management process. Our commitment to cybersecurity emphasizes using a risk-based, “defense in depth” approach to assess, educate, block, identify, respond to and recover from cybersecurity threats. Recognizing that no single technology, process or control can effectively prevent or mitigate all risks, we employ a strategy of technologies, processes and controls, all working independently but as part of a cohesive strategy to manage or reduce risk.

Our cybersecurity program assists in the management of risks associated with the confidentiality, integrity and availability of data and systems within the company environment to effectively support our business objectives and customer expectations. The program provides guidance to business stakeholders on cybersecurity risks as input into their risk management processes that balance cybersecurity risk with other important risks that may include strategic, regulatory, economic and financial considerations.

We seek to routinely refine our cybersecurity approach to adapt to changes in the threat landscape and manage emerging security risks. In order to evaluate risks from cybersecurity threats associated with the company’s use of certain third-party technology providers, we have incorporated a risk-based assessment into the corporate information technology (IT) procurement process designed to assess the security risk of certain third parties providing new technology solutions to our environment.

We believe cybersecurity is the responsibility of every employee, and regularly educate and share best practices with our employees to raise awareness of cybersecurity threats through a security awareness training program, including regular exercises, periodic cyber-event simulations and annual attestation to our Technology Acceptable Use Policy.

We do not reasonably believe there are currently any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the company or its business strategy, results of operations or financial condition. For more information on the risks related to our IT systems, see “A significant disruption in, or breach in security of, our IT systems or violation of data privacy laws could adversely affect our business or customers that use our products” under the heading “Risk Factors” in Part I, Item 1A.

**Cybersecurity Governance and Oversight**

The Board of Directors has delegated the oversight of cybersecurity risks to the Audit Committee. Our cybersecurity program is led by the company’s senior vice president and chief information officer, along with our vice president and chief information security officer (CISO). Management provides an operational update to the Audit Committee each quarter. In addition, the Audit Committee and our full Board of Directors receive an annual overview of the cybersecurity program, cybersecurity threat landscape, investments, and opportunities to enhance the company’s systems and security of products and operations.

The company’s corporate IT security team leads the company-wide cybersecurity strategy and advocates to protect the company systems, its employees and customers against cybersecurity risks. Through annual internal and external audits, we maintain an ISO/IEC 27001:2013 certification for the management of our cybersecurity program consisting of the following areas:

- cybersecurity program management and governance including risk management;
- cybersecurity operations including security operation centers;
- product security;
- security investigations;
- cybersecurity architecture and engineering; and
- security awareness and training.

Our senior vice president and chief information officer, and vice president and CISO, and vice president and chief product security officer have each served in various roles in IT and information security for over 20 years. These individuals’ knowledge and experience along with the culture and talent of the corporate IT security team organization are instrumental in developing and executing our cybersecurity strategies. The CISO meets with senior leadership to review and discuss the cybersecurity program, including emerging cybersecurity risks, threats and industry trends.

Cybersecurity is integrated into the risk management process for the company through various corporate mechanisms, including quarterly business reviews, annual budget planning, and targeted risk-based engagements.

**Item 2. Properties**

The company owns and leases office, engineering, laboratory, production and warehouse space throughout the world.

**Item 3. Legal Proceedings**

There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 5 to our Consolidated Financial Statements – “[Commitments and Contingencies](#)”.

**Item 4. Mine Safety Disclosures**

Not applicable.

**PART II**

**Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**

*Market Price of Common Stock*

Our common stock is traded on the New York Stock Exchange under the symbol TMO.

*Holder of Common Stock*

As of January 31, 2026, the company had 2,044 holders of record of its common stock. This does not include holdings in street or nominee names.

*Issuer Purchases of Equity Securities*

There was no share repurchase activity for the company's fourth quarter of 2025. On November 6, 2025, the Board of Directors authorized the repurchase of up to \$5.00 billion the company's common stock. Early in the first quarter of 2026, the company repurchased \$3.00 billion (4.9 million shares). At February 26, 2026, \$2.00 billion was available for future repurchases of the company's common stock under this authorization.

**Item 6. Reserved**

Not applicable.

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations**

Reference is made throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations to Notes to the [Consolidated Financial Statements](#), which begin on page 29 of this report. Management's Discussion and Analysis of Financial Condition and Results of Operations for 2023 is included in Item 7 of the company's 2024 [Annual Report on Form 10-K](#) filed with the Securities and Exchange Commission.

The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “[Non-GAAP Measures](#)” later in this “Management's Discussion and Analysis of Financial Condition and Results of Operations.”

Amounts and percentages reported within this Annual Report on Form 10-K are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

**Overview**

Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company's operations fall into four segments (Note 11): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

## THERMO FISHER SCIENTIFIC INC.

### Consolidated Results

(Dollars in millions except per share amounts)

	2025	2024	Change
Revenues	\$ 44,556	\$ 42,879	4 %
GAAP operating income	\$ 7,746	\$ 7,337	6 %
GAAP operating income margin	17.4 %	17.1 %	0.3 pt
Adjusted operating income ( <i>non-GAAP measure</i> )	\$ 10,109	\$ 9,707	4 %
Adjusted operating income margin ( <i>non-GAAP measure</i> )	22.7 %	22.6 %	0.1 pt
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.	\$ 17.74	\$ 16.53	7 %
Adjusted earnings per share ( <i>non-GAAP measure</i> )	\$ 22.87	\$ 21.86	5 %

### Organic Revenue Growth

Revenue growth	4 %
Impact of acquisitions	1 %
Impact of currency translation	1 %
Organic revenue growth ( <i>non-GAAP measure</i> )	2 %

During 2025, revenues grew in the pharma and biotech market due to increased demand from customers, partially offset by reduced demand for COVID-19 vaccine and therapy related products and services. Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S. and macro conditions in China. Revenue to customers in the industrial and applied market grew. Revenues to customers in the diagnostics and healthcare market were flat. During 2025, sales grew in North America, Europe and Asia-Pacific, but declined in China. Contributions to organic revenue during 2025 were led by the Laboratory Products and Biopharma Services and Life Sciences Solutions segments.

The company continues to execute its proven growth strategy which consists of three pillars:

- High-impact innovation;
- Our trusted partner status with customers; and
- Our unparalleled commercial engine.

GAAP operating income margin and adjusted operating income margin increased in 2025 due primarily to very strong productivity improvements, partially offset by unfavorable business mix and strategic investments. GAAP operating income margin in 2025 also benefited from lower amortization expense when compared to 2024; however, this was partially offset by higher transaction-related costs. We estimate that charges for restructuring and related actions incurred for headcount reductions and facility consolidations, which were approximately \$0.3 billion in 2025 and \$0.3 billion in 2024, will realize annual cost savings of approximately \$0.5 billion and \$0.2 billion, respectively, primarily due to reduced employee and facility expenses.

The company's references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company's references throughout this discussion to productivity improvements generally refer to the impact of its Practical Process Improvement (PPI) Business System to address inflation, drive cost efficiencies and improve profitability. The benefits of PPI include optimized price realization, reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.

### Notable Recent Acquisitions

On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation proteomics solutions. The acquisition enhances the segment's capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy opportunities.

On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment's bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing.

**THERMO FISHER SCIENTIFIC INC.**

**Segment Results**

The company's management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 11. Accordingly, the following segment data are reported on this basis.

(Dollars in millions)	2025	2024
<b>Revenues</b>		
Life Sciences Solutions	\$ 10,374	\$ 9,631
Analytical Instruments	7,554	7,463
Specialty Diagnostics	4,676	4,512
Laboratory Products and Biopharma Services	23,984	23,157
Eliminations	(2,033)	(1,885)
Consolidated revenues	<u>\$ 44,556</u>	<u>\$ 42,879</u>

*Life Sciences Solutions*

(Dollars in millions)	2025	2024	Total Change	Acquisitions/ Divestitures	Currency Translation	Organic (non-GAAP measure)
Revenues	\$ 10,374	\$ 9,631	8 %	3 %	1 %	3 %
Segment income	3,768	3,503	8 %			
Segment income margin	36.3 %	36.4 %	(0.1) pt			

The increase in organic revenues in 2025 was driven by the bioproduction business. On a reported basis, the bioproduction business grew \$548 million, driven by higher demand from pharma and biotech customers, as well as the impact from the 2025 acquisition of the filtration and separation business. Genetic sciences grew \$82 million, driven by the 2024 acquisition of Olink. The decrease in segment income margin resulted primarily from the impact from acquisitions, unfavorable business mix, and strategic investments, partially offset by very strong productivity improvements.

*Analytical Instruments*

(Dollars in millions)	2025	2024	Total Change	Acquisitions/ Divestitures	Currency Translation	Organic (non-GAAP measure)
Revenues	\$ 7,554	\$ 7,463	1 %	0 %	1 %	0 %
Segment income	1,736	1,955	(11) %			
Segment income margin	23.0 %	26.2 %	(3.2) pt			

Organic revenues were flat in 2025 primarily due to growth in the electron microscopy and chromatography and mass spectrometry businesses, largely offset by declines in the chemical analysis business. On a reported basis, the electron microscopy business and chromatography and mass spectrometry business grew \$87 million and \$83 million, respectively, partially offset by a decline of \$78 million in the chemical analysis business. The decrease in segment income margin resulted primarily from the impacts of tariffs and related foreign exchange, strategic investments, and unfavorable business mix, partially offset by strong productivity improvements.

*Specialty Diagnostics*

(Dollars in millions)	2025	2024	Total Change	Acquisitions/ Divestitures	Currency Translation	Organic (non-GAAP measure)
Revenues	\$ 4,676	\$ 4,512	4 %	0 %	1 %	2 %
Segment income	1,256	1,159	8 %			
Segment income margin	26.9 %	25.7 %	1.2 pt			

The increase in organic revenues in 2025 was led by growth in the healthcare market channel and the transplant diagnostics business. On a reported basis, the clinical diagnostic business grew \$52 million, the immunodiagnostics business grew \$48 million, and the transplant diagnostics business grew \$37 million, which were the principal drivers of reported revenue growth in the segment. The increase in segment income margin was due to strong productivity improvements.

**THERMO FISHER SCIENTIFIC INC.**

*Laboratory Products and Biopharma Services*

(Dollars in millions)	2025	2024	Total Change	Acquisitions/ Divestitures	Currency Translation	Organic ( <i>non- GAAP measure</i> )
Revenues	\$ 23,984	\$ 23,157	4 %	0 %	1 %	3 %
Segment income	3,350	3,090	8 %			
Segment income margin	14.0 %	13.3 %	0.7 pt			

The increase in organic revenues in 2025 primarily due to growth in the research and safety market channel and the pharma services business, partially offset by moderation in COVID-19 vaccines and therapies-related activity. On a reported basis, the pharma services business and research and safety market channel grew \$457 million and \$422 million, respectively. The increase in segment income margin was primarily due to exceptionally strong productivity improvements, partially offset by unfavorable business mix and strategic investments.

*Non-operating Items*

(Dollars in millions)	2025	2024
Net interest expense	\$ 426	\$ 312
GAAP other income/(expense)	(12)	12
Adjusted other income/(expense) ( <i>non-GAAP measure</i> )	(19)	(6)
GAAP tax rate	7.5 %	9.3 %
Adjusted tax rate ( <i>non-GAAP measure</i> )	10.4 %	10.5 %
Weighted average diluted shares	378	383

Net interest expense (interest expense less interest income) increased due primarily to lower cash, and cash equivalents and short-term investments balances, as well as lower interest rates on these balances when compared to 2024. See additional discussion under the caption "Liquidity and Capital Resources" below. In 2025 and 2024, the company's net interest expense was reduced by approximately \$283 million and \$264 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements (Note 10).

GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities, and net periodic pension benefit cost/(income), excluding the service cost component. GAAP other income/(expense) in 2025 and 2024 also includes \$14 million and \$20 million, respectively, of net gains/(losses) on investments. GAAP other income/(expense) in 2025 also includes \$8 million of settlement charges for pension plans.

The company's GAAP and adjusted tax rates in 2025 were impacted by a \$269 million deferred tax benefit resulting from the recognition of tax attributes related to domestication transactions, a deferred tax benefit of \$153 million related to capital losses generated as part of intra-entity transactions, a \$158 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income, and a \$93 million tax benefit from tax return reassessments. The company's GAAP rate was also impacted by \$51 million of tax expense related to tax legislation enacted during the third quarter of 2025 (Note 7).

The company's 2024 GAAP and adjusted tax rates were impacted by tax benefits of \$459 million, primarily in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. The company's GAAP tax rate in 2024 was also impacted by \$176 million of expense, net, for a provision associated with a tax audit.

The effective tax rates in both 2025 and 2024 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company's cash payments for income taxes were higher than its income tax expense for financial reporting purposes. See additional discussion under the caption "Liquidity and Capital Resources" below.

The company expects its GAAP effective tax rate in 2026 will be between 7% and 9% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 11.5% in 2026.

The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company's ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company's non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company's income tax provision or net income.

## THERMO FISHER SCIENTIFIC INC.

Equity in earnings/losses of unconsolidated entities was impacted by an \$88 million impairment of an equity method investment in 2024.

Weighted average diluted shares decreased in 2025 compared to 2024 due to share repurchases.

### Liquidity and Capital Resources

The company's proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.

(In millions)	December 31, 2025	December 31, 2024
Cash and cash equivalents	\$ 9,852	\$ 4,009
Short-term investments	253	1,561
Total debt	39,384	31,275

Approximately half of the company's cash balances and cash flows from operations are generated outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S., including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.

The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

As of December 31, 2025, the company's short-term obligations and current maturities of long-term obligations totaled \$3.53 billion. The company has a revolving credit facility with a bank group that provides up to \$5.00 billion of unsecured multi-currency revolving credit (Note 3). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of December 31, 2025, no borrowings were outstanding under the company's revolving credit facility, although available capacity was reduced by immaterial outstanding letters of credit.

(In millions)	2025	2024
Net cash provided by operating activities	\$ 7,818	\$ 8,667
Net cash used in investing activities	(4,047)	(5,841)
Net cash provided by (used in) financing activities	1,801	(6,792)
Free cash flow ( <i>non-GAAP measure</i> )	6,337	7,324

#### Operating Activities

During 2025, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable used cash of \$0.43 billion and changes in contract assets/liabilities used cash of \$0.38 billion. An increase in accounts payable provided cash of \$0.42 billion. Changes in other assets and liabilities used cash of \$1.31 billion primarily due to the timing of payments for income taxes. Cash payments for income taxes were \$1.78 billion during 2025.

During 2024, net income provided substantially all cash from operating activities. Changes in working capital were not significant. Cash payments for income taxes were \$1.83 billion during 2024.

#### Investing Activities

During 2025, acquisitions used cash of \$4.04 billion. The company's investing activities also included \$1.52 billion for the purchase of property, plant and equipment for capacity and capability investments, as well as \$1.18 billion of proceeds from net sales of investments.

During 2024, acquisitions used cash of \$3.13 billion. The company's investing activities also included net purchases of investments of \$1.63 billion, primarily to provide additional interest income, as well as \$1.40 billion for the purchase of property, plant and equipment for capacity and capability investments.

The company expects that for all of 2026, expenditures for property, plant and equipment, net of disposals, will be between \$1.8 billion and \$2.0 billion.

## THERMO FISHER SCIENTIFIC INC.

### *Financing Activities*

During 2025, issuance of debt provided \$7.76 billion of cash. Repayment of debt used cash of \$2.41 billion. The company's financing activities also included the repurchase of \$3.00 billion of the company's common stock (5.8 million shares) and the payment of \$0.64 billion in cash dividends. On November 6, 2025, the Board of Directors authorized the repurchase of up to \$5.00 billion of the company's common stock. Early in the first quarter of 2026, the company repurchased \$3.00 billion (4.9 million shares) of the company's common stock. At February 26, 2026, \$2.00 billion was available for future repurchases of the company's common stock under this authorization.

In the first quarter of 2026, the company issued \$3.80 billion of senior notes (Note 3).

During 2024, issuance of debt provided \$1.20 billion of cash. Repayment of debt used cash of \$3.61 billion. The company's financing activities also included the repurchase of \$4.00 billion of the company's common stock (7.4 million shares) and the payment of \$0.58 billion in cash dividends.

The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the heading "Product Liability, Workers Compensation and Other Personal Injury Matters" in Note 5 could have a material adverse effect on the company's financial position as well as its results of operations and cash flows.

In addition to the obligations on the balance sheet at December 31, 2025, which include, but are not limited to the agreement to acquire Clario Holdings, Inc. (Note 12), pension obligations (Note 14), unrecognized tax benefits (Note 7), debt (Note 3), operating leases (Note 13), and contingent consideration (Note 4), the company also has unconditional purchase obligations in the ordinary course of business that include agreements to purchase goods, services or fixed assets, pay royalties, and fund capital commitments pursuant to investments held by the company (Note 5).

### **Non-GAAP Measures**

In addition to the financial measures prepared in accordance with GAAP, we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company's short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

- Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
- Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.
- Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
- The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

**THERMO FISHER SCIENTIFIC INC.**

- The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations' ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

The non-GAAP financial measures of the company's results of operations and cash flows included in this Form 10-K are not meant to be considered superior to or a substitute for the company's results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the "Consolidated Results" and "Segment Results" sections and below.

(Dollars in millions except per share amounts)	2025		2024	
<b>Reconciliation of adjusted operating income and adjusted operating income margin</b>				
GAAP operating income	\$ 7,746	17.4 %	\$ 7,337	17.1 %
Cost of revenues adjustments (a)	64	0.1 %	47	0.1 %
Selling, general and administrative expenses adjustments (b)	207	0.5 %	(8)	0.0 %
Restructuring and other costs (c)	362	0.8 %	379	0.9 %
Amortization of acquisition-related intangible assets	1,730	3.9 %	1,952	4.6 %
Adjusted operating income ( <i>non-GAAP measure</i> )	<u>\$ 10,109</u>	<u>22.7 %</u>	<u>\$ 9,707</u>	<u>22.6 %</u>
<b>Reconciliation of adjusted other income/(expense)</b>				
GAAP other income/(expense)	\$ (12)		\$ 12	
Adjustments (d)	(6)		(19)	
Adjusted other income/(expense) ( <i>non-GAAP measure</i> )	<u>\$ (19)</u>		<u>\$ (6)</u>	
<b>Reconciliation of adjusted tax rate</b>				
GAAP tax rate	7.5 %		9.3 %	
Adjustments (e)	2.9 %		1.2 %	
Adjusted tax rate ( <i>non-GAAP measure</i> )	<u>10.4 %</u>		<u>10.5 %</u>	
<b>Reconciliation of adjusted earnings per share</b>				
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.	\$ 17.74		\$ 16.53	
Cost of revenues adjustments (a)	0.17		0.12	
Selling, general and administrative expenses adjustments (b)	0.55		(0.02)	
Restructuring and other costs (c)	0.96		0.99	
Amortization of acquisition-related intangible assets	4.58		5.09	
Other income/expense adjustments (d)	(0.02)		(0.05)	
Income taxes adjustments (e)	(1.21)		(0.86)	
Equity in earnings/losses of unconsolidated entities	0.11		0.11	
Noncontrolling interests adjustments (f)	0.00		(0.05)	
Adjusted EPS ( <i>non-GAAP measure</i> )	<u>\$ 22.87</u>		<u>\$ 21.86</u>	
<b>Reconciliation of free cash flow</b>				
GAAP net cash provided by operating activities	\$ 7,818		\$ 8,667	
Purchases of property, plant and equipment	(1,525)		(1,400)	
Proceeds from sale of property, plant and equipment	44		57	
Free cash flow ( <i>non-GAAP measure</i> )	<u>\$ 6,337</u>		<u>\$ 7,324</u>	

- (a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges for the sale of inventory revalued at the date of acquisition. Adjusted results in 2025 exclude \$4 million of transaction-related costs. Adjusted results in 2024 also exclude \$13 million of charges for inventory write-downs associated with large-scale abandonment of product lines.

## THERMO FISHER SCIENTIFIC INC.

- (b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, charges/credits for changes in estimates of contingent acquisition consideration, charges associated with product liability litigation, and accelerated depreciation on fixed assets to be abandoned due to facility consolidations.
- (c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, charges for environmental-related matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2025 also exclude \$51 million of charges for disposition of a consolidated joint venture.
- (d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2025 also exclude \$8 million of settlement charges for pension plans.
- (e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements.
- (f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

### **Critical Accounting Policies and Estimates**

The company's discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:

#### ***Acquisition-related Measurements***

##### Business Combinations

The company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in business combinations. The determinations of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company's acquisitions, require the use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and technology obsolescence rates, among others. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 12 for additional information about our recent business combinations.

##### Goodwill

The company evaluates goodwill for impairment annually and when events occur or circumstances change that would more likely than not reduce the fair value of an asset below its carrying amount. Events or circumstances that might require an interim evaluation include unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by governments and courts, among others. Goodwill totaled \$49.36 billion at December 31, 2025 (Note 2). Estimates of discounted future cash flows require assumptions related to revenue and operating income margin growth rates, discount rates and other factors. The company also considers (i) peer revenues and earnings trading multiples from companies that have operational and financial characteristics that are similar to the respective reporting units and (ii) estimated weighted average costs of capital. Different assumptions from those made in the company's analysis could materially affect projected cash flows and the company's evaluation of goodwill for impairment.

The company performed the quantitative goodwill impairment test for all of its reporting units, except as discussed below. Determinations of fair value based on projections of discounted cash flows, which generally increased from the prior year projections primarily due to lower discount rates, and based on peer revenues and earnings trading multiples, which were generally consistent with the prior year, were sufficient to conclude that no impairments of goodwill existed at the end of the tenth fiscal month of 2025, the date of the company's annual impairment testing. There were no interim impairments of goodwill in 2025. There can be no assurance, however, that adverse events or conditions will not cause the fair values of these

## THERMO FISHER SCIENTIFIC INC.

assets to decline. Should the fair values of the company's reporting units decline because of reduced operating performance, market declines, or other indicators of impairment, or as a result of changes in the discount rates, charges for impairment may be necessary.

With the completion of the filtration and separation business acquisition in September 2025, the company established a new reporting unit that solely consists of the legacy business, the book carrying value of which equaled its fair value as of the acquisition date. During its annual 2025 goodwill impairment assessment, the company performed a qualitative assessment of this reporting unit and determined that no events had occurred and no circumstances had changed that would more-likely-than-not reduce the fair value of the reporting unit below its carrying amount. As a result, the company did not perform the quantitative goodwill impairment test for this reporting unit. Given that the fair value of the reporting unit was not substantially in excess of its carrying value as of the annual 2025 assessment date, relatively small decreases in future cash flows versus anticipated results, decreases in peer trading multiples and/or increases in the weighted average cost of capital could result in impairment of goodwill. The reporting unit consisting of the filtration and separation business had \$2.10 billion of goodwill, and an overall carrying value of \$4.01 billion as of December 31, 2025.

### Definite-lived Intangible Assets

Definite-lived intangible assets totaled \$14.60 billion at December 31, 2025 (Note 2). Certain definite-lived intangible assets have largely independent cash flows. The company reviews these definite-lived intangible assets for impairment individually when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash flows arising from a particular intangible asset could vary from projected cash flows, which could imply different carrying values from those established at the dates of acquisition and which could result in impairment of such asset. Most of the company's definite-lived intangible assets are used in conjunction with other assets, such as property, plant and equipment and operating lease right-of-use assets. In these situations, the company considers the asset groups to be the units of account for impairment testing. The company recorded definite-lived intangible asset impairments of \$0.01 billion in 2023.

### *Income Taxes*

#### Unrecognized Tax Benefits

In the ordinary course of business there is inherent uncertainty in quantifying the company's income tax positions. The company assesses income tax positions and records tax benefits for all years subject to examination based upon management's evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the company has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Should tax return positions that the company expects are sustainable not be sustained upon audit, the company could be required to record an incremental tax provision for such taxes. The company's liability for these unrecognized tax benefits totaled \$0.42 billion at December 31, 2025, compared to \$0.52 billion at December 31, 2024, primarily as a result of audit settlements and reductions of prior year tax positions (Note 7).

The company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the company to interpret the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Changes in tax laws, regulations, agreements and treaties, currency exchange restrictions or the company's level of operations or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balances and hence the company's net income.

#### Valuation Allowances

The company estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which the company has been able to determine that its deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, the company reverses the related valuation allowance. Any such reversals are recorded as a reduction of the company's tax provision. The company's tax valuation allowance totaled \$3.56 billion and \$1.04 billion at December 31, 2025 and December 31, 2024, respectively (Note 7). Should the company's actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.

### Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.

### Item 7A. Quantitative and Qualitative Disclosures About Market Risk

The company is exposed to market risk from changes in interest rates and currency exchange rates, which could affect its future results of operations and financial condition. The company manages its exposure to these risks through its regular operating and financing activities. The company has periodically hedged interest rate risks of fixed-rate instruments with offsetting interest rate swaps. Additionally, the company uses short-term forward and option contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates. Such exposures result from purchases, sales, cash and intercompany loans that are denominated in currencies other than the functional currencies of the respective operations. The currency exchange contracts principally hedge transactions denominated in euro, Canadian dollars, British pounds sterling, Swiss franc, Swedish krona, Singapore dollars, and Hong Kong dollars. Income and losses arising from these derivative contracts are recognized as offsets to losses and income resulting from the underlying exposure being hedged. The company does not enter into speculative derivative agreements.

#### Interest Rates

The company is exposed to changes in interest rates while conducting normal business operations as a result of ongoing investing and financing activities, which affect the company’s debt as well as cash and cash equivalents. As of December 31, 2025, the company’s debt portfolio was comprised primarily of fixed rate borrowings. The fair market value of the company’s fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed interest rate debt will increase as interest rates fall and decrease as interest rates rise. The total estimated fair value of the company’s debt at December 31, 2025 was \$36.61 billion (Note 4). Fair values were determined from available market prices using current interest rates and terms to maturity. If interest rates were to decrease by 100 basis points, the fair value of the company’s debt at December 31, 2025 would increase by approximately \$2.45 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s debt at December 31, 2025 would decrease by approximately \$2.19 billion.

In addition, the fair value of the company’s cross-currency interest rate swap arrangements is subject to interest rate risk. If interest rates were to decrease by 100 basis points, the fair value of the company’s cross-currency interest rate swaps at December 31, 2025 would decrease by approximately \$0.28 billion. If interest rates were to increase by 100 basis points, the fair value of the company’s cross-currency interest rate swaps at December 31, 2025 would increase by approximately \$0.62 billion.

In addition, interest rate changes would result in a change in the company’s interest expense due to variable-rate debt instruments including swap arrangements. In 2025, a 100 basis point increase in interest rates on the swap arrangements and variable-rate debt would have increased the company’s annual pre-tax interest expense by approximately \$3 million.

#### Currency Exchange Rates

The company views its investments in international subsidiaries with a functional currency other than the U.S. dollar as permanent. The company’s investment in international subsidiaries is sensitive to fluctuations in currency exchange rates. The functional currencies of the company’s international subsidiaries are principally denominated in British pounds sterling, euro, Swedish krona, Canadian dollars and Norwegian kroner. The effect of a change in the period ending currency exchange rates on the company’s net investment in international subsidiaries is reflected in the “accumulated other comprehensive income/(loss)” component of shareholders’ equity. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A 10% depreciation in year-end 2025 functional currencies, relative to the U.S. dollar, would result in a reduction of shareholders’ equity of approximately \$2.93 billion.

The fair value of forward currency exchange contracts is sensitive to changes in currency exchange rates. The fair value of forward currency exchange contracts is the estimated amount that the company would pay or receive upon termination of the contract, taking into account the change in currency exchange rates. A 10% depreciation in year-end 2025 non-functional currency exchange rates related to the company’s contracts would result in an additional unrealized gain on forward currency exchange contracts of \$49 million. A 10% appreciation in year-end 2025 non-functional currency exchange rates related to the company’s contracts would result in an additional unrealized loss on forward currency exchange contracts of \$40 million. The unrealized gains or losses on forward currency exchange contracts resulting from changes in currency exchange rates are expected to approximately offset losses or gains on the exposures being hedged.

Certain of the company’s cash and cash equivalents are denominated in currencies other than the functional currency of the depositor and are sensitive to changes in currency exchange rates. A 10% depreciation in the related year-end 2025 non-functional currency exchange rates applied to such cash balances would result in a negative impact of \$12 million on the company’s net income.

THERMO FISHER SCIENTIFIC INC.

Item 8. Financial Statements and Supplementary Data

INDEX OF CONSOLIDATED FINANCIAL STATEMENTS

	Page
<a href="#">Report of Independent Registered Public Accounting Firm (PCAOB ID 238)</a>	<a href="#">30</a>
<a href="#">Consolidated Balance Sheets as of December 31, 2025 and 2024</a>	<a href="#">33</a>
<a href="#">Consolidated Statements of Income for the years ended December 31, 2025, 2024 and 2023</a>	<a href="#">34</a>
<a href="#">Consolidated Statements of Comprehensive Income for the years ended December 31, 2025, 2024 and 2023</a>	<a href="#">35</a>
<a href="#">Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023</a>	<a href="#">36</a>
<a href="#">Consolidated Statements of Redeemable Noncontrolling Interest and Equity for the years ended December 31, 2025, 2024 and 2023</a>	<a href="#">37</a>
<a href="#">Notes to Consolidated Financial Statements</a>	
<a href="#">Note 1. Nature of Operations and Summary of Significant Accounting Policies</a>	<a href="#">38</a>
<a href="#">Note 2. Supplemental Balance Sheet Information</a>	<a href="#">45</a>
<a href="#">Note 3. Debt and Other Financing Arrangements</a>	<a href="#">47</a>
<a href="#">Note 4. Fair Value Measurements</a>	<a href="#">49</a>
<a href="#">Note 5. Commitments and Contingencies</a>	<a href="#">51</a>
<a href="#">Note 6. Supplemental Income Statement Information</a>	<a href="#">53</a>
<a href="#">Note 7. Income Taxes</a>	<a href="#">55</a>
<a href="#">Note 8. Comprehensive Income/(Loss) and Shareholders' Equity</a>	<a href="#">60</a>
<a href="#">Note 9. Supplemental Cash Flow Information</a>	<a href="#">60</a>
<a href="#">Note 10. Derivatives</a>	<a href="#">61</a>
<a href="#">Note 11. Business Segment and Geographical Information</a>	<a href="#">62</a>
<a href="#">Note 12. Acquisitions</a>	<a href="#">66</a>
<a href="#">Note 13. Leases</a>	<a href="#">68</a>
<a href="#">Note 14. Pension and Other Postretirement Benefit Plans</a>	<a href="#">69</a>
<a href="#">Note 15. Stock-based Compensation Expense</a>	<a href="#">74</a>

## Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Thermo Fisher Scientific Inc.

### ***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of Thermo Fisher Scientific Inc. and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of income, of comprehensive income, of redeemable noncontrolling interest and equity and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

### ***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As described in Management's Annual Report on Internal Control Over Financial Reporting, management has excluded the filtration and separation business, which was acquired by the company from Solvatum Corporation, from its assessment of internal control over financial reporting as of December 31, 2025, because it was acquired by the Company in a purchase business combination during 2025. We have also excluded the filtration and separation business from our audit of internal control over financial reporting. The filtration and separation business's total assets and total revenues excluded from management's assessment and our audit of internal control over financial reporting represent approximately 1% and 1%, respectively, of the related consolidated financial statement amounts as of and for the year ended December 31, 2025.

### ***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### ***Critical Audit Matters***

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

#### *Income taxes*

As described in Note 7 to the consolidated financial statements, the Company's provision for income taxes for the year ended December 31, 2025 was \$547 million. The Company has deferred tax assets, net, of \$249 million (including a valuation allowance of \$3,561 million) and unrecognized tax benefits of \$419 million as of December 31, 2025. As disclosed by management, the Company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires management to interpret the related tax laws and regulations and to use estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the sources and character of income and tax credits. Management assesses income tax positions and records tax benefits for all years subject to examination based upon management's evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, management has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Management estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will more likely than not go unused. In situations in which management has been able to determine that the Company's deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a tax asset will be used, management reverses the related valuation allowance.

The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are (i) the significant judgment by management when interpreting the numerous and complex tax laws and regulations as it relates to determining the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the provision for income taxes, deferred tax assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits. These procedures also included, among others (i) testing the accuracy of the provision for income taxes, including the rate reconciliation and permanent and temporary differences, (ii) evaluating whether the data utilized in the calculations of the provision for income taxes, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits were appropriate and consistent with evidence obtained in other areas of the audit, (iii) evaluating management's assessment of the realizability of deferred tax assets on a jurisdictional basis, (iv) evaluating the identification of liabilities for unrecognized tax benefits and the reasonableness of the more likely than not determination in consideration of court decisions, legislative actions, statutes of limitations, and developments in tax examinations by jurisdiction, (v) testing the calculation of the liability for unrecognized tax benefits by jurisdiction, including estimates of the amount of income tax benefit expected to be sustained, and (vi) evaluating the adequacy of the Company's disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of management's judgments and estimates related to the application of foreign and domestic tax laws and regulations.

/s/ PricewaterhouseCoopers LLP  
Boston, Massachusetts  
February 26, 2026

We have served as the Company's auditor since 2002.

**THERMO FISHER SCIENTIFIC INC.**

**CONSOLIDATED BALANCE SHEETS**

(In millions except share and per share amounts)	December 31, 2025	December 31, 2024
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 9,852	\$ 4,009
Short-term investments	253	1,561
Accounts receivable, less allowances of \$147 and \$173	8,900	8,191
Inventories	5,425	4,978
Contract assets, net	1,666	1,435
Other current assets	2,612	1,964
<b>Total current assets</b>	<b>28,707</b>	<b>22,137</b>
Property, plant and equipment, net	10,565	9,306
Acquisition-related intangible assets, net	15,838	15,533
Other assets	5,871	4,492
Goodwill	49,362	45,853
<b>Total assets</b>	<b>\$ 110,343</b>	<b>\$ 97,321</b>
<b>Liabilities, redeemable noncontrolling interest and equity</b>		
Current liabilities:		
Short-term obligations and current maturities of long-term obligations	\$ 3,533	\$ 2,214
Accounts payable	3,622	3,079
Accrued payroll and employee benefits	1,995	1,988
Contract liabilities	2,710	2,852
Other accrued expenses	3,329	3,199
<b>Total current liabilities</b>	<b>15,189</b>	<b>13,332</b>
Deferred income taxes	1,493	1,268
Other long-term liabilities	4,273	3,989
Long-term obligations	35,852	29,061
Commitments and contingencies (Note 5)		
Redeemable noncontrolling interest	122	120
Equity:		
Thermo Fisher Scientific Inc. shareholders' equity:		
Preferred stock, \$100 par value, 50,000 shares authorized; none issued	—	—
Common stock, \$1 par value, 1,200,000,000 shares authorized; 445,160,301 and 443,841,240 shares issued	445	444
Capital in excess of par value	18,563	17,962
Retained earnings	59,156	53,102
Treasury stock at cost, 68,938,831 and 63,066,906 shares	(22,309)	(19,226)
Accumulated other comprehensive income/(loss)	(2,448)	(2,697)
<b>Total Thermo Fisher Scientific Inc. shareholders' equity</b>	<b>53,407</b>	<b>49,584</b>
Noncontrolling interests	7	(33)
<b>Total equity</b>	<b>53,415</b>	<b>49,551</b>
<b>Total liabilities, redeemable noncontrolling interest and equity</b>	<b>\$ 110,343</b>	<b>\$ 97,321</b>

The accompanying notes are an integral part of these consolidated financial statements.

**THERMO FISHER SCIENTIFIC INC.**

**CONSOLIDATED STATEMENTS OF INCOME**

(In millions except per share amounts)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Revenues</b>			
Product revenues	\$ 25,965	\$ 25,034	\$ 25,243
Service revenues	18,592	17,845	17,614
Total revenues	44,556	42,879	42,857
<b>Costs and operating expenses:</b>			
Cost of product revenues	13,405	12,523	13,168
Cost of service revenues	12,913	12,654	12,589
Selling, general and administrative expenses	8,732	8,595	8,445
Research and development expenses	1,397	1,390	1,337
Restructuring and other costs	362	379	459
Total costs and operating expenses	36,810	35,542	35,998
Operating income	7,746	7,337	6,859
Interest income	993	1,078	879
Interest expense	(1,419)	(1,390)	(1,375)
Other income/(expense)	(12)	12	(65)
Income before income taxes	7,308	7,037	6,298
Benefit from/(provision for) income taxes	(547)	(657)	(284)
Equity in earnings/(losses) of unconsolidated entities	(41)	(42)	(59)
<b>Net income</b>	6,721	6,338	5,955
Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	17	3	(40)
<b>Net income attributable to Thermo Fisher Scientific Inc.</b>	<u>\$ 6,704</u>	<u>\$ 6,335</u>	<u>\$ 5,995</u>
<b>Earnings per share attributable to Thermo Fisher Scientific Inc.</b>			
Basic	<u>\$ 17.77</u>	<u>\$ 16.58</u>	<u>\$ 15.52</u>
Diluted	<u>\$ 17.74</u>	<u>\$ 16.53</u>	<u>\$ 15.45</u>
<b>Weighted average shares</b>			
Basic	<u>377</u>	<u>382</u>	<u>386</u>
Diluted	<u>378</u>	<u>383</u>	<u>388</u>

The accompanying notes are an integral part of these consolidated financial statements.

**THERMO FISHER SCIENTIFIC INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Comprehensive income/(loss)</b>			
Net income	\$ 6,721	\$ 6,338	\$ 5,955
Other comprehensive income/(loss):			
Cumulative translation adjustment:			
Cumulative translation adjustment (net of tax provision (benefit) of \$(386), \$317 and \$(134))	223	525	(69)
Reclassification adjustment for losses included in net income	6	—	—
Unrealized gains and losses on hedging instruments:			
Reclassification adjustment for losses included in net income (net of tax benefit of \$1, \$1 and \$2)	3	3	5
Pension and other postretirement benefit liability adjustments:			
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of \$4, \$2 and \$(22))	13	(12)	(69)
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of \$1, \$1 and \$1)	5	4	—
Total other comprehensive income/(loss)	250	520	(133)
<b>Comprehensive income/(loss)</b>	<b>6,970</b>	<b>6,858</b>	<b>5,822</b>
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	17	(4)	(48)
<b>Comprehensive income attributable to Thermo Fisher Scientific Inc.</b>	<b>\$ 6,953</b>	<b>\$ 6,862</b>	<b>\$ 5,870</b>

The accompanying notes are an integral part of these consolidated financial statements.

**THERMO FISHER SCIENTIFIC INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In millions)	Year Ended		
	December 31, 2025	December 31, 2024	December 31, 2023
<b>Operating activities</b>			
Net income	\$ 6,721	\$ 6,338	\$ 5,955
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation of property, plant and equipment	1,050	1,156	1,068
Amortization of acquisition-related intangible assets	1,730	1,952	2,338
Change in deferred income taxes	(639)	(1,209)	(1,300)
Stock-based compensation	310	301	278
Other net non-cash expenses	455	508	604
Changes in assets and liabilities, excluding the effects of acquisitions:			
Accounts receivable	(426)	(171)	(43)
Inventories	(74)	(27)	598
Contract assets/liabilities	(375)	(162)	252
Accounts payable	421	212	(500)
Contributions to retirement plans	(42)	(45)	(42)
Other	(1,312)	(186)	(802)
Net cash provided by operating activities	7,818	8,667	8,406
<b>Investing activities</b>			
Purchases of property, plant and equipment	(1,525)	(1,400)	(1,479)
Proceeds from sale of property, plant and equipment	44	57	87
Proceeds from cross-currency interest rate swap interest settlements	268	252	70
Acquisitions, net of cash acquired	(4,037)	(3,132)	(3,660)
Purchases of investments	(383)	(3,396)	(208)
Proceeds from sales and maturities of investments	1,565	1,770	15
Other investing activities, net	21	8	33
Net cash used in investing activities	(4,047)	(5,841)	(5,142)
<b>Financing activities</b>			
Net proceeds from issuance of debt	7,759	1,204	5,942
Repayment of debt	(2,412)	(3,607)	(5,782)
Proceeds from issuance of commercial paper	1,095	—	1,620
Repayments of commercial paper	(1,095)	—	(1,935)
Purchases of company common stock	(3,000)	(4,000)	(3,000)
Dividends paid	(636)	(583)	(523)
Other financing activities, net	90	195	56
Net cash provided by/(used in) financing activities	1,801	(6,792)	(3,622)
Exchange rate effect on cash	267	(91)	(82)
Increase/(decrease) in cash, cash equivalents and restricted cash	5,839	(4,057)	(440)
Cash, cash equivalents and restricted cash at beginning of year	4,040	8,097	8,537
Cash, cash equivalents and restricted cash at end of year	\$ 9,879	\$ 4,040	\$ 8,097

The accompanying notes are an integral part of these consolidated financial statements.

**THERMO FISHER SCIENTIFIC INC.**

**CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY**

(In millions)	Redeemable Noncontrolling Interest	Common Stock		Capital in Excess of Par Value	Retained Earnings	Treasury Stock		Accumulated Other Comprehensive Income/(Loss)	Total Thermo Fisher Scientific Inc. Shareholders' Equity	Noncontrolling Interests	Total Equity
		Shares	Amount			Shares	Amount				
<b>Balance at December 31, 2022</b>	\$ 116	441	\$ 441	\$ 16,743	\$ 41,910	50	\$ (12,017)	\$ (3,099)	\$ 43,978	\$ 54	\$ 44,032
Issuance of shares under stock plans	—	1	1	265	—	1	(88)	—	178	—	178
Stock-based compensation	—	—	—	278	—	—	—	—	278	—	278
Purchases of company common stock	—	—	—	—	—	5	(3,000)	—	(3,000)	—	(3,000)
Dividends declared (\$1.40 per share)	—	—	—	—	(541)	—	—	—	(541)	—	(541)
Net income/(loss)	19	—	—	—	5,995	—	—	—	5,995	(59)	5,936
Other comprehensive income/(loss)	(3)	—	—	—	—	—	—	(125)	(125)	(5)	(130)
Contributions from (distributions to) noncontrolling interests	(14)	—	—	—	—	—	—	—	—	(1)	(1)
Excise tax from stock repurchases	—	—	—	—	—	—	(28)	—	(28)	—	(28)
<b>Balance at December 31, 2023</b>	118	442	442	17,286	47,364	56	(15,133)	(3,224)	46,735	(11)	46,724
Issuance of shares under stock plans	—	2	2	376	—	—	(67)	—	310	—	310
Stock-based compensation	—	—	—	301	—	—	—	—	301	—	301
Purchases of company common stock	—	—	—	—	—	7	(4,000)	—	(4,000)	—	(4,000)
Dividends declared (\$1.56 per share)	—	—	—	—	(596)	—	—	—	(596)	—	(596)
Net income/(loss)	23	—	—	—	6,335	—	—	—	6,335	(20)	6,315
Other comprehensive income/(loss)	(6)	—	—	—	—	—	—	527	527	—	527
Contributions from (distributions to) noncontrolling interests	(14)	—	—	—	—	—	—	—	—	(1)	(1)
Excise tax from stock repurchases	—	—	—	—	—	—	(26)	—	(26)	—	(26)
<b>Balance at December 31, 2024</b>	120	444	444	17,962	53,102	63	(19,226)	(2,697)	49,584	(33)	49,551
Issuance of shares under stock plans	—	1	1	291	—	—	(59)	—	234	—	234
Stock-based compensation	—	—	—	310	—	—	—	—	310	—	310
Purchases of company common stock	—	—	—	—	—	6	(3,000)	—	(3,000)	—	(3,000)
Dividends declared (\$1.72 per share)	—	—	—	—	(650)	—	—	—	(650)	—	(650)
Net income/(loss)	17	—	—	—	6,704	—	—	—	6,704	(1)	6,703
Other comprehensive income/(loss)	—	—	—	—	—	—	—	249	249	—	249
Contributions from (distributions to) noncontrolling interests	(16)	—	—	—	—	—	—	—	—	(2)	(2)
Excise tax from stock repurchases	—	—	—	—	—	—	(24)	—	(24)	—	(24)
Disposition	—	—	—	—	—	—	—	—	—	42	42
<b>Balance at December 31, 2025</b>	\$ 122	445	\$ 445	\$ 18,563	\$ 59,156	69	\$ (22,309)	\$ (2,448)	\$ 53,407	\$ 7	\$ 53,415

The accompanying notes are an integral part of these consolidated financial statements.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1. Nature of Operations and Summary of Significant Accounting Policies**

*Nature of Operations*

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

*Principles of Consolidation*

The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated.

*Redeemable Noncontrolling Interest*

The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.

*Presentation*

Certain reclassifications of prior year amounts have been made to conform to the current year presentation.

Amounts and percentages reported within these consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

*Use of Estimates*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

The company's estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.

*Cash and Cash Equivalents*

Cash equivalents consists principally of money market funds and other marketable securities purchased with a remaining maturity of three months or less. These investments are carried at cost, which approximates market value (Note 4).

*Inventories*

Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income (Note 2).

*Contract-related Balances*

Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for credit losses is the company's best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Contract assets include revenues recognized in advance of billings where the company's right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company's performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional.

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract.

Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheets, respectively (Note 2).

*Property, Plant and Equipment*

Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment, 8 to 10 years; internal use software, 3 to 5 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income (Note 2).

*Acquisition-related Intangible Assets*

Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, trade names, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company uses the income approach to initially measure acquired customer relationships for which the key assumptions are typically estimated customer attrition rates and discount rates. The company reviews intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.

In addition, the company has trade names that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable (Note 2).

*Investments*

Investments include marketable securities, such as marketable equity securities, available for sale debt securities, and bank time deposits with maturities greater than three months, equity method investments, and non-marketable equity investments. The company classifies investments as current or noncurrent based on the nature of the securities and their availability for use in current operations. Noncurrent investments are included in other assets.

Marketable securities are stated at fair value with all realized and unrealized gains and losses on investments in marketable equity securities and realized gains and losses on available-for-sale debt securities recognized in other income/(expense).

The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. The company's share of gains and losses in, and impairments of, equity method investments are recorded in equity in earnings/(losses) of unconsolidated entities. Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. All gains and losses on non-equity method investments are recognized in other income/(expense).

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Other Assets*

Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, insurance recovery receivables related to product liability matters, certain intangible assets and other assets.

*Goodwill*

The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company's reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the quantitative goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit's carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2025, 2024 or 2023 (Note 2).

*Fair Value Measurements*

Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.

Level 3: Inputs are unobservable data points that are not corroborated by market data.

The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures acquisition-related contingent consideration at fair value. Changes to the fair values of contingent consideration are recorded in selling, general and administrative expenses. The company determines the fair value of its equity method and non-marketable equity investments that are not eligible for the NAV practical expedient by considering factors such as financial position, operating results and cash flows of the investee; recent transactions in the same or similar securities; significant recent events affecting the investee; the price paid by the company; among others (Note 4).

*Loss Contingencies*

Accruals are recorded for various contingencies, including legal proceedings, environmental, workers' compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management's judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable.

The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management's knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites.

The company determines the probability and range of possible loss for its litigation and other contingencies based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management's judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates (Note 5).

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Warranty Obligations*

The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.

*Foreign Currency Translation*

All assets and liabilities of the company's subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the "accumulated other comprehensive income/(loss)" component of shareholders' equity. Revenues and expenses are translated at average exchange rates for the period (Note 6).

*Revenue Recognition*

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.

Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively.

Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.

*Research and Development*

The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.

*Restructuring Costs*

Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.

From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period (Note 6).

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Foreign Currency Transactions*

Foreign currency-denominated monetary assets and liabilities are measured at the end of each reporting period using the exchange rates at that date. The resulting foreign currency transaction gains/(losses) are classified in cost of product revenue or cost of service revenue if the transaction relates to an operating activity. All other foreign currency transaction gains/(losses) are generally classified in other income/(expense). Accounting for financial instruments designated as net investment hedges is discussed below.

*Earnings per Share*

Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units (Note 6).

*Income Taxes*

The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused. In situations in which the company has been able to determine that its deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences or expected future taxable income.

The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities' full knowledge of the positions and all relevant facts, but without discounting for the time value of money (Note 7).

*Derivative Contracts*

The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive income/(loss) until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings together with the corresponding, offsetting gains/(losses) on the underlying hedged transactions.

The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency exchange contracts principally hedge transactions denominated in euro, Canadian dollars, British pounds sterling, Swiss franc, Swedish krona, Singapore dollars, and Hong Kong dollars. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management.

*Cash flow hedges.* For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive income/(loss) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item.

*Net investment hedges.* The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company's euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in cumulative translation adjustment within other comprehensive income/(loss) and shareholders' equity.

The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheets under the caption other current assets, other assets, other current liabilities, or other long-term liabilities. The fair value of the currency exchange contracts is included in the accompanying balance sheets under the captions other current assets or other accrued expenses. (Notes 4 and 10).

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Leases*

Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company's obligations.

Right-of-use (ROU) assets represent the company's right to use an underlying asset for the lease term and lease liabilities represent the company's obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense.

Because most of the company's leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option.

As a lessee, the company accounts for the lease and non-lease components as a single lease component (Note 13).

*Pension and Other Postretirement Benefit Plans*

The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive income/(loss), net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost/(income). Other comprehensive income/(loss) is adjusted as these amounts are later recognized in income as components of net periodic benefit cost/(income).

When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.

The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined.

The discount rate used to determine projected benefit obligations and net periodic pension benefit cost/(income) reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.

The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows.

The expected long-term rate of return on plan assets used to determine net periodic pension benefit cost/(income) reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.

Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements.

The expected rate of compensation increase used to determine net periodic pension benefit cost/(income) reflects the long-term average rate of salary increases and is based on historic salary increase experience and management's expectations of future salary increases (Note 14).

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Stock-based Compensation Expense*

Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses.

The company's practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company's stock. Historical data on exercise patterns, where available, are the bases for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company's annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures.

Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company's shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award (Note 15).

*Government Assistance*

From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2025, 2024 and 2023.

*Recent Accounting Pronouncements*

The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.

Standard	Description	Adoption timing and approach	Impact of adoption or other significant matters
<b>Standards recently adopted</b>			
ASU No. 2022-04, <i>Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations</i>	New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented.	Some aspects adopted in 2023 using a retrospective method and other aspects adopted in 2024 using a prospective method	Not material
ASU No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>	Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.	2025 annual report and interim periods thereafter using a prospective method	Increased disclosures in Notes 7 and 9
<b>Standards not yet adopted</b>			
ASU No. 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i>	New guidance to disclose specified information about certain costs and expenses.	2027 annual report and interim periods thereafter using a prospective or retrospective method	Will increase disclosures in Note 6

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Standard	Description	Adoption timing and approach	Impact of adoption or other significant matters
ASU No. 2025-06, <i>Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</i>	Among other things, new guidance to modernize the accounting for costs to develop software for internal use.	2028 annual report and interim periods thereafter using a prospective, retrospective, or modified transition method; early adoption is permitted.	Currently evaluating adoption impact, timing, and method
ASU No. 2025-10, <i>Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</i>	Among other things, establishes guidance for the recognition, measurement, and presentation of government grants.	2029 using a retrospective, modified retrospective, or modified prospective approach; early adoption is permitted.	Currently evaluating adoption impact, timing, and method

**Note 2. Supplemental Balance Sheet Information**

*Inventories*

The components of inventories are as follows:

(In millions)	December 31, 2025	December 31, 2024
Raw materials	\$ 1,877	\$ 1,803
Work in process	889	755
Finished goods	2,659	2,420
Inventories	<u>\$ 5,425</u>	<u>\$ 4,978</u>

*Contract-related Balances*

Contract asset and liability balances are as follows:

(In millions)	December 31, 2025	December 31, 2024
Current contract assets, net	\$ 1,666	\$ 1,435
Noncurrent contract assets, net	1	6
Current contract liabilities	2,710	2,852
Noncurrent contract liabilities	1,183	1,138

Substantially all of the current contract liability balances at December 31, 2024 and 2023 was recognized in revenues during 2025 and 2024, respectively.

*Remaining Performance Obligations*

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2025 was \$27.92 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 52% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.

*Property, Plant and Equipment*

Property, plant and equipment consists of the following:

(In millions)	December 31, 2025	December 31, 2024
Land	\$ 500	\$ 439
Buildings and improvements	4,570	3,728
Machinery, equipment and leasehold improvements	11,005	9,858
Construction in progress	2,305	2,034
Property, plant and equipment, at cost	<u>18,380</u>	<u>16,059</u>
Less: Accumulated depreciation and amortization	7,815	6,753
Property, plant and equipment, net	<u>\$ 10,565</u>	<u>\$ 9,306</u>

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Acquisition-related Intangible Assets*

Acquisition-related intangible assets are as follows:

(In millions)	Balance at December 31, 2025			Balance at December 31, 2024		
	Gross	Accumulated Amortization	Net	Gross	Accumulated Amortization	Net
<i>Definite lived:</i>						
Customer relationships	\$ 23,290	\$ (10,515)	\$ 12,775	\$ 22,644	\$ (10,047)	\$ 12,596
Product technology	5,196	(3,891)	1,305	5,557	(4,423)	1,134
Trade names	1,804	(1,318)	486	1,706	(1,180)	527
Backlog	1,084	(1,047)	37	1,084	(1,043)	41
	31,374	(16,771)	14,604	30,991	(16,693)	14,298
<i>Indefinite lived:</i>						
Trade names	1,235	N/A	1,235	1,235	N/A	1,235
Acquisition-related intangible assets	\$ 32,609	\$ (16,771)	\$ 15,838	\$ 32,226	\$ (16,693)	\$ 15,533

The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2025 is as follows:

(In millions)	
2026	\$ 1,638
2027	1,608
2028	1,573
2029	1,457
2030	1,160
2031 and thereafter	7,169
Estimated future amortization expense of definite-lived intangible assets	\$ 14,604

At December 31, 2025 and 2024, the company had \$21 million and \$34 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.

*Other Assets*

At December 31, 2025 and 2024, the company had equity method investments with carrying amounts of \$178 million and \$357 million, respectively.

At December 31, 2025 and 2024, the company's equity investments that do not have readily determinable fair values and are not eligible for the NAV practical expedient investments had carrying amounts of \$196 million and \$41 million, respectively. Investments measured at NAV were \$64 million and \$40 million at December 31, 2025 and 2024, respectively.

*Goodwill*

The changes in the carrying amount of goodwill by segment are as follows:

(In millions)	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Total
<b>Balance at December 31, 2023</b>	\$ 10,151	\$ 5,051	\$ 4,923	\$ 23,895	\$ 44,020
Acquisitions	2,302	—	—	—	2,302
Currency translation	(117)	(92)	(139)	(122)	(470)
<b>Balance at December 31, 2024</b>	12,336	4,959	4,784	23,773	45,853
Acquisitions	2,101	—	—	15	2,117
Currency translation	473	184	292	444	1,393
<b>Balance at December 31, 2025</b>	\$ 14,910	\$ 5,143	\$ 5,076	\$ 24,232	\$ 49,362

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**Note 3. Debt and Other Financing Arrangements**

The company's debt and other financing arrangements are as follows:

(Dollars in millions)	Effective interest rate at December 31, 2025	December 31, 2025	December 31, 2024
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)		\$ —	\$ 828
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)		—	663
0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)		—	142
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)		—	569
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)	3.18 %	587	518
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.45 %	822	725
4.953% 3-Year Senior Notes, Due 8/10/2026	5.18 %	600	600
0.832% 1.5-Year Senior Notes, Due 9/7/2026 (Swiss franc-denominated)	1.14 %	517	—
5.000% 3-Year Senior Notes, Due 12/5/2026	5.25 %	1,000	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.66 %	587	518
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)	1.97 %	705	621
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)	1.18 %	184	184
4.80% 5-Year Senior Notes, Due 11/21/2027	5.00 %	600	600
Floating Rate (EURIBOR + 0.280%) 2-Year Senior Notes, Due 12/1/2027 (euro-denominated)	2.58 %	1,175	—
0.790% 3-Year Senior Notes, Due 1/6/2028 (Swiss franc-denominated)	1.35 %	111	—
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)	0.78 %	940	828
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)	1.79 %	416	364
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)	0.90 %	185	184
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46 %	705	621
1.750% 7-Year Senior Notes, Due 10/15/2028	1.89 %	700	700
5.000% 5-Year Senior Notes Due 1/31/2029	5.24 %	1,000	1,000
1.125% 4-Year Senior Notes, Due 3/7/2029 (Swiss franc-denominated)	1.26 %	397	—
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.08 %	822	725
2.60% 10-Year Senior Notes, Due 10/1/2029	2.74 %	900	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)	1.44 %	30	30
1.120% 5-Year Senior Notes, Due 1/6/2030 (Swiss franc-denominated)	1.25 %	295	—
4.977% 7-Year Senior Notes, Due 8/10/2030	5.12 %	750	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)	0.89 %	2,056	1,812
4.200% 5.5-Year Senior Notes Due 3/1/2031	4.41 %	500	—
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)	1.14 %	1,057	932
2.00% 10-Year Senior Notes, Due 10/15/2031	2.23 %	1,200	1,200
1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)	1.92 %	524	457
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)	2.55 %	705	621
4.473% 7-Year Senior Notes, Due 10/7/2032	4.62 %	750	—
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)	1.60 %	40	40
4.95% 10-Year Senior Notes, Due 11/21/2032	5.09 %	600	600
1.4175% 8-Year Senior Notes, Due 3/7/2033 (Swiss franc-denominated)	1.49 %	442	—
5.086% 10-Year Senior Notes, Due 8/10/2033	5.20 %	1,000	1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)	1.21 %	1,762	1,553
5.200% 10-Year Senior Notes, Due 1/31/2034	5.34 %	500	500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)	3.76 %	881	777
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)	1.58 %	137	137
4.794% 10-Year Senior Notes, Due 10/7/2035	4.91 %	750	—
3.628% 10-Year Senior Notes, Due 12/1/2035 (euro-denominated)	3.70 %	1,292	—
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)	2.10 %	410	358
1.520% 12-Year Senior Notes, Due 1/6/2037 (Swiss franc-denominated)	1.56 %	392	—

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

(Dollars in millions)	Effective interest rate at December 31, 2025	December 31, 2025	December 31, 2024
1.6524% 12-Year Senior Notes, Due 3/6/2037 (Swiss franc-denominated)	1.71 %	271	—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94 %	822	725
4.894% 12-Year Senior Notes, Due 10/7/2037	5.00 %	500	—
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)	1.73 %	1,057	932
2.80% 20-Year Senior Notes, Due 10/15/2041	2.90 %	1,200	1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)	1.78 %	1,468	1,294
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)	2.13 %	93	93
5.404% 20-Year Senior Notes, Due 8/10/2043	5.50 %	600	600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)	2.06 %	185	184
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37 %	400	400
1.49% 20-Year Senior Notes, Due 1/6/2045 (Swiss franc-denominated)	1.54 %	233	—
1.8975% 20-Year Senior Notes, Due 3/7/2045 (Swiss franc-denominated)	1.95 %	170	—
4.10% 30-Year Senior Notes, Due 8/15/2047	4.23 %	750	750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)	1.99 %	1,175	1,035
1.47% 25-Year Senior Notes, Due 1/6/2050 (Swiss franc-denominated)	1.49 %	413	—
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)	2.07 %	881	777
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)	2.43 %	212	212
Other		1	73
<b>Total borrowings at par value</b>		<b>39,459</b>	<b>31,332</b>
Unamortized discount		(94)	(95)
Unamortized debt issuance costs		(194)	(164)
<b>Total borrowings at carrying value</b>		<b>39,172</b>	<b>31,072</b>
Finance lease liabilities		213	202
Less: Short-term obligations and current maturities		3,533	2,214
<b>Long-term obligations</b>		<b>\$ 35,852</b>	<b>\$ 29,061</b>

EURIBOR - Euro Interbank Offered Rate

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.

See Note 4 for fair value information pertaining to the company's long-term borrowings.

As of December 31, 2025, the annual repayment requirements for debt obligations are as follows:

(In millions)	Borrowings	Finance Lease Liabilities
2026	\$ 3,528	\$ 9
2027	3,254	8
2028	3,057	8
2029	3,150	9
2030	3,105	10
2031 and thereafter	23,366	170
	<b>\$ 39,459</b>	<b>\$ 213</b>

In addition to available borrowings under the company's revolving credit agreements, discussed below, the company had unused lines of credit of \$73 million as of December 31, 2025. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.

*Credit Facilities*

The company has a revolving credit facility (the Facility) with a bank group that provides for up to \$5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2028. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), EURIBOR-based rate (for funds drawn in euro), or a rate based on

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2025, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.

*Commercial Paper Programs*

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.

*Senior Notes*

Interest is payable annually on the euro and public Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes, and Japanese yen-denominated and Swiss franc-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of the Japanese yen-denominated and Swiss franc-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at December 31, 2025.

Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of December 31, 2025, included in the table above (collectively, the “Euronotes”) in registered public offerings: the Floating Rate Senior Notes due 2027, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 3.628% Senior Notes due 2035, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.

*February 2026 Debt Issuances*

In the first quarter of 2026 the company issued the following senior notes:

(In millions)	Principal value issued
4.215% 5-Year Senior Notes, Due 2/12/2031	\$ 1,000
4.550% 7.3-Year Senior Notes, Due 6/15/2033	750
4.902% 10-Year Senior Notes, Due 2/12/2036	1,300
5.546% 20-Year Senior Notes, Due 2/12/2046	750

**Note 4. Fair Value Measurements**

*Fair Value Measurements*

The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2025. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in bank time deposits, publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following tables present information about the company's financial assets and liabilities measured at fair value on a recurring basis:

(In millions)	December 31, 2025	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Assets</b>				
Cash equivalents	\$ 6,907	\$ 6,907	\$ —	\$ —
Bank time deposits	250	250	—	—
Investments	103	27	—	76
Insurance contracts	280	—	280	—
Derivative contracts	685	—	685	—
Contingent consideration	67	—	—	67
Total assets	<u>\$ 8,292</u>	<u>\$ 7,184</u>	<u>\$ 966</u>	<u>\$ 143</u>
<b>Liabilities</b>				
Derivative contracts	\$ 506	\$ —	\$ 506	\$ —
Contingent consideration	16	—	—	16
Total liabilities	<u>\$ 522</u>	<u>\$ —</u>	<u>\$ 506</u>	<u>\$ 16</u>

(In millions)	December 31, 2024	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Assets</b>				
Cash equivalents	\$ 1,103	\$ 1,103	\$ —	\$ —
Bank time deposits	1,560	1,560	—	—
Investments	39	18	—	21
Insurance contracts	240	—	240	—
Derivative contracts	460	—	460	—
Total assets	<u>\$ 3,401</u>	<u>\$ 2,680</u>	<u>\$ 700</u>	<u>\$ 21</u>
<b>Liabilities</b>				
Derivative contracts	\$ 59	\$ —	\$ 59	\$ —
Contingent consideration	13	—	—	13
Total liabilities	<u>\$ 72</u>	<u>\$ —</u>	<u>\$ 59</u>	<u>\$ 13</u>

The following table provides a rollforward of investments classified as level 3:

(In millions)	2025	2024
<b>Investments</b>		
Beginning balance	\$ 21	\$ —
Purchases	55	21
Ending balance	<u>\$ 76</u>	<u>\$ 21</u>

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of a qualifying transaction), of the contingent consideration asset:

(In millions)	2025
<b>Contingent consideration asset</b>	
Beginning balance	\$ —
Acquisition	66
Changes in fair value included in earnings	1
Ending balance	<u>\$ 67</u>

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration liabilities.

(In millions)	2025	2024
<b>Contingent consideration liabilities</b>		
Beginning balance	\$ 13	\$ 87
Acquisitions (including assumed balances)	3	—
Payments	(6)	(2)
Changes in fair value included in earnings	7	(73)
Ending balance	<u>\$ 16</u>	<u>\$ 13</u>

*Fair Value of Other Financial Instruments*

The carrying value and fair value of the company's debt instruments are as follows:

(In millions)	December 31, 2025		December 31, 2024	
	Carrying value	Fair value	Carrying value	Fair value
Senior notes	\$ 39,171	\$ 36,606	\$ 30,999	\$ 28,454
Other	1	1	73	73
	<u>\$ 39,172</u>	<u>\$ 36,607</u>	<u>\$ 31,072</u>	<u>\$ 28,527</u>

The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

**Note 5. Commitments and Contingencies**

*Purchase Obligations*

The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company's unconditional purchase obligations totaled \$1.98 billion at December 31, 2025, the majority of which are expected to be settled during 2026.

*Letters of Credit, Guarantees and Other Commitments*

Outstanding letters of credit and bank guarantees totaled \$379 million at December 31, 2025. Substantially all of these letters of credit and guarantees expire through 2039.

Outstanding surety bonds and other guarantees totaled \$175 million at December 31, 2025. The expiration of these bonds and guarantees ranges through 2030.

The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.

The company has funding commitments totaling \$162 million at December 31, 2025, related to investments.

The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits; however, the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2025 was \$24 million.

In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Indemnifications*

In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications.

In connection with the company's efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company's financial position or results of operations.

In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions.

*Environmental Matters*

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company's responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company's domestic and international facilities were not material in any period presented. At December 31, 2025, the company's total environmental liability was approximately \$86 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company's operations, which could have a material adverse effect on the company's financial position, results of operations and cash flows.

*Litigation and Related Contingencies*

The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company's current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company's results of operations, financial position and cash flows.

*Product Liability, Workers Compensation and Other Personal Injury Matters*

The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company's continuing operations at December 31, 2025, was approximately \$218 million to \$376 million. The company's accrual for these matters totaled \$223 million at December 31, 2025. The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of \$81 million at December 31, 2025 that are included in other assets in the accompanying balance sheet. In addition, as of December 31, 2025, the company had a product liability accrual of \$19 million relating to divested businesses.

Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

adverse effect on the company's results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

**Note 6. Supplemental Income Statement Information**

*Disaggregated Revenues*

Revenues by type are as follows:

(In millions)	2025	2024	2023
<b>Revenues</b>			
Consumables	\$ 18,664	\$ 17,587	\$ 17,597
Instruments	7,301	7,446	7,646
Services	18,592	17,845	17,614
Consolidated revenues	<u>\$ 44,556</u>	<u>\$ 42,879</u>	<u>\$ 42,857</u>

Revenues by geographic region based on customer location are as follows:

(In millions)	2025	2024	2023
<b>Revenues</b>			
North America	\$ 23,033	\$ 22,504	\$ 22,764
Europe	11,826	10,857	10,741
Asia-Pacific	8,101	7,956	7,873
Other regions	1,597	1,561	1,479
Consolidated revenues	<u>\$ 44,556</u>	<u>\$ 42,879</u>	<u>\$ 42,857</u>

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 11 for revenues by reportable segment and other geographic data.

Revenues by business are as follows:

(In millions)	2025	2024	2023
<b>Revenues</b>			
Biosciences	\$ 4,169	\$ 4,192	\$ 4,238
Genetic sciences	2,870	2,787	2,816
BioProduction	3,200	2,652	2,923
Other	136	—	1
Life Sciences Solutions	10,374	9,631	9,977
Chromatography and mass spectrometry	3,360	3,278	3,329
Chemical analysis	1,237	1,315	1,371
Electron microscopy	2,957	2,870	2,564
Analytical Instruments	7,554	7,463	7,263
Clinical diagnostics	1,115	1,063	1,104
ImmunoDiagnostics	912	864	802
Microbiology	645	633	618
Transplant diagnostics	492	454	393
Healthcare market channel	1,788	1,764	1,712
Elimination of intrasegment revenues and other	(275)	(266)	(222)
Specialty Diagnostics	4,676	4,512	4,405
Laboratory products	2,407	2,525	2,613
Research and safety market channel	7,440	7,019	6,841
Pharma services	7,142	6,685	6,806
Clinical research	7,915	7,836	7,691
Elimination of intrasegment revenues and other	(920)	(907)	(910)
Laboratory Products and Biopharma Services	23,984	23,157	23,041
Elimination of intersegment revenues	(2,033)	(1,885)	(1,829)
Consolidated revenues	<u>\$ 44,556</u>	<u>\$ 42,879</u>	<u>\$ 42,857</u>

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Restructuring and Other Costs*

Restructuring and other costs in 2025 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, net charges for disposition of a consolidated joint venture, impairments of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company's workforce.

Restructuring and other costs in 2024 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2024, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company's workforce.

Restructuring and other costs in 2023 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2023, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company's workforce.

As of February 26, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services, Life Sciences Solutions, and Analytical Instruments segments, that it expects will result in additional charges of approximately \$250 million, primarily in 2026, and expects to identify additional actions in future periods.

Restructuring and other costs by segment are as follows:

(In millions)	2025	2024	2023
Life Sciences Solutions	\$ 154	\$ 69	\$ 105
Analytical Instruments	81	4	33
Specialty Diagnostics	10	17	11
Laboratory Products and Biopharma Services	147	280	295
Corporate	(29)	9	15
	<u>\$ 362</u>	<u>\$ 379</u>	<u>\$ 459</u>

The following table summarizes the changes in the company's accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.

(In millions)	Total (a)
<b>Balance at December 31, 2022</b>	\$ 41
Net restructuring charges incurred in 2023 (b) (c)	194
Payments	(175)
<b>Balance at December 31, 2023</b>	60
Net restructuring charges incurred in 2024 (d) (e)	97
Payments	(105)
Currency translation and other	(2)
<b>Balance at December 31, 2024</b>	50
Net restructuring charges incurred in 2025 (f)	197
Payments	(175)
Currency translation and other	(1)
<b>Balance at December 31, 2025</b>	<u>\$ 70</u>

(a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.

(b) Excludes \$264 million of charges, principally \$126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, \$26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and \$19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.

(c) Excludes \$93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by \$46 million attributable to a noncontrolling interest.

(d) Excludes \$282 million of net charges, principally \$211 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments.

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

- (e) Excludes \$41 million of charges in the Laboratory Products and Biopharma Services segment for impairment of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by \$19 million attributable to a noncontrolling interest.
- (f) Excludes \$165 million of net charges, principally \$94 million of charges for impairments of long-lived assets in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments, as well as \$51 million of net charges for disposition of a consolidated joint venture.

The company expects to pay accrued restructuring costs primarily through 2026.

*Earnings per Share*

The company's earnings per share are as follows:

(In millions except per share amounts)	2025	2024	2023
Net income attributable to Thermo Fisher Scientific Inc.	\$ 6,704	\$ 6,335	\$ 5,995
Basic weighted average shares	377	382	386
Plus effect of: stock options and restricted stock units	1	1	2
Diluted weighted average shares	378	383	388
Basic earnings per share	\$ 17.77	\$ 16.58	\$ 15.52
Diluted earnings per share	\$ 17.74	\$ 16.53	\$ 15.45
Antidilutive stock options excluded from diluted weighted average shares	3	2	2

*Other Income/(Expense)*

In all periods, other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/(income), excluding the service cost component, which is included in operating expenses on the accompanying statements of income. In 2025, 2024, and 2023 other income/(expense) includes \$13 million, \$21 million, and \$(46) million of net gains/(losses) on investments, respectively. In 2025, other income/(expense) includes \$7 million of settlement charges for pension plans (Note 14).

*Foreign Currency Transactions*

The aggregate foreign currency transaction gains/(losses) included in the accompanying statements of income were \$(130) million, \$0 million and \$(67) million in 2025, 2024 and 2023, respectively.

**Note 7. Income Taxes**

The components of income before provision for income taxes are as follows:

(In millions)	2025	2024	2023
U.S.	\$ 2,608	\$ 2,226	\$ 2,431
Non-U.S.	4,700	4,812	3,867
Income before income taxes	\$ 7,308	\$ 7,037	\$ 6,298

The components of the provision for income taxes are as follows:

(In millions)	2025	2024	2023
<b>Current income tax provision</b>			
Federal	\$ 402	\$ 561	\$ 228
Non-U.S.	658	1,175	1,206
State	126	130	150
	1,186	1,866	1,584
<b>Deferred income tax provision/(benefit)</b>			
Federal	\$ (385)	\$ (1,026)	\$ (551)
Non-U.S.	(221)	(72)	(647)
State	(34)	(111)	(102)
	(639)	(1,209)	(1,300)
Provision for/(benefit from) income taxes	\$ 547	\$ 657	\$ 284

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:

(Dollars in millions)	2025	
<b>U.S. federal statutory tax rate</b>	\$ 1,535	21.0 %
<b>State and local income taxes, net of federal income tax effect (a)</b>	68	0.9 %
<b>Foreign tax effects</b>		
Malta		
Changes in valuation allowances	2,351	32.2 %
Statutory tax rate difference between Malta and United States	473	6.5 %
Deferred interest	(2,351)	(32.2)%
Notional interest deduction	(1,186)	(16.2)%
Other	19	0.3 %
Netherlands		
Changes in valuation allowances	144	2.0 %
Deferred interest	(97)	(1.3)%
Other	(27)	(0.4)%
United Kingdom		
Partnership income/(loss)	(118)	(1.6)%
Foreign exchange	131	1.8 %
Other	(41)	(0.6)%
Other foreign jurisdictions	166	2.3 %
<b>Effect of changes in tax laws or rates enacted in the current period</b>	12	0.2 %
<b>Effect of cross-border tax laws</b>		
Foreign-derived intangible income	(268)	(3.7)%
U.S. tax on branch income/(loss)	390	5.3 %
Other	125	1.7 %
<b>Tax credits</b>		
Foreign tax credits	(181)	(2.5)%
Other	(36)	(0.5)%
<b>Changes in valuation allowances</b>	(157)	(2.1)%
<b>Nontaxable or nondeductible items</b>	1	0.0 %
<b>Changes in unrecognized tax benefits</b>	(64)	(0.9)%
<b>Other adjustments</b>		
Intra-entity transfer	(133)	(1.8)%
Domestication transaction	(240)	(3.3)%
Other	31	0.4 %
<b>Effective tax rate</b>	<u>\$ 547</u>	<u>7.5 %</u>

(a) State taxes in California, Massachusetts, Illinois, and Pennsylvania comprise the majority of the tax effect in this category.

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Under previous tax disclosure guidance, the provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following:

(In millions)	2024	2023
Statutory federal income tax rate	21 %	21 %
Provision for income taxes at statutory rate	\$ 1,478	\$ 1,323
Increases (decreases) resulting from:		
Foreign rate differential	(131)	(223)
Income tax credits	(333)	(276)
Global intangible low-taxed income	57	113
Foreign-derived intangible income	(133)	(108)
Excess tax benefits from stock options and restricted stock units	(67)	(69)
Provision for (reversal of) tax reserves, net	218	13
Intra-entity transfers	(106)	(233)
Foreign exchange loss on inter-company debt refinancing	—	(112)
Provision for (reversal of) valuation allowances, net	(229)	(32)
Withholding taxes	74	33
Tax return reassessments and settlements	(192)	(187)
State income taxes, net of federal tax	66	70
Other, net	(45)	(28)
Provision for/(benefit from) income taxes	<u>\$ 657</u>	<u>\$ 284</u>

The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, nondeductible interest in certain foreign jurisdictions, and foreign taxes that are different than the U.S. federal statutory rate.

During 2025, the company recorded tax benefits of \$269 million and \$153 million for domestication transactions and capital losses generated as part of intra-entity transactions, respectively, as well as \$93 million of tax benefits related to tax return reassessments associated with the company's foreign-derived intangible income. The company also recorded net tax benefits of \$157 million, primarily in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income.

During 2024, the company recorded a tax reserve and associated interest of \$240 million related to the settlement of international tax audits for tax years 2009 through 2016, which were settled in 2024. The company also recorded tax benefits of \$459 million, primarily in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. The benefits were partially offset by tax provisions primarily associated with disallowed interest expense and net operating loss carryforwards that are not expected to be realized.

During 2023, the company released valuation allowances of \$32 million in jurisdictions where the deferred tax assets are now expected to be realized. In 2023, the company also recorded a tax benefit of \$127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a \$91 million tax benefit, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, and \$233 million of tax benefits resulting from intra-entity transactions.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Net deferred tax asset/(liability) in the accompanying balance sheets consists of the following:

(In millions)	2025	2024
<b>Deferred tax asset/(liability)</b>		
Depreciation and amortization	\$ (4,304)	\$ (4,133)
Net operating loss and credit carryforwards	3,662	2,915
Reserves and accruals	139	161
Accrued compensation	321	318
Inventory basis difference	293	309
Deferred interest	3,365	534
Research and development and other capitalized costs	372	536
Unrealized (gains) losses on hedging instruments	20	(363)
Contract liabilities	289	280
Other, net	(346)	147
Deferred tax assets/(liabilities), net before valuation allowance	3,811	705
Less: Valuation allowance	3,561	1,043
Deferred tax assets/(liabilities), net	<u>\$ 249</u>	<u>\$ (338)</u>

Prior to 2025, certain of the company's non-U.S. attributes were determined to have a remote possibility of realization and therefore were not reported in the table above. In connection with the Organization for Economic Cooperation and Development global minimum tax initiative, Pillar Two, any existing deferred taxes not disclosed in the company's 2025 financial statements will not be available in the future to reduce tax otherwise due under Pillar Two. Accordingly, beginning in 2025, the company is disclosing in the above table the tax effects of these non-US attributes offset with a full valuation allowance.

The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2025, all of the company's valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense.

The changes in the valuation allowance are as follows:

(In millions)	Year Ended December 31,		
	2025	2024	2023
<b>Beginning balance</b>	\$ 1,043	\$ 1,317	\$ 1,322
Additions/(reductions) recognized in income tax provision, net	2,455	(229)	(32)
Additions due to acquisitions	—	—	4
Currency translation and other	64	(46)	23
<b>Ending balance</b>	<u>\$ 3,561</u>	<u>\$ 1,043</u>	<u>\$ 1,317</u>

At December 31, 2025, the company had net federal, state and non-U.S. net operating loss carryforwards of \$317 million, \$72 million and \$2.20 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, \$38 million expire in the years 2026 through 2037, and the remainder do not expire. Of the state net operating loss carryforwards, \$56 million expire in the years 2026 through 2044, and the remainder do not expire. Of the net non-U.S. net operating loss carryforwards, \$1.04 billion expire in the years 2028 through 2045, and the remainder do not expire.

At December 31, 2025, the company had foreign tax credit carryforwards of \$554 million and deferred interest carryforwards of \$3.36 billion. The foreign tax credit carryforwards will expire in the years 2026 through 2034. Of the deferred interest carryforwards, \$301 million expire in the years 2026 through 2035 and the remainder do not expire.

A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company's undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company's intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

*Unrecognized Tax Benefits*

As of December 31, 2025, the company had \$0.42 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.

A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:

(In millions)	2025	2024	2023
<b>Beginning balance</b>	\$ 525	\$ 540	\$ 572
Additions due to acquisitions	—	19	—
Additions for tax positions of current year	25	91	4
Additions for tax positions of prior years	—	244	34
Reductions for tax positions of prior years	(34)	(182)	(43)
Closure of tax years	(19)	—	(6)
Settlements	(78)	(187)	(21)
<b>Ending balance</b>	<u>\$ 419</u>	<u>\$ 525</u>	<u>\$ 540</u>

Substantially all of the unrecognized tax benefits are classified as long-term liabilities.

During 2025, the company's tax benefits decreased by \$103 million as a result of uncertain tax positions relating to foreign tax positions, which included \$72 million of reserve and associated interest from the settlement of international tax audits and decreased \$3 million relating to U.S. federal and state tax positions.

During 2024, the company's unrecognized tax benefits decreased by \$99 million as a result of uncertain tax positions relating to foreign tax positions which included \$240 million of reserve and associated interest from the settlement of international tax audits for tax years 2009 through 2016 and increased \$84 million relating to U.S. federal and state tax positions.

During 2023, the company's unrecognized tax benefits decreased by \$12 million as a result of uncertain tax positions relating to foreign tax positions and decreased \$19 million relating to U.S. federal and state tax positions.

The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2025 and 2024 was \$39 million and \$75 million, respectively.

The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted. The OBBBA includes a broad range of provisions, such as the permanent extension of certain otherwise expiring provisions, modifications to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions. While most of the changes made by the OBBBA are effective in future tax years, some of its provisions are effective in 2025. There was no material impact on the company's effective tax rate. We will continue to monitor and assess the impact of OBBBA on our consolidated financial statements.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**Note 8. Comprehensive Income/(Loss) and Shareholders' Equity**

*Comprehensive Income/(Loss)*

Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:

(In millions)	Cumulative translation adjustment	Unrealized gains/(losses) on hedging instruments	Pension and other postretirement benefit liability adjustment	Total
<b>Balance at December 31, 2024</b>	\$ (2,409)	\$ (25)	\$ (263)	\$ (2,697)
Other comprehensive income/(loss) before reclassifications	223	—	13	236
Amounts reclassified from accumulated other comprehensive income/(loss)	5	3	5	13
Net other comprehensive income/(loss)	228	3	18	249
<b>Balance at December 31, 2025</b>	<u>\$ (2,181)</u>	<u>\$ (23)</u>	<u>\$ (245)</u>	<u>\$ (2,448)</u>

*Shareholders' Equity*

At December 31, 2025, the company had reserved 36 million unissued shares of its common stock for possible issuance under stock-based compensation plans. Early in the first quarter of 2026, the company repurchased \$3.00 billion of the company's common stock (4.9 million shares).

**Note 9. Supplemental Cash Flow Information**

Supplemental cash flow information is as follows:

(In millions)	2025	2024	2023
<b>Cash paid for:</b>			
Interest	\$ 1,612	\$ 1,570	\$ 1,385
Income taxes, net of refunds received			
Federal	408		
U.S. state and local	184		
Foreign			
United Kingdom	207		
Netherlands	179		
Germany	97		
China	97		
Other	603		
Total income taxes, net of refunds received	1,776	1,834	1,482
<b>Non-cash investing and financing activities</b>			
Acquired but unpaid property, plant and equipment	\$ 264	\$ 303	\$ 296
Finance lease ROU assets obtained in exchange for new finance lease liabilities	21	—	2
Declared but unpaid dividends	164	150	137
Issuance of stock upon vesting of restricted stock units	164	186	234
Excise tax from stock repurchases	24	26	28

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:

(In millions)	December 31, 2025	December 31, 2024
Cash and cash equivalents	\$ 9,852	\$ 4,009
Restricted cash included in other current assets	5	10
Restricted cash included in other assets	22	21
Cash, cash equivalents and restricted cash	<u>\$ 9,879</u>	<u>\$ 4,040</u>

Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees, pension related deposits, and incoming cash in China awaiting government administrative clearance.

**Note 10. Derivatives**

*Derivative Contracts*

The following table provides the aggregate notional value of outstanding derivative contracts.

(In millions)	December 31, 2025	December 31, 2024
<b>Notional amount</b>		
Cross-currency interest rate swaps designated as net investment hedge - euro	\$ 1,000	\$ 1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen	4,650	4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc	5,000	2,500
Currency exchange contracts	2,248	1,588

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.

(In millions)	Fair value – assets		Fair value – liabilities	
	December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
<b>Derivatives designated as hedging instruments</b>				
Cross-currency interest rate swaps	\$ 684	\$ 458	\$ 504	\$ 57
<b>Derivatives not designated as hedging instruments</b>				
Currency exchange contracts	2	2	2	2
<b>Total derivatives</b>	<u>\$ 685</u>	<u>\$ 460</u>	<u>\$ 506</u>	<u>\$ 59</u>

The following table provides information on the company's derivative positions subject to master netting arrangements, presented on a net basis, had the company elected to offset the asset and liability balances of its positions in the consolidated balance sheets:

(In millions)	Fair value – assets		Fair value – liabilities	
	December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
Gross amounts recognized in the consolidated balance sheets	\$ 685	\$ 460	\$ 506	\$ 59
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheets	(319)	(56)	(319)	(56)
<b>Total derivatives, net</b>	<u>\$ 366</u>	<u>\$ 404</u>	<u>\$ 187</u>	<u>\$ 3</u>

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

(In millions)	Gain/(loss) recognized		
	2025	2024	2023
<b>Derivatives designated as cash flow hedges</b>			
Interest rate swaps			
Amount reclassified from accumulated other comprehensive income/(loss) to interest expense	\$ (3)	\$ (3)	\$ (4)
Amount reclassified from accumulated other comprehensive items to other income/(loss)	—	—	(3)
<b>Financial instruments designated as net investment hedges</b>			
Foreign currency-denominated debt and other payables			
Included in cumulative translation adjustment within other comprehensive income/(loss)	(1,252)	686	(356)
Cross-currency interest rate swaps			
Included in cumulative translation adjustment within other comprehensive income/(loss)	(222)	682	(222)
Included in interest expense	287	267	120
<b>Derivatives not designated as hedging instruments</b>			
Currency exchange contracts			
Included in cost of product revenues	(7)	21	1
Included in other income/(expense)	66	(16)	(29)

See Note 1 and Note 3 for additional information on the company's risk management objectives and strategies.

**Note 11. Business Segment and Geographical Information**

The company's financial performance is reported in four segments. A description of each segment follows.

**Life Sciences Solutions:** provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

**Analytical Instruments:** provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.

**Specialty Diagnostics:** offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner.

**Laboratory Products and Biopharma Services:** offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing.

The company's management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, restructuring and other costs, and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments' core operating results and facilitates comparison of performance for determining compensation.

The company's chairman, president and chief executive officer is its chief operating decision maker (CODM). The CODM uses total revenues and segment income predominantly in the strategic plan, annual operating plan and quarterly business review processes. During these processes, the CODM considers budget-to-actual variances to evaluate both internal (e.g., changes in selling prices, strategic growth investments, productivity, business mix, newly acquired/divested businesses, etc.) and external (e.g., inflation, foreign currency, etc.) events and conditions.

The company generally accounts for intersegment revenues at current market prices.

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Other segment items included in the below tables consist of stock-based compensation and other incentive compensation expenses, allocations of corporate and certain overhead expenses, as well as elimination of intersegment and intrasegment profits, all of which are included in the company's measurement of segment income, but not regularly provided to the CODM at the segment level. Cost of revenues adjustments consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative adjustments consist of certain transaction-related third-party costs (including reimbursement thereof), charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation. Restructuring and other costs include charges arising from headcount reductions and facility consolidations such as severance and abandoned lease expense and gains and losses on the sale of real estate and product lines, as well as impacts of pre-acquisition matters, net charges for significant litigation-related matters, and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability (Note 6).

Prior period segment expense amounts have been recast to reflect the method for allocating expenses to segments in the current period.

Segment assets included in the below tables consist of third-party accounts receivable and inventories, which are regularly provided to the CODM.

Geographical revenues are attributed to countries based on customer location. Long-lived assets by geographical location includes property, plant and equipment, net, and operating lease ROU assets.

*Business Segment Information*

2025

(In millions)	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Total
<b>Revenues</b>					
Revenues from external customers	\$ 8,781	\$ 7,353	\$ 4,604	\$ 23,818	\$ 44,556
Intersegment revenues	1,593	201	72	167	2,033
	10,374	7,554	4,676	23,984	46,589
Elimination of intersegment revenues					(2,033)
Consolidated revenues				\$	\$ 44,556
<b>Segment Income</b>					
Cost of revenues	3,929	3,850	2,718	18,609	
Selling, general, and administrative expenses	1,912	1,244	708	2,392	
Research and development expenses	553	573	178	56	
Other segment items	213	151	(183)	(422)	
Segment income	3,768	1,736	1,256	3,350	10,109
<b>Unallocated amounts</b>					
Cost of revenues adjustments					(64)
Selling, general and administrative expenses adjustments					(207)
Restructuring and other costs					(362)
Amortization of acquisition-related intangible assets					(1,730)
Interest income					993
Interest expense					(1,419)
Other income/(expense)					(12)
Consolidated income before income taxes				\$	\$ 7,308

(In millions)	Unallocated amounts	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Consolidated
Segment assets	\$ 95,919	\$ 3,446	\$ 3,170	\$ 1,323	\$ 6,485	\$ 110,343
Purchases of property, plant and equipment	116	152	124	128	1,005	1,525
Depreciation of property, plant and equipment	—	251	104	91	604	1,050

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

2024

(In millions)	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Total
<b>Revenues</b>					
Revenues from external customers	\$ 8,160	\$ 7,267	\$ 4,449	\$ 23,002	\$ 42,879
Intersegment revenues	1,471	196	63	155	1,885
	9,631	7,463	4,512	23,157	44,764
Elimination of intersegment revenues					(1,885)
Consolidated revenues				\$	\$ 42,879
<b>Segment Income</b>					
Cost of revenues	3,560	3,532	2,605	18,020	
Selling, general, and administrative expenses	1,797	1,250	732	2,356	
Research and development expenses	551	551	176	66	
Other segment items	221	174	(159)	(375)	
Segment income	3,503	1,955	1,159	3,090	9,707
<b>Unallocated amounts</b>					
Cost of revenues adjustments					(47)
Selling, general and administrative expenses adjustments					8
Restructuring and other costs					(379)
Amortization of acquisition-related intangible assets					(1,952)
Interest income					1,078
Interest expense					(1,390)
Other income/(expense)					12
Consolidated income before income taxes				\$	\$ 7,037

(In millions)	Unallocated amounts	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Consolidated
Segment assets	\$ 84,031	\$ 2,982	\$ 2,944	\$ 1,218	\$ 6,145	\$ 97,321
Purchases of property, plant and equipment	85	123	95	125	971	1,400
Depreciation of property, plant and equipment	—	230	103	104	721	1,156

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

2023

(In millions)	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Total
<b>Revenues</b>					
Revenues from external customers	\$ 8,545	\$ 7,101	\$ 4,324	\$ 22,888	\$ 42,857
Intersegment revenues	1,432	163	82	154	1,829
	9,977	7,263	4,405	23,041	44,686
Elimination of intersegment revenues					(1,829)
Consolidated revenues				\$	\$ 42,857
<b>Segment Income</b>					
Cost of revenues	4,078	3,467	2,584	17,978	
Selling, general, and administrative expenses	1,766	1,244	716	2,276	
Research and development expenses	558	528	156	68	
Other segment items	155	116	(174)	(638)	
Segment income	3,420	1,908	1,124	3,358	9,810
<b>Unallocated amounts</b>					
Cost of revenues adjustments					(95)
Selling, general and administrative expenses adjustments					(59)
Restructuring and other costs					(459)
Amortization of acquisition-related intangible assets					(2,338)
Interest income					879
Interest expense					(1,375)
Other income/(expense)					(65)
Consolidated income before income taxes				\$	\$ 6,298

(In millions)	Unallocated amounts	Life Sciences Solutions	Analytical Instruments	Specialty Diagnostics	Laboratory Products and Biopharma Services	Consolidated
Segment assets	\$ 85,314	\$ 3,186	\$ 2,726	\$ 1,150	\$ 6,350	\$ 98,726
Purchases of property, plant and equipment	80	178	87	121	1,013	1,479
Depreciation of property, plant and equipment	—	220	93	86	669	1,068

*Geographical Information*

(In millions)	2025	2024	2023
<b>Revenues</b>			
United States	\$ 22,240	\$ 21,755	\$ 22,013
Other	22,316	21,124	20,844
Consolidated revenues	\$ 44,556	\$ 42,879	\$ 42,857
<b>Long-lived Assets</b>			
United States	\$ 6,547	\$ 6,245	\$ 6,352
Other	5,465	4,550	4,652
Consolidated long-lived assets	\$ 12,012	\$ 10,795	\$ 11,004

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**Note 12. Acquisitions**

*Acquisitions*

The company's acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company's existing commercial infrastructure to expand sales of the acquired businesses' products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies' results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

*Pending Acquisition*

The company has entered into an agreement to acquire Clario Holdings, Inc. for approximately \$8.875 billion in cash at the closing of the transaction, with an additional \$125 million in deferred consideration and up to \$400 million in contingent consideration to be payable following the closing. Clario is a leading provider of endpoint data solutions for clinical trials. The transaction, which is expected to be completed by the middle of 2026, is subject to customary closing conditions and regulatory approvals. Upon completion, Clario will become part of the Laboratory Products and Biopharma Services segment.

*2025*

On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment's bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this business combination is not expected to be tax deductible.

The components of the preliminary purchase price and net assets acquired are as follows:

(In millions)	Filtration and separation business
<b>Purchase price</b>	
Cash paid	\$ 3,944
Fair value of contingent consideration	(66)
Cash acquired	(9)
	<u>\$ 3,870</u>
<b>Net assets acquired</b>	
Property, plant and equipment	\$ 454
Definite-lived intangible assets	
Customer relationships	1,115
Product technology	386
Trade names	51
Goodwill	2,101
Net other assets/(liabilities)	141
Deferred tax assets (liabilities)	(377)
	<u>\$ 3,870</u>

The preliminary allocation of the purchase price for the acquisition of Solventum's Filtration and Separation business is based on the estimates of the fair value of the purchase price and net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, real and personal property, inventory and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

In addition, in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging facility to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2025 are 18 years for customer relationships, 19 years for product technology, and 15 years for trade names. The weighted-average amortization period for all definite-lived intangible assets acquired in 2025 is 18 years.

*2024*

On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation proteomics solutions. The acquisition enhances the segment's capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy opportunities. The goodwill recorded as a result of this business combination is not tax deductible.

The components of the purchase price and net assets acquired are as follows:

(In millions)	Olink
<b>Purchase price</b>	
Cash paid	\$ 3,215
Purchase price payable	28
Cash acquired	(97)
	<u>\$ 3,146</u>
<b>Net assets acquired</b>	
Definite-lived intangible assets	
Customer relationships	\$ 708
Product technology	207
Trade names	97
Goodwill	2,301
Net other assets/(liabilities)	9
Deferred tax assets/(liabilities)	(176)
	<u>\$ 3,146</u>

The weighted-average amortization periods for definite-lived intangible assets acquired in 2024 are 19 years for customer relationships, 15 years for product technology, and 15 years for trade names. The weighted-average amortization period for definite-lived intangible assets acquired in 2024 is 18 years.

*2023*

On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment's portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible.

On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment's portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The components of the purchase price and net assets acquired are as follows:

(In millions)	The Binding Site	CorEvitas
<b>Purchase price</b>		
Cash paid	\$ 2,412	\$ 730
Debt settled	307	184
Cash acquired	(20)	(4)
	<u>\$ 2,699</u>	<u>\$ 910</u>
<b>Net assets acquired</b>		
Definite-lived intangible assets		
Customer relationships	\$ 868	\$ 260
Product technology	162	47
Trade names	42	—
Backlog	—	46
Goodwill	1,741	627
Net tangible assets	174	(2)
Deferred tax assets (liabilities)	(288)	(68)
	<u>\$ 2,699</u>	<u>\$ 910</u>

In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for trade names, and 13 years for backlog. The weighted-average amortization period for definite-lived intangible assets acquired in 2023 is 17 years.

**Note 13. Leases**

As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year.

The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2028, 2029, and 2030. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 3). The aggregate maximum guarantee under these three lease arrangements is \$147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2025, but exclude any amounts for residual value guarantees.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

As a lessee, the consolidated financial statements include the following relating to operating leases:

(Dollars in millions)	2025	2024	2023
<b>Statement of income</b>			
Operating lease costs	\$ 381	\$ 353	\$ 355
Variable lease costs	116	115	115
<b>Statement of cash flows</b>			
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities	\$ 374	\$ 327	\$ 410
Operating lease ROU assets obtained in exchange for new operating lease liabilities	197	262	234
<b>Balance sheet</b>			
ROU assets - included in other assets	\$ 1,447	\$ 1,489	
Operating lease liabilities - included in other accrued expenses	275	261	
Operating lease liabilities - included in other long-term liabilities	1,195	1,239	
<b>Weighted average at end of year</b>			
Remaining operating lease term	7.9 years	8.6 years	
Discount rate	4.7 %	4.6 %	

Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 3 for additional information relating to finance leases.

As of December 31, 2025, future payments of operating lease liabilities are as follows:

(In millions)		
2026	\$	331
2027		283
2028		237
2029		174
2030		142
2031 and thereafter		652
Total lease payments		1,819
Less: imputed interest		349
Total operating lease liability	\$	1,470

As a lessor, operating leases, sales-type leases and direct financing leases are not material.

**Note 14. Pension and Other Postretirement Benefit Plans**

*401(k) Savings Plan and Other Defined Contribution Plans*

The company's 401(k) savings and other defined contribution plans cover the majority of the company's eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both employees and the company. Company contributions are based on the level of employee contributions and formulas determined by the company. In 2025, 2024, and 2023, the company charged to expense \$472 million, \$443 million, and \$468 million, respectively, related to its defined contribution plans.

*Defined Benefit Pension Plans*

Employees of a number of the company's non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company's postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Contributions to the plans included in the following table are estimated at between \$45 million and \$50 million for 2026.

The following table provides a reconciliation of benefit obligations and plan assets of the company's domestic and non-U.S. pension plans:

(In millions)	Domestic pension benefits		Non-U.S. pension benefits	
	2025	2024	2025	2024
<b>Accumulated benefit obligation</b>	\$ 946	\$ 937	\$ 1,176	\$ 1,079
<b>Change in projected benefit obligations</b>				
Projected benefit obligation at beginning of year	\$ 937	\$ 1,005	\$ 1,135	\$ 1,221
Acquisitions	2	—	46	—
Service costs	—	—	33	28
Interest costs	47	46	41	40
Settlements	—	—	(69)	(29)
Plan participants' contributions	—	—	10	10
Actuarial (gains)/losses	42	(32)	(59)	(59)
Benefits paid	(83)	(81)	(23)	(26)
Currency translation and other	—	—	121	(49)
Projected benefit obligation at end of year	\$ 946	\$ 937	\$ 1,236	\$ 1,135
<b>Change in fair value of plan assets</b>				
Fair value of plan assets at beginning of year	\$ 895	\$ 947	\$ 867	\$ 944
Acquisitions	2	—	22	—
Actual return on plan assets	84	22	16	(37)
Employer contributions	5	7	40	37
Settlements	—	—	(69)	(29)
Plan participants' contributions	—	—	10	10
Benefits paid	(83)	(81)	(23)	(26)
Currency translation and other	—	—	88	(32)
Fair value of plan assets at end of year	\$ 903	\$ 895	\$ 952	\$ 867
<b>Funded status</b>	\$ (43)	\$ (43)	\$ (284)	\$ (268)
<b>Amounts recognized in balance sheet</b>				
Noncurrent assets	\$ 3	\$ 5	\$ 71	\$ 57
Current liability	(5)	(5)	(13)	(12)
Noncurrent liabilities	(40)	(42)	(342)	(313)
Net amount recognized	\$ (43)	\$ (43)	\$ (284)	\$ (268)
<b>Amounts recognized in accumulated other comprehensive income/(loss)</b>				
Net actuarial (gain)/loss	\$ 234	\$ 218	\$ 118	\$ 156
Prior service (credits)/cost	—	—	(9)	(7)
Net amount recognized	\$ 234	\$ 218	\$ 109	\$ 149

Actuarial (gains)/losses experienced in 2025 for domestic pension plans were driven by differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns, as well as decreases in the weighted average discount rates used to determine the projected benefit obligation when compared to 2024. For non-U.S. pension plans, actuarial (gains)/losses experienced in 2025 were primarily driven by increases in the weighted average discount rates used to determine the projected benefit obligation when compared to 2024.

Actuarial (gains)/losses experienced in 2024 for both domestic and non-U.S. pension plans were primarily driven by increases in the weighted average discount rates used to determine the projected benefit obligation when compared to 2023.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2025 and 2024 and are as follows:

	Domestic pension benefits		Non-U.S. pension benefits	
	2025	2024	2025	2024
<b>Weighted average assumptions used to determine projected benefit obligations</b>				
Discount rate for determining benefit obligation	5.20 %	5.48 %	4.05 %	3.74 %
Interest crediting rate for cash balance plans	5.00 %	5.39 %	2.52 %	2.28 %
Average rate of increase in employee compensation	N/A	N/A	2.52 %	2.58 %

The actuarial assumptions used to compute the net periodic pension benefit cost/(income) are based upon information available as of the beginning of the year, as presented in the following table:

	Domestic pension benefits			Non-U.S. pension benefits		
	2025	2024	2023	2025	2024	2023
<b>Weighted average assumptions used to determine net benefit cost/(income)</b>						
Discount rate - service cost	N/A	N/A	N/A	2.77 %	3.00 %	3.62 %
Discount rate - interest cost	5.49 %	4.82 %	5.01 %	3.62 %	3.48 %	3.95 %
Interest crediting rate for cash balance plans	5.39 %	4.76 %	4.96 %	2.28 %	2.06 %	2.19 %
Average rate of increase in employee compensation	N/A	N/A	N/A	2.58 %	2.64 %	2.77 %
Expected long-term rate of return on assets	6.50 %	6.00 %	6.25 %	4.52 %	4.28 %	4.33 %

The projected benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows:

(In millions)	Pension plans	
	2025	2024
<b>Pension plans with projected benefit obligations in excess of plan assets</b>		
Projected benefit obligation	\$ 850	\$ 727
Fair value of plan assets	449	376

The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows:

(In millions)	Pension plans	
	2025	2024
<b>Pension plans with accumulated benefit obligations in excess of plan assets</b>		
Accumulated benefit obligation	\$ 792	\$ 671
Fair value of plan assets	451	376

The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.

The net periodic pension benefit cost/(income) includes the following components:

(In millions)	Domestic pension benefits			Non-U.S. pension benefits		
	2025	2024	2023	2025	2024	2023
<b>Components of net benefit cost/(income)</b>						
Service cost	\$ —	\$ —	\$ —	\$ 33	\$ 28	\$ 26
Interest cost on benefit obligation	47	46	47	41	40	42
Expected return on plan assets	(59)	(56)	(59)	(37)	(36)	(37)
Amortization of actuarial net loss	—	—	—	4	4	2
Amortization of prior service cost/(benefit)	—	—	—	(1)	(1)	(1)
Settlement/curtailment loss/(gain)	—	—	—	7	2	1
Net periodic benefit cost/(income)	<u>\$ (11)</u>	<u>\$ (10)</u>	<u>\$ (12)</u>	<u>\$ 47</u>	<u>\$ 38</u>	<u>\$ 33</u>

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Expected benefit payments are estimated using the same assumptions used in determining the company's benefit obligation at December 31, 2025. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows:

(In millions)	Domestic pension benefits		Non-U.S. pension benefits	
<b>Expected benefit payments</b>				
2026	\$	84	\$	61
2027		83		61
2028		83		67
2029		81		72
2030		80		71
2031-2035		370		394

*Domestic Pension Plan Assets*

The company's overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.

*Non-U.S. Pension Plan Assets*

The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments, real estate funds and derivative funds with the target asset allocations ranging from approximately 0% - 10% for equity funds, 30% - 75% for fixed income funds, 0% - 45% for multi-asset funds, 0% - 4% for alternative investments, 0% - 2% for real estate funds and 0% - 35% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The fair values of the company's plan assets at December 31, 2025 and 2024, by asset category are as follows:

(In millions)	December 31, 2025	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Not subject to leveling (a)
<b>Domestic pension plan assets</b>					
U.S. equity funds	\$ 120	\$ —	\$ —	\$ —	\$ 120
International equity funds	71	—	—	—	71
Fixed income funds	693	—	—	—	693
Money market funds	20	—	—	—	20
Total domestic pension plans	<u>\$ 903</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 903</u>
<b>Non-U.S. pension plan assets</b>					
Equity funds	\$ 10	\$ —	\$ —	\$ —	\$ 10
Fixed income funds	325	9	—	—	316
Multi-asset funds	100	—	—	—	100
Derivative funds	133	—	—	—	133
Insurance contracts	378	—	378	—	—
Cash / money market funds	6	4	—	—	2
Total non-U.S. pension plans	<u>\$ 952</u>	<u>\$ 13</u>	<u>\$ 378</u>	<u>\$ —</u>	<u>\$ 561</u>

(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

(In millions)	December 31, 2024	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Not subject to leveling (a)
<b>Domestic pension plan assets</b>					
U.S. equity funds	\$ 91	\$ —	\$ —	\$ —	\$ 91
International equity funds	89	—	—	—	89
Fixed income funds	692	—	—	—	692
Money market funds	23	—	—	—	23
Total domestic pension plans	<u>\$ 895</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 895</u>
<b>Non-U.S. pension plan assets</b>					
Equity funds	\$ 7	\$ —	\$ —	\$ —	\$ 7
Fixed income funds	288	7	—	—	281
Multi-asset funds	69	—	—	—	69
Derivative funds	169	—	—	—	169
Insurance contracts	325	—	325	—	—
Cash / money market funds	9	4	—	—	5
Total non-U.S. pension plans	<u>\$ 867</u>	<u>\$ 10</u>	<u>\$ 325</u>	<u>\$ —</u>	<u>\$ 532</u>

(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

The tables above present the fair value of the company's plan assets in accordance with the fair value hierarchy (Note 1). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.

**THERMO FISHER SCIENTIFIC INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**Note 15. Stock-based Compensation Expense**

The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options, or performance-based shares, as determined by the compensation committee of the company's Board of Directors or, for certain non-officer grants, by the company's employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder's employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment).

*Stock Options*

The weighted average assumptions used in the Black-Scholes option pricing model are as follows:

	2025	2024	2023
Expected stock price volatility	25 %	25 %	25 %
Risk free interest rate	4.4 %	4.3 %	4.2 %
Expected life of options (years)	5.9	5.0	4.7
Expected annual dividend	0.3 %	0.3 %	0.3 %
Weighted average per share grant-date fair values of options granted	\$ 166.69	\$ 166.92	\$ 159.32

The total intrinsic value of options exercised during the same periods was \$247 million, \$395 million and \$320 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option.

A summary of the company's option activity for the year ended December 31, 2025 is presented below:

	Shares (in millions)	Weighted average exercise price	Weighted average remaining contractual term (in years)	Aggregate intrinsic value (in millions)
<b>Outstanding at December 31, 2024</b>	4.5	\$ 465.80		
Granted	0.9	507.42		
Exercised	(0.8)	267.66		
Canceled/expired	(0.3)	558.52		
<b>Outstanding at December 31, 2025</b>	4.3	\$ 507.59	5.0	\$ 336
<b>Vested and unvested expected to vest at December 31, 2025</b>	4.2	\$ 507.05	4.9	\$ 327
<b>Exercisable at December 31, 2025</b>	2.3	\$ 488.09	3.0	\$ 237

As of December 31, 2025, there was \$180 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2029 with a weighted average amortization period of 2.2 years.

*Restricted Share/Unit Awards*

A summary of the company's restricted unit activity for the year ended December 31, 2025 is presented below:

	Units (in millions)	Weighted average grant-date fair value
<b>Unvested at December 31, 2024</b>	0.6	\$ 551.81
Granted	0.6	480.35
Performance adjustments	0.1	560.12
Vested	(0.3)	546.98
Forfeited	(0.1)	547.42
<b>Unvested at December 31, 2025</b>	0.8	\$ 505.62

**THERMO FISHER SCIENTIFIC INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The weighted average per share grant-date fair values of restricted units granted during 2024 and 2023 were \$556.83 and \$545.73, respectively. The total fair value of shares vested during 2025, 2024 and 2023 was \$178 million, \$165 million and \$207 million, respectively.

As of December 31, 2025, there was \$278 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2030 with a weighted average amortization period of 2.4 years.

*Employee Stock Purchase Plans*

Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee's qualifying gross wages. The company issued 0.2 million, 0.1 million and 0.1 million shares, respectively, of its common stock in 2025, 2024 and 2023 under the employee stock purchase plan.

**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

Not applicable.

**Item 9A. Controls and Procedures**

*Management’s Evaluation of Disclosure Controls and Procedures*

The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.

*Changes in Internal Control over Financial Reporting*

There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2025, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.

*Management’s Annual Report on Internal Control Over Financial Reporting*

The company’s management, including the company’s chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The company’s management conducted an assessment of the effectiveness of the company’s internal control over financial reporting as of December 31, 2025 based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, the company’s management concluded that, as of December 31, 2025, the company’s internal control over financial reporting was effective. Management’s assessment of the effectiveness of the company’s internal control over financial reporting as of December 31, 2025, excluded our filtration and separation business, which was acquired by the company from Solventum Corporation in September 2025 in a purchase business combination. Total assets (excluding goodwill and acquisition-related intangible assets) and total revenues of the company’s filtration and separation business represented approximately 1% and 1%, respectively, of the consolidated amounts as of and for the year ended December 31, 2025. Based upon Securities and Exchange Commission staff guidance, companies are allowed to exclude certain acquisitions from their assessments of internal control over financial reporting during the first year of an acquisition while integrating the acquired companies.

The company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the company’s internal control over financial reporting as of December 31, 2025, as stated in their report that appears on page 30 of this Annual Report on Form 10-K.

**Item 9B. Other Information**

*Director and Officer Trading Arrangements*

During the three months ended December 31, 2025, no director or executive officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below:

Name and Title	Action	Plan Type	Date of adoption of Rule 10b5-1 trading plan	Scheduled expiration of Rule 10b5-1 trading plan	Aggregate number of securities to be purchased or sold
Marc N. Casper, CEO, President and Chairman	Adoption	10b5-1	11/11/2025	6/9/2027	137,496
Stephen Williamson, Senior Vice President and CFO	Adoption	10b5-1	11/30/2025	3/4/2026	6,000
Michael D. Shafer, Executive Vice President	Adoption	10b5-1	12/11/2025	12/16/2026	28,501

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

Not applicable.

# THERMO FISHER SCIENTIFIC INC.

## PART III

### Item 10. Directors, Executive Officers and Corporate Governance

The information with respect to directors required by this Item will be contained in our Proxy Statement to be filed with the SEC not later than 120 days after the close of business of the fiscal year including under “Corporate governance,” and is incorporated in this report by reference.

The information with respect to executive officers required by this Item is included in [Item 1 of Part I](#) of this report.

The information with respect to our insider trading arrangements and policies required by this Item will be contained in our Proxy Statement under “Executive compensation” and is incorporated in this report by reference.

The other information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.

### Item 11. Executive Compensation

The information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and “Executive compensation,” and is incorporated in this report by reference.

### Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item will be contained in our Proxy Statement including under “Information about stock ownership,” and is incorporated in this report by reference.

### Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and is incorporated in this report by reference.

### Item 14. Principal Accountant Fees and Services

The information required by this Item will be contained in our Proxy Statement including under “Audit matters,” and is incorporated in this report by reference.

## PART IV

### Item 15. Exhibits and Financial Statement Schedules

(a) The following documents are filed as part of this report:

- (1) Consolidated Financial Statements (see Index on page 29 of this report)
- (2) All schedules are omitted because they are not applicable or not required, or because the required information is included either in the consolidated financial statements or in the notes thereto.

(b) Exhibits

Exhibit Number	Description of Exhibit
3.1	<a href="#">Amended and Restated Certificate of Incorporation of the Registrant</a> (filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2005 [File No. 1-8002] and incorporated in this document by reference).
3.2	<a href="#">Amendment to Thermo Fisher Scientific Inc.’s Third Amended and Restated Certificate of Incorporation</a> (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 14, 2006 [File No. 1-8002] and incorporated in this document by reference).
3.3	<a href="#">Certificate of Elimination of the Series B Junior Participating Preferred Stock of the Company, dated November 13, 2015</a> (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed November 16, 2015 [File No. 1-8002] and incorporated in this document by reference).
3.4	<a href="#">Amended and Restated By-Laws of the Registrant, as amended and effective as of February 19, 2025</a> (filed as Exhibit 3.4 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 [File No. 1-8002] and incorporated in this document by reference).
	<i>The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.</i>
4.1	<a href="#">Indenture dated as of November 20, 2009 between the Company and The Bank of New York Mellon Trust Company, N.A.</a> (filed as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in this document by reference).

**THERMO FISHER SCIENTIFIC INC.**

Exhibit Number	Description of Exhibit
4.2	<a href="#">Sixth Supplemental Indenture, dated as of December 11, 2013, between the Company and The Bank of New York Mellon Trust Company, N.A.</a> (filed as Exhibit 99.2 to the Registrant's Current Report on Form 8-K filed December 11, 2013 [File No. 1-8002] and incorporated in this document by reference).
4.3	<a href="#">Eighth Supplemental Indenture, dated as of November 24, 2014, among the Company, The Bank of New York Mellon Trust Company, N.A., as trustee, and The Bank of New York Mellon, London Branch, as paying agent</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed November 24, 2014 [File No. 1-8002] and incorporated in this document by reference).
4.4	<a href="#">Thirteenth Supplemental Indenture, dated as of September 12, 2016, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed September 12, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.5	<a href="#">Fifteenth Supplemental Indenture, dated as of March 16, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed March 16, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.6	<a href="#">Sixteenth Supplemental Indenture, dated as of July 24, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed July 24, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.7	<a href="#">Seventeenth Supplemental Indenture, dated as of August 14, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed August 14, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.8	<a href="#">Eighteenth Supplemental Indenture, dated as of September 30, 2019, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed September 30, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.9	<a href="#">Nineteenth Supplemental Indenture, dated as of October 8, 2019, between the Company, and the Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed October 8, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.10	<a href="#">Twenty-First Supplemental Indenture, dated as of April 2, 2020, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed April 2, 2020 [File No. 1-8002] and incorporated in this document by reference).
4.11	<a href="#">Twenty-Second Supplemental Indenture, dated as of August 23, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed August 23, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.12	<a href="#">Twenty-Fourth Supplemental Indenture, dated as of October 20, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed October 20, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.13	<a href="#">Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.14	<a href="#">Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.3 to the Registrant's Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this document by reference).
4.15	<a href="#">Twenty-Seventh Supplemental Indenture, dated as of August 10, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed August 10, 2023 [File No. 1-8002] and incorporated in this document by reference).
4.16	<a href="#">Twenty-Eighth Supplemental Indenture, dated as of December 5, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed December 5, 2023 [File No. 1-8002] and incorporated in this document by reference).
4.17	<a href="#">Twenty-Ninth Supplemental Indenture, dated as of October 7, 2025, between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed October 7, 2025 [File No. 1-8002] and incorporated in this document by reference).
4.18	<a href="#">Indenture, dated as of August 9, 2016, among Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed August 9, 2016 [File No. 1-8002] and incorporated in this document by reference).
4.19	<a href="#">Third Supplemental Indenture, dated as of October 18, 2021, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed October 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.20	<a href="#">Fourth Supplemental Indenture, dated as of November 18, 2021, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed November 18, 2021 [File No. 1-8002] and incorporated in this document by reference).
4.21	<a href="#">Fifth Supplemental Indenture, dated as of December 1, 2025, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee</a> (filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed December 1, 2025 [File No. 1-8002] and incorporated in this document by reference).

**THERMO FISHER SCIENTIFIC INC.**

Exhibit Number	Description of Exhibit
4.22	<a href="#">Description of the Registrant's Securities</a> (filed as Exhibit 4.19 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).
10.1	<a href="#">Credit Agreement, dated January 7, 2022, among Thermo Fisher Scientific Inc., certain Subsidiaries of Thermo Fisher Scientific Inc. from time to time party thereto, Bank of America, N.A., as Administrative Agent and each lender from time to time party thereto</a> (filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed January 7, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.2	Form of Amended and Restated Indemnification Agreement between the Registrant and its directors and officers (filed as Exhibit 10.2 to the <a href="#">Registrant's Registration Statement on Form S-4</a> [Reg. No. 333-90661] and incorporated in this document by reference).*
10.3	<a href="#">Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers, effective as of January 1, 2009</a> (filed as Exhibit 10.25 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.4	<a href="#">Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers</a> (filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.5	<a href="#">Noncompetition Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009</a> (filed as Exhibit 10.7 to the Registrant's Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.6	<a href="#">Thermo Fisher Scientific Inc. Executive Severance Policy</a> (filed as Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.7	<a href="#">2009 Restatement of Executive Severance Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009</a> (filed as Exhibit 10.5 to the Registrant's Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.8	<a href="#">Amendment No. 1 to 2009 Restatement of Executive Severance Agreement, dated February 25, 2010, between the Registrant and Marc N. Casper</a> (filed as Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed February 25, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.9	<a href="#">Amendment No. 2 to 2009 Restatement of Executive Severance Agreement, dated November 30, 2010, between the Registrant and Marc N. Casper</a> (filed as Exhibit 10.55 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.10	<a href="#">Form of Executive Change in Control Retention Agreement for Officers (other than Marc N. Casper)</a> (filed as Exhibit 10.7 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.11	<a href="#">Executive Change In Control Retention Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009</a> (filed as Exhibit 10.6 to the Registrant's Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.12	<a href="#">Amendment No. 1 to Executive Change In Control Retention Agreement, dated November 30, 2010, between Marc N. Casper and the Registrant</a> (filed as Exhibit 10.56 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.13	<a href="#">Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant</a> (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by reference).*
10.14	<a href="#">Summary of Thermo Fisher Scientific Inc. Annual Non-Management Director Compensation</a> (filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed February 24, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.15	Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.12 to Fisher Scientific International Inc.'s Annual Report on Form 10-K for the year ended December 31, 1992 [File No. 1-10920] and incorporated in this document by reference).*
10.16	<a href="#">First Amendment to the Fisher Scientific International Inc. Retirement Plan for Non-Employee Directors</a> (filed as Exhibit 10.04 to Fisher Scientific International Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 [File No. 1-10920] and incorporated in this document by reference).*
10.17	<a href="#">Amendment to Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc.</a> (filed as Exhibit 10.02 to Fisher Scientific International Inc.'s Current Report on Form 8-K filed March 7, 2006 [File No. 1-10920] and incorporated in this document by reference).*
10.18	<a href="#">Thermo Fisher Scientific Inc. Deferred Compensation Plan for Directors of the Registrant, as amended and restated effective February 21, 2024</a> (filed as Exhibit 10.1 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.19	<a href="#">Thermo Electron Corporation Deferred Compensation Plan, effective November 1, 2001</a> (filed as Exhibit 10.13 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 29, 2001 [File No. 1-8002] and incorporated in this document by reference).*
10.20	<a href="#">Thermo Fisher Scientific Inc. Amended and Restated 2005 Deferred Compensation Plan, effective January 1, 2020</a> (filed as Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 27, 2020 [File No. 1-8002] and incorporated in this document by reference).*

**THERMO FISHER SCIENTIFIC INC.**

Exhibit Number	Description of Exhibit
10.21	<a href="#">Thermo Fisher Scientific Inc. Deferred Compensation Plan, as amended and restated January 1, 2024</a> (filed as Exhibit 10.49 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.22	<a href="#">Patheon N.V. 2016 Omnibus Incentive Plan</a> (filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Patheon N.V. on July 26, 2016 [File No. 001-37837] and incorporated in this document by reference).*
10.23	<a href="#">Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated March 7, 2017</a> (filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.24	<a href="#">Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated August 23, 2017</a> (filed as Exhibit 4.6 to the Registrant's Registration Statement on Form S-8 filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.25	<a href="#">PPD, Inc. 2020 Omnibus Incentive Plan</a> (filed as Exhibit 10.38 to PPD Inc.'s Form S-1/A filed January 27, 2020 [File No. 333-235860] and incorporated in this document by reference).*
10.26	<a href="#">Thermo Fisher Scientific Inc. Amended and Restated 2013 Stock Incentive Plan</a> (filed as Exhibit 99.1 to the Registrant's Form S-8 filed on May 24, 2023 [File No. 333-272173] and incorporated in this document by reference).*
10.27	<a href="#">Form of Thermo Fisher Scientific Inc.'s Nonstatutory Stock Option Agreement for Officers</a> (filed as Exhibit 10.44 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2016 [File No. 1-8002] and incorporated in this document by reference).*
10.28	<a href="#">Form of Thermo Fisher Scientific Inc.'s Nonstatutory Stock Option Agreement for Officers effective as of February 25, 2020</a> (filed as Exhibit 10.47 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.29	<a href="#">Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020</a> (filed as Exhibit 10.50 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.30	<a href="#">Amendment to Nonstatutory Stock Option Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper</a> (filed as Exhibit 10.45 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.31	<a href="#">Form of Thermo Fisher Scientific Inc.'s Nonstatutory Stock Option Agreement effective as of February 22, 2023</a> (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.32	<a href="#">Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 22, 2023</a> (filed as Exhibit 10.6 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.33	<a href="#">Form of Thermo Fisher Scientific Inc.'s Nonstatutory Stock Option Agreement effective as of February 21, 2024</a> (filed as Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
10.34	<a href="#">Form of Thermo Fisher Scientific Inc.'s Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper, effective as of February 21, 2024</a> (filed as Exhibit 10.6 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
10.35	<a href="#">Form of Thermo Fisher Scientific Inc.'s Restricted Stock Unit Agreement effective as of February 25, 2020</a> (filed as Exhibit 10.46 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.36	<a href="#">Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020</a> (filed as Exhibit 10.47 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.37	<a href="#">Amendment to Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper</a> (filed as Exhibit 10.46 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.38	<a href="#">Form of Thermo Fisher Scientific Inc.'s Restricted Stock Unit Agreement effective as of February 22, 2023</a> (filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.39	<a href="#">Form of Thermo Fisher Scientific Inc.'s Restricted Stock Unit Agreement for Directors</a> (filed as Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended July 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.40	<a href="#">Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 22, 2023</a> (filed as Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.41	<a href="#">Form of Thermo Fisher Scientific Inc.'s Restricted Stock Unit Agreement effective as of February 21, 2024</a> (filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
10.42	<a href="#">Form of Thermo Fisher Scientific Inc.'s Performance Restricted Stock Unit Agreement effective as of February 25, 2020</a> (filed as Exhibit 10.49 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*

**THERMO FISHER SCIENTIFIC INC.**

Exhibit Number	Description of Exhibit
10.43	<a href="#">Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020</a> (filed as Exhibit 10.48 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.44	<a href="#">Amendment to Performance Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper</a> (filed as Exhibit 10.47 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.45	<a href="#">Form of Thermo Fisher Scientific Inc.'s Performance Restricted Stock Unit Agreement effective as of February 22, 2023</a> (filed as Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.46	<a href="#">Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 22, 2023</a> (filed as Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.47	<a href="#">Form of Thermo Fisher Scientific Inc.'s Performance Restricted Stock Unit Agreement effective as of February 21, 2024</a> (filed as Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
10.48	<a href="#">Form of Thermo Fisher Scientific Inc.'s Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper, effective as of February 21, 2024</a> (filed as Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
10.49	<a href="#">Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of May 21, 2025</a> (filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed May 22, 2025 [File No. 1-8002] and incorporated in this document by reference).*
10.50	<a href="#">Form of Thermo Fisher Scientific Inc.'s Performance Nonstatutory Stock Option Agreement effective as of February 21, 2024</a> (filed as Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
10.51	<a href="#">Form of Thermo Fisher Scientific Inc.'s Performance Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper, effective as of February 21, 2024</a> (filed as Exhibit 10.7 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 30, 2024 [File No. 1-8002] and incorporated in this document by reference).*
19	<a href="#">Thermo Fisher Scientific Inc. Insider Trading Policy</a> (filed as Exhibit 19 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2024 [File No. 1-8002] and incorporated in this document by reference).
21	<a href="#">Subsidiaries of the Registrant.</a>
22	<a href="#">Subsidiary Issuer of Guaranteed Securities.</a>
23.1	<a href="#">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</a>
31.1	<a href="#">Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2	<a href="#">Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1	<a href="#">Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**</a>
32.2	<a href="#">Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**</a>
97	<a href="#">Clawback Policy</a> (filed as Exhibit 97 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 [File No. 1-8002] and incorporated in this document by reference).*
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Definition Linkbase Document.
101.LAB	XBRL Taxonomy Label Linkbase Document.
101.PRE	XBRL Taxonomy Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

\*Indicates management contract or compensatory plan, contract or arrangement.

\*\* Certification is not deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.

**Item 16. Form 10-K Summary**

None.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 26, 2026

THERMO FISHER SCIENTIFIC INC.

By: /s/ Marc N. Casper  
Marc N. Casper  
Chairman, President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated, as of February 26, 2026.

By: /s/ Marc N. Casper  
Marc N. Casper  
Chairman, President and Chief Executive Officer  
(Principal Executive Officer)

By: /s/ Jennifer M. Johnson  
Jennifer M. Johnson  
Director

By: /s/ Stephen Williamson  
Stephen Williamson  
Senior Vice President and Chief Financial Officer  
(Principal Financial Officer)

By: /s/ R. Alexandra Keith  
R. Alexandra Keith  
Director

By: /s/ Joseph R. Holmes  
Joseph R. Holmes  
Vice President and Chief Accounting Officer  
(Principal Accounting Officer)

By: /s/ Karen S. Lynch  
Karen S. Lynch  
Director

By: /s/ Nelson J. Chai  
Nelson J. Chai  
Director

By: /s/ James C. Mullen  
James C. Mullen  
Director

By: /s/ Ruby R. Chandy  
Ruby R. Chandy  
Director

By: /s/ Debora L. Spar  
Debora L. Spar  
Director

By: /s/ C. Martin Harris  
C. Martin Harris  
Director

By: /s/ Scott M. Sperling  
Scott M. Sperling  
Director

By: /s/ Tyler E. Jacks  
Tyler E. Jacks  
Director

By: /s/ Dion J. Weisler  
Dion J. Weisler  
Director

THERMO FISHER SCIENTIFIC INC.

NAME	STATE OR JURISDICTION OF ORGANIZATION
0972792 B.C. LTD	Canada
236 Perinton Parkway, LLC	New York
27 Forge Parkway LLC	Delaware
Abgene Inc.	Delaware
Abgene Limited	England
ABII 2 Limited	England
ACI Holdings Inc.	New York
Acoustic Cytometry Systems, Inc.	Delaware
AcroMetrix LLC	California
Acros Organics BV	Belgium
Acurian, Inc.	Delaware
Advanced Biotechnologies Limited	England
Advanced Scientifics International, Inc.	Pennsylvania
Advanced Scientifics, Inc.	Pennsylvania
Affymetrix Biotech Shanghai Ltd	China
Affymetrix Japan K.K.	Japan
Affymetrix UK Ltd	England
Affymetrix, Inc	Delaware
Agrisera AB	Sweden
Alchematrix LLC	Delaware
Alchematrix, Inc.	Delaware
Alfa Aesar (China) Chemical Co. Ltd.	China
Alfa Aesar (Hong Kong) Limited	Hong Kong
Allergon AB	Sweden
Ambion, Inc.	Delaware
APBI Finance Corporation	Delaware
Apogent Finance Company	Delaware
Apogent Holding Company	Delaware
Apogent Technologies Inc.	Wisconsin
Apogent Transition Corp.	Delaware
Apogent U.K. Limited	England
Applied Bioscience International, LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Applied Biosystems B.V.	Netherlands
Applied Biosystems de Mexico S. de R.L. de C.V.	Mexico
Applied Biosystems International, Inc.	Delaware
Applied Biosystems Taiwan LLC	Delaware
Applied Biosystems, LLC	Delaware
Applied Scientific Corporation	California
App-Tek International Pty Ltd	Australia
Arapo LLC	Delaware
ARG Services LLC	Delaware
ASPEX Corporation	Pennsylvania
ATP, LLC	North Carolina
Avances Cientificos de Mexico, S. de R.L. de C.V.	Mexico
Avocado Research Chemicals Limited	England
B.R.A.H.M.S. Biotech GmbH	Germany
B.R.A.H.M.S. GmbH	Germany
BAC BV	Netherlands
BAC IP BV	Netherlands
Barnstead Thermolyne LLC	Delaware
Beijing Phadia Diagnostics Co Ltd	China
Bender MedSystems GmbH	Austria
Biochemical Sciences LLC	Delaware
Bio-Sciences Ltd	Ireland
BioTrove Corporation	Delaware
BioTrove International, Inc.	Delaware
BmT GmbH Laborprodukte	Germany
Brammer Bio Holding Company, LLC	Delaware
Brammer Bio MA, LLC	Delaware
Brammer Bio, LLC	Delaware
Bumi-Sains Sendirian Berhad	Malaysia
CAC Limited	England
Capitol Scientific Products, Inc.	New York
Capitol Vial, Inc.	Alabama

NAME	STATE OR JURISDICTION OF ORGANIZATION
CB Diagnostics AB	Sweden
CB Diagnostics Holding AB	Sweden
CB Diagnostics I AB	Sweden
CCBR (Beijing) Company Limited	China
Cellomics, Inc.	Delaware
CellzDirect, Inc.	Delaware
Center for Clinical and Basic Research A/S	Denmark
CEPH International Corporation	Puerto Rico
Cezanne S.A.S.	France
Chase Scientific Glass, Inc.	Wisconsin
CHK Holdings Inc.	Delaware
Chromacol Limited	England
Clinical Technology Centre (International) Limited	England
Clinical Technology Centre (Ireland) Limited	Ireland
Clintrak Clinical Labeling Services, LLC	Delaware
Clintrak Pharmaceutical Services, LLC	Delaware
Cohesive Technologies (UK) Limited	England
Cohesive Technologies Inc.	Delaware
Columbia Diagnostics, Inc.	Delaware
Combinati Incorporated	Delaware
Compass NeuroHealth, LLC	Florida
Compass Research, LLC	Florida
Compendia Bioscience, Inc.	Michigan
Comtest Limited	England
Consolidated Technologies, Inc.	Wisconsin
Consultores Fisher Scientific Chile Ltd	Chile
Core Informatics UK Ltd.	England
Core Informatics, LLC	Connecticut
CorEvitas, LLC	Delaware
Corrona Intermediate Holdings, Inc.	Delaware
Corrona UK Holdings Limited	England
Crown Holding Inc.	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
CTPS LLC	Delaware
Cuno CIS Limited Liability Company	Russia
Cuno Europe Holding SNC	France
Cuno International Holding Inc.	Delaware
Cuno LLC	Delaware
DCG Systems G.K.	Japan
D-finitive Technologies, Inc.	South Carolina
Diagnostix Ltd.	Canada
Dionex (Switzerland) AG	Switzerland
Dionex (UK) Limited	England
Dionex Austria GmbH	Austria
Dionex Canada Ltd.	Canada
Dionex China Limited	Hong Kong
Dionex Corporation	Delaware
Dionex Denmark A/S	Denmark
Dionex Holding GmbH	Germany
Dionex I, LLC	Delaware
Dionex S.A.	France
Dionex S.p.A.	Italy
Dionex Softron GmbH	Germany
Dionex Sweden AB	Sweden
Distribution Solutions International, Inc.	Michigan
Doe & Ingalls Investors, Inc.	Delaware
Doe & Ingalls Limited	Ireland
Doe & Ingalls Management, LLC	Delaware
Doe & Ingalls of California Operating LLC	North Carolina
Doe & Ingalls of Florida Operating LLC	Florida
Doe & Ingalls of Maryland Operating LLC	North Carolina
Doe & Ingalls of Massachusetts Operating LLC	North Carolina
Doe & Ingalls of North Carolina Operating LLC	North Carolina
Doe & Ingalls Properties II, LLC	North Carolina
Doe & Ingalls Properties, LLC	North Carolina

NAME	STATE OR JURISDICTION OF ORGANIZATION
Doublecape Holding Limited	England
Doublecape Limited	England
DPI Newco LLC	Delaware
Drakeside Real Estate Holding Company LLC	Delaware
DSM Pharmaceutical Products, Inc.	Delaware
Duke Scientific Corporation	California
Eagle Holding Company II, LLC	Delaware
eBioscience, Ltd	England
EGS Gauging Ltd.	England
EGS Gauging Technical Services Company	Delaware
EP Scientific Products LLC	Delaware
Epsom Glass Industries Limited	England
Erie (GC) Holding Limited	England
Erie Finance 1 Limited	England
Erie Finance 2 Limited	England
Erie Finance Holding Limited	England
Erie Finance Limited	England
Erie Finance LLC	Delaware
Erie GC Holding LLC	Delaware
Erie GC Limited	England
Erie LP Holding LLC	Delaware
Erie Luxembourg LLC	Delaware
Erie N10 LLC	Delaware
Erie N2 LLC	Delaware
Erie N2 UK Limited	England
Erie Scientific Company of Puerto Rico	Delaware
Erie Scientific Hungary Ipari és Szolgáltató Kft	Hungary
Erie Scientific LLC	Delaware
Erie U.K. Limited	England
Erie UK 1 Limited	England
Erie UK 1 LLC	Delaware
Erie UK 2 Limited	England

NAME	STATE OR JURISDICTION OF ORGANIZATION
Erie UK 3 Limited	England
Erie UK 4 Limited	England
Erie UK 5 Limited	England
Erie UK 6 Limited	England
Erie UK Holding Company	Delaware
Erie UK Senior Holding Limited	England
Erie US II LLC	Delaware
Erie US III LLC	Delaware
European Laboratory Holdings Limited	Ireland
Eutech Instruments Pte Ltd.	Singapore
Ever Ready Thermometer Co., Inc.	Wisconsin
Evidera Access Consulting Ltd	England
Evidera Holdings Ltd	England
Evidera Ltd	England
Evidera, Inc.	Delaware
Excel PharmaStudies Inc.	Cayman Islands
FB2 Blocker, LLC	Delaware
FEI Asia Pacific Co., Ltd.	China
FEI Australia Pty Ltd	Australia
FEI Company	Oregon
FEI Company Japan Ltd.	Japan
FEI Company of USA (S.E.A.) Pte Ltd.	Singapore
FEI CPD B.V.	Netherlands
FEI Deutschland GmbH	Germany
FEI EFA International Pte. Ltd.	Singapore
FEI EFA, Inc.	Delaware
FEI Electron Optics B.V.	Netherlands
FEI Electron Optics International B.V.	Netherlands
FEI Europe B.V.	Netherlands
FEI France SAS	France
FEI Hong Kong Company Limited	Hong Kong
FEI Houston, Inc.	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
FEI Italia Srl	Italy
FEI Korea Ltd.	Korea
FEI Melbourne Pty Ltd.	Australia
FEI Microscopy Solutions Ltd	Israel
FEI SAS	France
FEI Saudi Arabia LLC	Saudi Arabia
FEI Technologies, Inc.	Oregon
FEI Technology de Mexico S.A. de C.V.	Mexico
FEI Trading (Shanghai) Co., Ltd.	China
FEI UK Limited	England
Fermentas Inc.	Maryland
FHP LLC	Delaware
Fiberlite Centrifuge LLC	Delaware
Finesse Scientific Equipment (Shanghai) Co., Ltd.	China
Finesse Solutions, Inc.	Delaware
Fisher Alder S. de R.L. de C.V.	Mexico
Fisher Bermuda Holdings Limited	Bermuda
Fisher Bioblock Holding II SNC	France
Fisher BioPharma Services (India) Private Limited	India
Fisher BioSciences Japan G.K.	Japan
Fisher BioServices Inc.	Virginia
Fisher Bioservices Netherlands B.V.	Netherlands
Fisher Canada Holding ULC 1	Canada
Fisher Canada Holding ULC 2	Canada
Fisher Canada Holding ULC 3	Canada
Fisher Clinical Logistics LLC	Delaware
Fisher Clinical Services (Beijing) Co., Ltd.	China
Fisher Clinical Services (Bristol), LLC	Delaware
Fisher Clinical Services (Colombia) LLC	Delaware
Fisher Clinical Services (Korea) Co., Ltd	Korea
Fisher Clinical Services (Mexico) LLC	Delaware
Fisher Clinical Services (Peru) LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Fisher Clinical Services (Suzhou) Co., Ltd.	China
Fisher Clinical Services Colombia S.A.S.	Colombia
Fisher Clinical Services GmbH	Germany
Fisher Clinical Services GmbH	Switzerland
Fisher Clinical Services Inc.	Pennsylvania
Fisher Clinical Services Japan K.K.	Japan
Fisher Clinical Services Latin America S.R.L.	Argentina
Fisher Clinical Services Limited Liability Company	Russia
Fisher Clinical Services Mexico, S. de R.L. de C.V.	Mexico
Fisher Clinical Services Peru S.R.L	Peru
Fisher Clinical Services Pte Ltd.	Singapore
Fisher Clinical Services Rheinfelden GmbH	Germany
Fisher Clinical Services U.K. Limited	England
Fisher CLP Holding Limited Partnership	Canada
Fisher Diagnostics LLC	Delaware
Fisher Emergo B.V.	Netherlands
Fisher Hamilton China Inc.	Delaware
Fisher Hamilton Mexico LLC	Delaware
Fisher Internet Minority Holdings L.L.C.	Delaware
Fisher Luxembourg Danish Holdings SARL	Luxembourg
Fisher Manufacturing (Malaysia) Sdn Bhd	Malaysia
Fisher Maybridge Holdings Limited	England
Fisher Mexico, S. de R.L. de C.V.	Mexico
Fisher Scientific (Austria) GmbH	Austria
Fisher Scientific (Hong Kong) Limited	Hong Kong
Fisher Scientific (M) Sdn Bhd	Malaysia
Fisher Scientific (SEA) Pte. Ltd.	Singapore
Fisher Scientific A/S	Norway
Fisher Scientific AG	Switzerland
Fisher Scientific Australia Pty Limited	Australia
Fisher Scientific Biotech Line ApS	Denmark
Fisher Scientific Brazil Inc.	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Fisher Scientific Central America Inc.	Delaware
Fisher Scientific Chile Inc.	Delaware
Fisher Scientific Colombia Inc.	Delaware
Fisher Scientific Company	Canada
Fisher Scientific Company L.L.C.	Delaware
Fisher Scientific Costa Rica Sociedad de Responsabilidad Limitada	Costa Rica
Fisher Scientific de Mexico S.A.	Mexico
Fisher Scientific Europe Holdings B.V.	Netherlands
Fisher Scientific Germany Beteiligungs GmbH	Germany
Fisher Scientific GmbH	Germany
Fisher Scientific GTF AB	Sweden
Fisher Scientific Holding Company LLC	Delaware
Fisher Scientific Holding HK Limited	Hong Kong
Fisher Scientific Holding U.K., Limited	England
Fisher Scientific Holdings (S) Pte Ltd	Singapore
Fisher Scientific International LLC	Delaware
Fisher Scientific Ireland Limited	Ireland
Fisher Scientific Japan, Ltd.	Japan
Fisher Scientific Jersey Island Limited	Jersey
Fisher Scientific Korea Ltd	Korea
Fisher Scientific Latin America Inc.	Delaware
Fisher Scientific Luxembourg S.a.r.l.	Luxembourg
Fisher Scientific Mexicana, S. de R.L. de C.V.	Mexico
Fisher Scientific Mexico Inc.	Delaware
Fisher Scientific Middle East and Africa Inc.	Delaware
Fisher Scientific Norway AS	Norway
Fisher Scientific Operating Company	Delaware
Fisher Scientific Oxoid Holdings Ltd.	England
Fisher Scientific Oy	Finland
Fisher Scientific Pte. Ltd.	Singapore
Fisher Scientific S.A.S.	France
Fisher Scientific S.L.	Spain

NAME	STATE OR JURISDICTION OF ORGANIZATION
Fisher Scientific SRL	Belgium
Fisher Scientific The Hague II B.V.	Netherlands
Fisher Scientific The Hague III B.V.	Netherlands
Fisher Scientific The Hague V B.V.	Netherlands
Fisher Scientific U.K., Limited	England
Fisher Scientific UK Holding Company 2	England
Fisher Scientific UK Holding Company Limited	England
Fisher Scientific Venezuela Inc.	Delaware
Fisher Scientific Worldwide (Shanghai) Co., Ltd.	China
Fisher Scientific Worldwide Inc.	Delaware
Fisher Scientific, spol. S.r.o	Czech Republic
Fisher Scientific, Unipessoal, Lda.	Portugal
Fisher Servicios Clinicos (Chile) LLC	Delaware
Fisher Servicios Clinicos Chile Ltda	Chile
Fisher Worldwide Gene Distribution SPV	Cayman Islands
Fisher WWD Holding L.L.C.	Delaware
FRC Holding Inc., V	Delaware
FS Casa Rocas Holdings LLC	Delaware
FS Mexicana Holdings LLC	Delaware
FSI Receivables Company LLC	Delaware
FSII Sweden Holdings AB	Sweden
FSII Sweden Holdings I AB	Sweden
FSII Sweden Holdings II AB	Sweden
FSIR Holdings (UK) Limited	England
FSIR Holdings (US) Inc.	Delaware
FSUK Holdings Limited	England
FSWH Company LLC	Delaware
FSWH I LLC	Delaware
FSWH I LP	Delaware
FSWH II LLC	Delaware
FSWH International Holdings LLC	Delaware
Fuji Partnership	Japan

NAME	STATE OR JURISDICTION OF ORGANIZATION
G & M Procter Limited	Scotland
G V Instruments Limited	England
General Scientific Company Sdn Bhd (M)	Malaysia
Ginkgo Parc SA	Belgium
Gold Cattle Standard Testing Labs, Inc.	Texas
Golden West Indemnity Company Limited	Bermuda
Goring Kerr Detection Limited	England
Greenbird Limited	Cyprus
GV Instruments Inc	Delaware
Hangar 215, Inc.	Delaware
Health iQ Limited	England
HealthUnlocked Holdings Limited	England
Helmet Securities Limited	England
Henogen SRL	Belgium
HighChem s.r.o.	Slovakia
Hybaid Limited	England
HyClone International Trade (Tianjin) Co., Ltd	China
I.Q. (BIO) Limited	England
Indigo Merger Subsidiary Inc.	Delaware
Inel Inc.	Delaware
Inel SAS	France
InnaPhase Limited	England
IntegenX Ltd	England
IntegenX, Inc.	California
Intrinsic BioProbes, Inc.	Arizona
Invitrogen (Shanghai) Investment Co., Ltd.	China
Invitrogen Argentina SA	Argentina
Invitrogen BioServices India Private Limited	India
Invitrogen Europe Limited	Scotland
Invitrogen Finance Corporation	Delaware
Invitrogen Holdings Limited	Scotland
Invitrogen Holdings LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Invitrogen Hong Kong Limited	Hong Kong
Invitrogen IP Holdings, Inc.	Delaware
Invitrogen Trading (Shanghai) Co., Ltd.	China
Ion Torrent Systems, Inc.	Delaware
Jaguar (Barbados) Finance SRL	Barbados
Jaguar Holding Company I, LLC	Delaware
Jaguar Holding Company II	Delaware
Jouan Limited	England
Jouan LLC	Delaware
Kendro Laboratory Products Ltd	England
Kettlebrook Insurance Co. ltd.	Hawaii
Kyle Jordan Investments LLC	Delaware
Lab-Chrom-Pack LLC	New York
Lab-Line Instruments, Inc.	Delaware
Labomex MBP, S. de R. L. De C.V.	Mexico
Laboratoire Service International - L.S.I	France
Laboratory Management Systems, Inc.	Delaware
Laboratory Specialties Proprietary Ltd.	South Africa
LambTrack Limited	England
La-Pha-Pack GmbH	Germany
Laser Analytical Systems, Inc.	California
Liberty Lane Investment LLC	Delaware
Liberty Lane Real Estate Holding Company LLC	Delaware
Life Sciences International Holdings BV	Netherlands
Life Sciences International Limited	England
Life Sciences International LLC	Delaware
Life Technologies AS	Norway
Life Technologies Bioprocessing GmbH	Switzerland
Life Technologies BPD UK Limited	England
Life Technologies Brasil Comercio e Industria de Produtos para Biotecnologia Ltda	Brazil
Life Technologies Chile SpA	Chile
Life Technologies Clinical Services Lab, Inc.	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Life Technologies Co., Ltd.	Taiwan
Life Technologies Corporation	Delaware
Life Technologies Czech Republic s.r.o.	Czech Republic
Life Technologies Europe B.V.	Netherlands
Life Technologies Finance Ltd.	Scotland
Life Technologies GmbH	Germany
Life Technologies Holdings PTE Ltd.	Singapore
Life Technologies Inc.	Canada
Life Technologies Japan Ltd.	Japan
Life Technologies Limited	Hong Kong
Life Technologies Limited	Scotland
Life Technologies Magyarorszag Kft	Hungary
Life Technologies Norway Investments US LLC	Delaware
Life Technologies Polska Sp z.o.o.	Poland
Life Technologies s.r.o	Slovakia
Life Technologies SA	Spain
Life Technologies SAS	France
Limited Liability Company Contract Research Organisation Innopharm	Ukraine
Limited Liability Company PPD Development (Smolensk)	Russia
LLC PPD Ukraine	Ukraine
Loftus Furnace Company	Pennsylvania
Lomb Scientific (Aust) Pty Limited	Australia
LTC Tech South Africa (Pty) Ltd.	South Africa
Marketbase International Limited	Hong Kong
MarqMetrix, Inc.	Washington
Matrix MicroScience Inc.	Delaware
Matrix Microscience Limited	England
Matrix Technologies Corporation Limited	England
Matrix Technologies LLC	Delaware
Maybridge Chemical Holdings Limited	England
Maybridge Limited	England
Medical Analysis Systems International, Inc.	California

NAME	STATE OR JURISDICTION OF ORGANIZATION
Medical Analysis Systems, Inc.	Delaware
Medical Centre Synexus Sofia EOOD	Bulgaria
Medical Diagnostics Systems, Inc.	California
MediciGroup, Inc.	Pennsylvania
Medimix Latam Pesquisa de Mercado Ltda	Brazil
Mesa Biotech LLC	Delaware
Metavac LLC	Delaware
Microgenics B.V. & Co. KG	Germany
Microgenics Corporation	Delaware
MLS ACQ, Inc.	Delaware
Molecular BioProducts, Inc.	California
Molecular Probes, Inc.	Oregon
Molecular Transfer, Inc.	Delaware
Nalge Nunc International (Monterrey) LLC	Delaware
Nalge Nunc International Corporation	Delaware
NanoDrop Technologies LLC	Delaware
NAPCO, Inc.	Connecticut
National Scientific Company	Wisconsin
Navaho Acquisition Corp.	Delaware
NERL Diagnostics LLC	Wisconsin
NeuroHealth, Inc.	Florida
New FS Holdings Inc.	Delaware
NewcoGen-PE, LLC	Delaware
Niton Asia Limited	Hong Kong
NovaWave Technologies, Inc.	California
Nunc A/S	Denmark
Odyssey Holdings Corporation	Delaware
Odyssey Venture Corporation	Delaware
Olink Biotechnology (Shanghai) Co., LTD	China
Olink Finance AB	Sweden
Olink Holding AB	Sweden
Olink OldCo AB	Sweden

NAME	STATE OR JURISDICTION OF ORGANIZATION
Olink Proteomics AB	Sweden
Olink Proteomics B.V.	Netherlands
Olink Proteomics GmbH	Germany
Olink Proteomics Inc.	Delaware
Olink Proteomics KK	Japan
Olink Proteomics Limited	England
Olink Proteomics SAS	France
Olink Proteomics SG Pte Ltd.	Singapore
Oncomine India Private Limited	India
Oncomine K.K.	Japan
Oncomine LLC	Delaware
Oncomine Molecular Inc.	Delaware
Oncomine Pte. Ltd	Singapore
Oncomine S.r.l	Italy
Oncomine ULC	Canada
One Lambda, Inc	California
Onix Holdings Limited	England
ONIX Systems Inc.	Delaware
Optimal Research, LLC	Maryland
Orion Acquisition AB	Sweden
Owl Separation Systems LLC	Wisconsin
Oxoid (ELY) Limited	England
Oxoid 2000 Limited	England
Oxoid Australia Pty. Limited	Australia
Oxoid Company	Canada
Oxoid Deutschland GmbH	Germany
Oxoid Holdings Limited	England
Oxoid Inc.	Delaware
Oxoid International Limited	England
Oxoid Investments GmbH	Germany
Oxoid Limited	England
Oxoid Limited	Ireland

NAME	STATE OR JURISDICTION OF ORGANIZATION
Oxoid NV	Belgium
Oxoid Senior Holdings Limited	England
Oxoid UKH LLC	Delaware
Pacific Rim Far East Industries LLC	Delaware
Pacific Rim Investment, LLC	Delaware
Panomics, L.L.C.	California
Pasteur U.S. Corporation	Delaware
Patheon API Inc.	South Carolina
Patheon API Manufacturing Inc.	South Carolina
Patheon API Services Inc.	South Carolina
Patheon Austria GmbH & Co. KG	Austria
Patheon B.V.	Netherlands
Patheon Banner U.S. Holdings Inc.	Delaware
Patheon Biologics (NJ) LLC	Delaware
Patheon Biologics Australia Pty Ltd	Australia
Patheon Biologics B.V.	Netherlands
Patheon Biologics LLC	Delaware
Patheon Calculus Merger LLC	Delaware
Patheon Development Services Inc.	Delaware
Patheon France SAS	France
Patheon Holdings B.V.	Netherlands
Patheon Holdings I B.V.	Netherlands
Patheon Holdings II B.V.	Netherlands
Patheon Holdings SAS	France
Patheon I B.V.	Netherlands
Patheon I Holding GmbH	Austria
Patheon Inc.	Canada
Patheon Italia S.p.A.	Italy
Patheon KK	Japan
Patheon Life Science Products International GmbH	Austria
Patheon Logistics Switzerland GmbH	Switzerland
Patheon Manufacturing Services LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Patheon Pharmaceuticals Inc.	Delaware
Patheon Pharmaceuticals Services Inc.	Delaware
Patheon Puerto Rico Acquisitions Corporation	Puerto Rico
Patheon Puerto Rico, Inc.	Puerto Rico
Patheon Regensburg GmbH	Germany
Patheon Softgels B.V.	Netherlands
Patheon Softgels Inc.	Delaware
Patheon U.S. Holdings Inc.	Delaware
Patheon U.S. Holdings LLC	Delaware
Patheon UK Limited	England
PAX – DSI Acquisition LLC	Delaware
Pelican Acquisition Corporation	Delaware
PeproTech Asia Ltd	Israel
PeproTech BioTech (Suzhou) Co., Ltd.	China
PeproTech EC Ltd.	England
PeproTech France	France
PeproTech, Inc.	New Jersey
Perbio Science (Canada) Company	Canada
Perbio Science AB	Sweden
Perbio Science International Netherlands B.V.	Netherlands
Perbio Science Sweden Holdings AB	Sweden
Perbio Science UK Limited	England
Perbio Science, Inc.	Delaware
Percivia LLC	Delaware
Phadia AB	Sweden
Phadia Diagnosticos Ltda	Brazil
Phadia GmbH	Germany
Phadia Holding AB	Sweden
Phadia International LLC	Delaware
Phadia Real Property AB	Sweden
Phadia s.r.o.	Czech Republic
Phadia Taiwan Inc.	Taiwan

NAME	STATE OR JURISDICTION OF ORGANIZATION
Phadia US Inc.	Delaware
Phadia US Market Holdings LLC	Delaware
Pharmacaps Mexicana S.A. de C.V.	Mexico
Pharmaceutical Product Development OÜ	Estonia
Pharmaceutical Product Development South Africa (Proprietary) Ltd	South Africa
Pharmaceutical Product Development Spain SL	Spain
Pharmaceutical Product Development, LLC	Delaware
Pharmaco Investments, Inc.	Delaware
PharmaFluidics NV	Belgium
Phitonex, Inc.	North Carolina
picoSpin, LLC	Colorado
Pierce Milwaukee Holding Corp.	Delaware
Pierce Milwaukee, Inc.	Delaware
Power Sweden Holdings I AB	Sweden
Power Sweden Holdings II AB	Sweden
PPD (Netherlands) B.V.	Netherlands
PPD (Netherlands) LLC	Delaware
PPD Aeronautics Corporation	Delaware
PPD Aeronautics, LLC	North Carolina
PPD Argentina S.A.	Argentina
PPD Australia Pty Limited	Australia
PPD Bulgaria EOOD	Bulgaria
PPD Canada	Canada
PPD Colombia S.A.S	Colombia
PPD CT Investments LLP	England
PPD Czech Republic S.R.O.	Czech Republic
PPD Development (HK) Limited	Hong Kong
PPD Development (S) Pte. Ltd.	Singapore
PPD Development (Thailand) Co., Ltd.	Thailand
PPD Development Ireland Limited	Ireland
PPD Development, L.P.	Delaware
PPD do Brasil- Suporte a Pesquisa Clinica Ltd	Brazil

NAME	STATE OR JURISDICTION OF ORGANIZATION
PPD France SAS	France
PPD Georgia LLC	Georgia (country)
PPD Germany GmbH	Germany
PPD Germany GmbH & Co. KG	Germany
PPD Global Central Labs (S) Pte. Ltd.	Singapore
PPD Global Central Labs BV	Belgium
PPD Global Central Labs, LLC	Kentucky
PPD Global Ltd.	England
PPD GP, LLC	Delaware
PPD Holdings, LLC	Delaware
PPD Hrvatska d.o.o.	Croatia
PPD Hungary Research and Development Ltd.	Hungary
PPD International Holdings (UK) Ltd	England
PPD International Holdings GmbH	Germany
PPD International Holdings, Inc. y Compania Limitada	Chile
PPD International Holdings, LLC	Delaware
PPD International Investments Limited	England
PPD Investigator Services, LLC	Delaware
PPD Italy S.r.l	Italy
PPD Laboratories (Suzhou) Co., Ltd.	China
PPD Laboratories Sweden AB	Sweden
PPD Latvia SIA	Latvia
PPD Mexico S.A. de C.V.	Mexico
PPD Netherlands International LLC	Delaware
PPD PANAMA, S. de R.L.	Panama
PPD Peru S.A.C.	Peru
PPD Pharmaceutical Development (Beijing) Co., Ltd.	China
PPD Pharmaceutical Development India Private Limited	India
PPD Pharmaceutical Development Japan K.K.	Japan
PPD Pharmaceutical Development Philippines Corp.	Philippines
PPD Pharmaceutical Development Vietnam Company Limited	Vietnam
PPD Poland Sp.Z o.o.	Poland

NAME	STATE OR JURISDICTION OF ORGANIZATION
PPD Professional Services Corporation	Delaware
PPD Research Pharmaceutical Product Development, LLC	Slovenia
PPD Romania SRL	Romania
PPD Scandinavia AB	Sweden
PPD Serbia D.O.O. Beograd	Serbia
PPD Services, Inc.	North Carolina
PPD Slovak Republic s.r.o.	Slovak Republic
PPD Switzerland GmbH	Switzerland
PPD UK Holdings Limited	England
PPD Vaccines and Biologics, LLC	Pennsylvania
PPD, Inc.	Delaware
PPD-SNBL K.K.	Japan
Pregistry Holdings Limited	England
Pregistry, LLC	Delaware
Princeton Gamma-Tech Instruments LLC	Delaware
Prionics Lelystad B.V.	Netherlands
Prionics USA Inc.	Delaware
Priority Air Express Pte. Ltd.	Singapore
Priority Air Express UK Limited	England
Priority Air Express, LLC	Delaware
Priority Air Holdings Corp	Delaware
Proxeon Biosystems ApS	Denmark
PT Thermo Fisher Scientific	Indonesia
Quebec B.V.	Netherlands
Quebec Court B.V.	Netherlands
Remel Europe Limited	England
Remel Inc.	Wisconsin
REP GBP I-B Blocker, Inc.	Delaware
River Ventures, LLC	North Carolina
Robbins Scientific LLC	California
Robocon Labor- und Industrieroboter Gesellschaft m.b.H	Austria
Samco Scientific (Monterrey) LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Samco Scientific LLC	Delaware
Saroph Sweden AB	Sweden
Schantz Road LLC	Pennsylvania
SCI Inno 92	France
Seradyn Inc.	Delaware
Shanghai Life Technologies Biotechnology Co. Limited	China
Shanghai Thermo Fisher (C-I) Trading Co. Ltd	China
Shanghai Thermo Fisher (S) Trading Co. Ltd	China
Shorecloud Corporation	Philippines
Silver NewCo Limited	Ireland
Solventum Purification Inc.	Delaware
Solventum Purification SAS	France
Southern Trials (Pty) Ltd.	South Africa
Specialty (SMI) Inc.	California
Spectra-Physics AB	Sweden
Spectra-Physics Holdings Limited	England
Spectra-Physics Holdings USA, LLC	Delaware
Staten Island Cogeneration Corporation	New York
STC Bio Manufacturing, Inc.	Illinois
Sterilin Limited	England
Stokes Bio Ltd.	Ireland
SwissAnalytic Group GmbH	Switzerland
Synexus Bulgaria EOOD	Bulgaria
Synexus Clinical Research GmbH	Germany
Synexus Clinical Research Limited	England
Synexus Clinical Research Midco No1 Limited	England
Synexus Clinical Research South Africa (Pty) Limited	South Africa
Synexus Clinical Research Topco Limited	England
Synexus Clinical Research US, Inc.	Arizona
Synexus Compass, Inc. (fmr. Synarc Inc.)	Delaware
Synexus Czech s.r.o.	Czech Republic
Synexus Limited	England

NAME	STATE OR JURISDICTION OF ORGANIZATION
Synexus Magyarország Egszsggyi Szolgtat Korltolt Felelssg Trsasg	Hungary
Synexus Polska Sp. Z o.o	Poland
Synexus Ukraine Limited Liability Company	Ukraine
SystemLink, Inc.	Virginia
Systems Manufacturing Corporation	Delaware
TBS Howard Hill, LLC	Vermont
Technology Design Solutions Pty Ltd	Australia
TFLP LLC	Delaware
TFS (Barbados) I Srl	Barbados
TFS Brammer Holding Corporation	Delaware
TFS Breda B.V.	Netherlands
TFS FEI Holding LLC	Delaware
TFS Group Holding I LLC	Delaware
TFS Group Holding II LLC	Delaware
TFS Group Holdings III LLC	Delaware
TFS Group Holdings IV LLC	Delaware
TFS Life Holding LLC	Delaware
TFS LLC	Massachusetts
TFS Singapore HK Limited	Hong Kong
TFS Venture Holdings I LLC	Delaware
TFS Venture Holdings III S.C.S.	Luxembourg
The Binding Site Benelux BV	Belgium
The Binding Site Brasil Comercio De Produtos Para Laboratorio Ltda.	Brazil
The Binding Site Corporation Limited	England
The Binding Site Denmark ApS	Denmark
The Binding Site France SAS	France
The Binding Site GmbH	Germany
The Binding Site Group (Shanghai) Trading Co., Ltd.	China
The Binding Site Group Limited	England
The Binding Site Group Limited	Jordan
The Binding Site Holding GmbH	Germany
The Binding Site Holding Inc.	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
The Binding Site Ireland Limited	Ireland
The Binding Site KK	Japan
The Binding Site Limited	New Zealand
The Binding Site Portugal, Specialist Protein Company, Unip Lda	Portugal
The Binding Site Pte Ltd.	Singapore
The Binding Site Pty Limited	Australia
The Binding Site S. de R.L. de C.V.	Mexico
The Binding Site S.r.l.	Italy
The Binding Site s.r.o.	Czech Republic
The Binding Site Spain (Specialist Protein Company) S.L.	Spain
The Binding Site VT, Inc.	Vermont
The Binding Site, Inc.	California
The Compass Clinic, LLC	Florida
The Nettleton Gate Limited	England
The Thermo Fisher Scientific Phambili Trust	South Africa
Thermo Asset Management Services Inc.	Delaware
Thermo BioAnalysis Limited	England
Thermo BioAnalysis LLC	Delaware
Thermo BioSciences Holdings LLC	Delaware
Thermo Cambridge Limited	England
Thermo Cayman Holdings 2 Ltd	Cayman Islands
Thermo Cayman Holdings Ltd.	Cayman Islands
Thermo CIDTEC Inc.	New York
Thermo CN Luxembourg LLC	Delaware
Thermo Corporation	Delaware
Thermo CRS Holdings Ltd.	Canada
Thermo CRS Ltd.	Canada
Thermo Detection de Mexico S. de R.L. de C.V.	Mexico
Thermo DMA Inc.	Texas
Thermo Eberline Holdings I LLC	Delaware
Thermo Eberline Holdings II LLC	Delaware
Thermo Eberline LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo EGS Gauging LLC	Delaware
Thermo Electron (Calgary) Limited	Canada
Thermo Electron (Chile) S.p.A.	Chile
Thermo Electron (Karlsruhe) GmbH	Germany
Thermo Electron (Management Services) Limited	England
Thermo Electron (Proprietary) Limited	South Africa
Thermo Electron A/S	Denmark
Thermo Electron Australia Pty Limited	Australia
Thermo Electron Export Inc.	Barbados
Thermo Electron Holdings SAS	France
Thermo Electron LED GmbH	Germany
Thermo Electron LED S.A.S.	France
Thermo Electron Limited	England
Thermo Electron Manufacturing Limited	England
Thermo Electron Metallurgical Services, Inc.	Texas
Thermo Electron North America LLC	Delaware
Thermo Electron Pension Trust GmbH	Germany
Thermo Electron Puerto Rico, Inc.	Puerto Rico
Thermo Electron SAS	France
Thermo Electron Scientific Instruments LLC	Delaware
Thermo Electron Sweden AB	Sweden
Thermo Electron Sweden Forvaltning AB	Sweden
Thermo Electron Weighing & Inspection Limited	England
Thermo Environmental Instruments LLC	California
Thermo Finland Holdings MT1 B.V.	Netherlands
Thermo Finnigan LLC	Delaware
Thermo Fisher (Cayman) Holdings I Ltd.	Cayman Islands
Thermo Fisher (Cayman) Holdings II Ltd.	Cayman Islands
Thermo Fisher (China) Analytical Ltd.	China
Thermo Fisher (CN) Luxembourg Financing S.à r.l	Luxembourg
Thermo Fisher (CN) Luxembourg Holding S.a.r.l.[Domesticated in the State of Delaware under the name of Thermo Fisher (CN) Luxembourg Holding S.a.r.l. LLC]	Luxembourg
Thermo Fisher (CN) Luxembourg S.a.r.l.	Luxembourg

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher (CN) Malta Holdings Limited	Malta
Thermo Fisher (CN-I) Luxembourg LLC	Delaware
Thermo Fisher (CN-II) Luxembourg LLC	Delaware
Thermo Fisher (Gibraltar) II Limited	Gibraltar
Thermo Fisher (Gibraltar) Limited	Gibraltar
Thermo Fisher (Heysham) Limited	England
Thermo Fisher (Kandel) GmbH	Germany
Thermo Fisher Advanced Solutions Company	Saudi Arabia
Thermo Fisher Biopharma Services (Hangzhou) Ltd.	China
Thermo Fisher Biopharma Services Pte. Ltd.	Singapore
Thermo Fisher Bioprocessing Inc.	Delaware
Thermo Fisher Bioprocessing Research and Development (Shanghai) Co., Ltd.	China
Thermo Fisher China Business Trust	China
Thermo Fisher CHK Holding LLC	Delaware
Thermo Fisher Clinical Switzerland Holding LLC	Delaware
Thermo Fisher CM II LLC	Delaware
Thermo Fisher Detection Mexico LLC	Delaware
Thermo Fisher Diagnostics (Ireland) Limited	Ireland
Thermo Fisher Diagnostics AB	Sweden
Thermo Fisher Diagnostics AG	Switzerland
Thermo Fisher Diagnostics Aps	Denmark
Thermo Fisher Diagnostics AS	Norway
Thermo Fisher Diagnostics Austria GmbH	Austria
Thermo Fisher Diagnostics B.V.	Netherlands
Thermo Fisher Diagnostics CZ s.r.o.	Czech Republic
Thermo Fisher Diagnostics GmbH	Germany
Thermo Fisher Diagnostics K.K.	Japan
Thermo Fisher Diagnostics Limited	England
Thermo Fisher Diagnostics NV	Belgium
Thermo Fisher Diagnostics Oy	Finland
Thermo Fisher Diagnostics S.p.A.	Italy
Thermo Fisher Diagnostics SAS	France

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Diagnostics sp. z o.o	Poland
Thermo Fisher Diagnostics, S.L.U.	Spain
Thermo Fisher Diagnostics, Sociedade Unipessoal Lda	Portugal
Thermo Fisher Electronic Technology Research and Development (Shanghai) Co., Ltd	China
Thermo Fisher Financial Services B.V.	Netherlands
Thermo Fisher Financial Services Inc.	Delaware
Thermo Fisher German Holdings LLC	Delaware
Thermo Fisher Germany B.V.	Netherlands
Thermo Fisher GP LLC	Delaware
Thermo Fisher India Holding B.V.	Netherlands
Thermo Fisher Insurance Holdings Inc.	Delaware
Thermo Fisher Insurance Holdings LLC	Delaware
Thermo Fisher Integrated Solutions Israel Limited	Israel
Thermo Fisher Investments (Cayman) LLC	Delaware
Thermo Fisher Investments (Cayman) Ltd.	Cayman Islands
Thermo Fisher Israel Ltd.	Israel
Thermo Fisher Project Cyprus LLC	Delaware
Thermo Fisher RE I Corporation	Delaware
Thermo Fisher RE II Corporation	Delaware
Thermo Fisher Scientific (Asheville) LLC	Delaware
Thermo Fisher Scientific (Barbados) Holdings I SRL	Barbados
Thermo Fisher Scientific (Barbados) Holdings II SRL	Barbados
Thermo Fisher Scientific (Barbados) Holdings IV SRL	Barbados
Thermo Fisher Scientific (Barbados) Holdings IX SRL	Barbados
Thermo Fisher Scientific (Barbados) Holdings V SRL	Barbados
Thermo Fisher Scientific (Barbados) Holdings VI SRL	Barbados
Thermo Fisher Scientific (BR) Holdings I SRL	Barbados
Thermo Fisher Scientific (Breda) Holding BV	Netherlands
Thermo Fisher Scientific (Bremen) GmbH	Germany
Thermo Fisher Scientific (Cayman) LLC	Delaware
Thermo Fisher Scientific (CH EQ) LLC	Delaware
Thermo Fisher Scientific (CH) 1 LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific (CH) 2 LLC	Delaware
Thermo Fisher Scientific (China) Co., Ltd.	China
Thermo Fisher Scientific (China) Holding Limited	England
Thermo Fisher Scientific (China-HK) Holding Limited	Hong Kong
Thermo Fisher Scientific (CP1) Limited	England
Thermo Fisher Scientific (CP2) Limited	England
Thermo Fisher Scientific (DE) Holding S.a.r.l.	Luxembourg
Thermo Fisher Scientific (DE) Luxembourg S.à r.l.	Luxembourg
Thermo Fisher Scientific (DPI) Limited Partnership	Canada
Thermo Fisher Scientific SARL	Switzerland
Thermo Fisher Scientific (FCS) Holding LLC	Delaware
Thermo Fisher Scientific (Finance I) B.V.	Netherlands
Thermo Fisher Scientific (Finance I) S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Finance II) S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Finance III) LLC	Delaware
Thermo Fisher Scientific (Finance III) S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Fuji) LLC	Delaware
Thermo Fisher Scientific (Guangzhou) Biotechnology Co., Ltd.	China
Thermo Fisher Scientific (Guangzhou) Co., Ltd	China
Thermo Fisher Scientific (Holding II) B.V. & Co. KG	Germany
Thermo Fisher Scientific (Hong Kong) Limited	Hong Kong
Thermo Fisher Scientific (IVGN) B.V.	Netherlands
Thermo Fisher Scientific (IVGN) Holding LLC	Delaware
Thermo Fisher Scientific (IVGN) Limited	Hong Kong
Thermo Fisher Scientific (IVGN) Luxembourg S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Johannesburg) (Proprietary) Limited	South Africa
Thermo Fisher Scientific (Luxembourg) II Holdings S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Luxembourg) II S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Malta) Holdings I Limited	Malta
Thermo Fisher Scientific (Malta) Holdings II Limited	Malta
Thermo Fisher Scientific (Malta) Holdings III Limited	Malta
Thermo Fisher Scientific (Malta) Holdings IV Limited	Malta

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific (Malta) I Limited	Malta
Thermo Fisher Scientific (Malta) II Limited	Malta
Thermo Fisher Scientific (Mexico City) LLC	Delaware
Thermo Fisher Scientific (Milwaukee) LLC	Delaware
Thermo Fisher Scientific (Mississauga) Inc.	Canada
Thermo Fisher Scientific (Monterrey), S. De R.L. De C.V.	Mexico
Thermo Fisher Scientific (NK) LLC	Delaware
Thermo Fisher Scientific (OLI) 1 Limited	England
Thermo Fisher Scientific (OLI) 2 Limited	England
Thermo Fisher Scientific (OLI) 3 Limited	England
Thermo Fisher Scientific (OLI) 3 LLC	Delaware
Thermo Fisher Scientific (OLI) 4 Limited	England
Thermo Fisher Scientific (OLI) Barbados SRL	Barbados
Thermo Fisher Scientific (OLI) Limited	England
Thermo Fisher Scientific (OLI) LLC	Delaware
Thermo Fisher Scientific (OLI) LP	Canada
Thermo Fisher Scientific (OLI) UK Limited	England`
Thermo Fisher Scientific (Panama) B.V. [Domesticated in the State of Delaware under the name of Thermo Fisher Scientific (Panama) B.V.]	Netherlands
Thermo Fisher Scientific (PN) UK Limited Partnership	England
Thermo Fisher Scientific (PN) UK LLC	Delaware
Thermo Fisher Scientific (PN1) UK Ltd	England
Thermo Fisher Scientific (PN-I) SRL	Barbados
Thermo Fisher Scientific (PN-II) SRL	Barbados
Thermo Fisher Scientific (PN-III) (Barbados) 2 SRL	Barbados
Thermo Fisher Scientific (PN-III) (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific (PN-III) (BR) 2 SRL	Barbados
Thermo Fisher Scientific (PN-III) (Malta) Limited.	Delaware
Thermo Fisher Scientific (PN-III) SRL	Barbados
Thermo Fisher Scientific (Praha) s.r.o.	Czech Republic
Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG	Germany
Thermo Fisher Scientific (Real Estate 1) S.a.r.l.	Luxembourg
Thermo Fisher Scientific (Schweiz) AG	Switzerland

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific (Shanghai) Instruments Co., Ltd.	China
Thermo Fisher Scientific (Shanghai) Management Co., Ltd.	China
Thermo Fisher Scientific (Shanghai) Supply Chain Management Co., Ltd	China
Thermo Fisher Scientific (Suzhou) Instruments Co., Ltd	China
Thermo Fisher Scientific (Suzhou) Research and Development Co., Ltd.	China
Thermo Fisher Scientific (Thailand) Co., Ltd.	Thailand
Thermo Fisher Scientific (US) Holdings III LLC	Delaware
Thermo Fisher Scientific 3 LLC	Delaware
Thermo Fisher Scientific Africa Proprietary Ltd	South Africa
Thermo Fisher Scientific AL-1 LLC	Delaware
Thermo Fisher Scientific API Holding LLC	Delaware
Thermo Fisher Scientific API Senior Holding LLC	Delaware
Thermo Fisher Scientific Aquasensors LLC	Delaware
Thermo Fisher Scientific Asset Management 1 GmbH	Germany
Thermo Fisher Scientific Asset Management 2 GmbH	Germany
Thermo Fisher Scientific AU C.V.	Netherlands
Thermo Fisher Scientific AU II Limited	England
Thermo Fisher Scientific AU Limited	England
Thermo Fisher Scientific AU LLC	Delaware
Thermo Fisher Scientific Australia Pty Ltd	Australia
Thermo Fisher Scientific B.V.	Netherlands
Thermo Fisher Scientific Baltics UAB	Lithuania
Thermo Fisher Scientific Barbados Financing 3 SRL	Barbados
Thermo Fisher Scientific Beteiligungsverwaltungs GmbH	Germany
Thermo Fisher Scientific BHK (I) Limited	Hong Kong
Thermo Fisher Scientific BHK (II) Limited	Hong Kong
Thermo Fisher Scientific Biosciences Corp.	Canada
Thermo Fisher Scientific Blade I Limited	England
Thermo Fisher Scientific Blade II Limited	England
Thermo Fisher Scientific Blade III Limited	England
Thermo Fisher Scientific Blade IV Limited	England
Thermo Fisher Scientific Blade V Limited	England

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Blade VI Limited	England
Thermo Fisher Scientific Blade VII Limited	England
Thermo Fisher Scientific BLG Limited	England
Thermo Fisher Scientific BPG GmbH	Germany
Thermo Fisher Scientific Brahms LLC	Delaware
Thermo Fisher Scientific Brasil Instrumentos de Processo Ltda.	Brazil
Thermo Fisher Scientific Brasil Serviços de Logística Ltda	Brazil
Thermo Fisher Scientific Brno s.r.o.	Czech Republic
Thermo Fisher Scientific Brussels BV	Belgium
Thermo Fisher Scientific BV	Belgium
Thermo Fisher Scientific C.F. GmbH	Germany
Thermo Fisher Scientific C.V.	Netherlands
Thermo Fisher Scientific Canada Financing 1 ULC	Canada
Thermo Fisher Scientific Canada Financing 2 ULC	Canada
Thermo Fisher Scientific Canada Holdings LLC	Delaware
Thermo Fisher Scientific Cayman Investments LLC	Delaware
Thermo Fisher Scientific Chemicals Inc.	Delaware
Thermo Fisher Scientific China (C-I) LLC	Delaware
Thermo Fisher Scientific China (S) LLC	Delaware
Thermo Fisher Scientific China Holdings I B.V.	Netherlands
Thermo Fisher Scientific China Holdings II B.V.	Netherlands
Thermo Fisher Scientific China Holdings III B.V.	Netherlands
Thermo Fisher Scientific China Holdings IV B.V.	Netherlands
Thermo Fisher Scientific CHK 2 LLC	Delaware
Thermo Fisher Scientific CHK Senior Holdings LLC	Delaware
Thermo Fisher Scientific CHN Holding Limited	England
Thermo Fisher Scientific Chromatography Holdings Aps	Denmark
Thermo Fisher Scientific Chromatography Holdings S.à r.l.	Luxembourg
Thermo Fisher Scientific Clinical Services Ireland Limited	Ireland
Thermo Fisher Scientific CMN LLC	Delaware
Thermo Fisher Scientific CN Holding LLC	Delaware
Thermo Fisher Scientific Colombia S.A.S.	Colombia

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Cork Limited	Ireland
Thermo Fisher Scientific Cyprus I Ltd	Cayman Islands
Thermo Fisher Scientific Cyprus II Ltd	Cayman Islands
Thermo Fisher Scientific Cyprus III Ltd	Cayman Islands
Thermo Fisher Scientific Denmark Senior Holdings ApS	Denmark
Thermo Fisher Scientific Dutch Holdings B.V.	Netherlands
Thermo Fisher Scientific Dutch Holdings II B.V.	Netherlands
Thermo Fisher Scientific Dutch Senior Holdings B.V.	Netherlands
Thermo Fisher Scientific eCommerce Solutions, LLC	Delaware
Thermo Fisher Scientific EMEA Limited	Ireland
Thermo Fisher Scientific Erie 1 Financing (Barbados) 2 SRL	Barbados
Thermo Fisher Scientific Erie 1 Financing (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific Erie 1 Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific Erie 1 Financing (BR) 2 SRL	Barbados
Thermo Fisher Scientific Erie 1 Financing (Malta) Limited	Malta
Thermo Fisher Scientific Erie 1 Luxembourg S.à r.l.	Luxembourg
Thermo Fisher Scientific Erie 2 Financing (Malta) Limited	Malta
Thermo Fisher Scientific Erie Financing (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific Erie Financing (Barbados) 4 SRL	Barbados
Thermo Fisher Scientific Erie Financing (Barbados) I SRL	Barbados
Thermo Fisher Scientific Erie Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific Erie Financing (BR) 3 SRL	Barbados
Thermo Fisher Scientific Erie Financing (Malta) Limited	Malta
Thermo Fisher Scientific Erie Financing S.a r.l	Luxembourg
Thermo Fisher Scientific Erie LLC	Delaware
Thermo Fisher Scientific Erie LP	Delaware
Thermo Fisher Scientific Erie Luxembourg S.à r.l.	Luxembourg
Thermo Fisher Scientific Falcon Senior Holdings Inc.	Delaware
Thermo Fisher Scientific FCS Limited	England
Thermo Fisher Scientific FCS Switzerland Holdings GmbH	Switzerland
Thermo Fisher Scientific Flagship I LLC	Delaware
Thermo Fisher Scientific Flagship II LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific FLC B.V.	Netherlands
Thermo Fisher Scientific FLC II B.V. [Domesticated in the State of Delaware under the name of Thermo Fisher Scientific FLC II B.V.]	Netherlands
Thermo Fisher Scientific FLC LLC	Delaware
Thermo Fisher Scientific FSI (Barbados) Srl	Barbados
Thermo Fisher Scientific FSI (BR) SRL	Barbados
Thermo Fisher Scientific FSI LLC	Delaware
Thermo Fisher Scientific FSIR Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific FSIR Financing S.a.r.l.	Luxembourg
Thermo Fisher Scientific FSIR Holdings (UK) Financing Limited	England
Thermo Fisher Scientific FSUKHCO 2 LLC	Delaware
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific FSUKHCO Financing (Malta) Limited	Malta
Thermo Fisher Scientific FSUKHCO LLC	Delaware
Thermo Fisher Scientific GCL Limited	England
Thermo Fisher Scientific GCL LLC	Delaware
Thermo Fisher Scientific GENEART GmbH	Germany
Thermo Fisher Scientific Germany BV & Co. KG	Germany
Thermo Fisher Scientific GmbH	Germany
Thermo Fisher Scientific Holdings Europe Limited	England
Thermo Fisher Scientific HR Services Mexico, S. de R.L. de C.V.	Mexico
Thermo Fisher Scientific India Holding LLC	Delaware
Thermo Fisher Scientific India Private Ltd	India
Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l.	Luxembourg
Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l.	Luxembourg
Thermo Fisher Scientific Investments (Sweden) II LLC	Delaware
Thermo Fisher Scientific Investments (Sweden) S.a.r.l.	Luxembourg
Thermo Fisher Scientific Invitrogen (US) LLC	Delaware
Thermo Fisher Scientific Invitrogen Financing (Barbados) 2 SRL	Barbados
Thermo Fisher Scientific Invitrogen Financing (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific Invitrogen Financing (Barbados) 4 SRL	Barbados
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific Invitrogen Financing (BR) 3 SRL	Barbados

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Invitrogen Financing (Malta) Limited	Malta
Thermo Fisher Scientific Invitrogen Holding 2 LLC	Delaware
Thermo Fisher Scientific Invitrogen LLC	Delaware
Thermo Fisher Scientific Invitrogen Luxembourg S.à r.l.	Luxembourg
Thermo Fisher Scientific Ireland CH Limited	Ireland
Thermo Fisher Scientific IT Services GmbH	Germany
Thermo Fisher Scientific Jaguar II LLC	Delaware
Thermo Fisher Scientific Japan 1 LLC	Delaware
Thermo Fisher Scientific Japan 2 LLC	Delaware
Thermo Fisher Scientific Japan Holdings I B.V.	Netherlands
Thermo Fisher Scientific Japan Holdings I LLC	Delaware
Thermo Fisher Scientific Japan Holdings I LP	Delaware
Thermo Fisher Scientific Japan Holdings II B.V.	Netherlands
Thermo Fisher Scientific Japan Holdings II LLC	Delaware
Thermo Fisher Scientific Japan Holdings II LP	Delaware
Thermo Fisher Scientific Japan Holdings III B.V.	Netherlands
Thermo Fisher Scientific Japan Holdings III LLC	Delaware
Thermo Fisher Scientific Japan Holdings IV LLC	Delaware
Thermo Fisher Scientific Japan Holdings V LLC	Delaware
Thermo Fisher Scientific Joensuu Oy	Finland
Thermo Fisher Scientific K.K.	Japan
Thermo Fisher Scientific Korea Ltd.	Korea
Thermo Fisher Scientific L1 LLC	Delaware
Thermo Fisher Scientific L1 S.a.r.l.	Luxembourg
Thermo Fisher Scientific L10 LLC	Delaware
Thermo Fisher Scientific L11 LLC	Delaware
Thermo Fisher Scientific L12 LLC	
Thermo Fisher Scientific L2 LLC	Delaware
Thermo Fisher Scientific L2 S.a.r.l.	Luxembourg
Thermo Fisher Scientific L3 LLC	Delaware
Thermo Fisher Scientific L3 S.a.r.l.	Luxembourg
Thermo Fisher Scientific L4 LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific L5 LLC	Delaware
Thermo Fisher Scientific L6 LLC	Delaware
Thermo Fisher Scientific L7 LLC	Delaware
Thermo Fisher Scientific L8 LLC	Delaware
Thermo Fisher Scientific L9 LLC	Delaware
Thermo Fisher Scientific Life Canada Holding ULC	Canada
Thermo Fisher Scientific Life Financing (Barbados) 2 SRL	Barbados
Thermo Fisher Scientific Life Financing (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific Life Financing (Barbados) 4 SRL	Barbados
Thermo Fisher Scientific Life Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific Life Financing (Malta) Limited	Malta
Thermo Fisher Scientific Life Financing 2 Limited	England
Thermo Fisher Scientific Life Financing Limited	England
Thermo Fisher Scientific Life Holding MRP LLC	Delaware
Thermo Fisher Scientific Life Holdings 1 Limited	England
Thermo Fisher Scientific Life Holdings 2 Limited	England
Thermo Fisher Scientific Life Holdings III C.V. LLC	Delaware
Thermo Fisher Scientific Life Holdings Limited	England
Thermo Fisher Scientific Life International Holdings II LP	England
Thermo Fisher Scientific Life Investments II S.à r.l.	Luxembourg
Thermo Fisher Scientific Life Investments IV S.a.r.l	Luxembourg
Thermo Fisher Scientific Life Investments US Financing I LLC	Delaware
Thermo Fisher Scientific Life Investments US Financing II LLC	Delaware
Thermo Fisher Scientific Life Sciences COE Corporation	Delaware
Thermo Fisher Scientific Life Senior Holdings MRP LLC	Delaware
Thermo Fisher Scientific Life Senior Holdings, Inc.	Delaware
Thermo Fisher Scientific Life Tech Korea Holdings LLC	Delaware
Thermo Fisher Scientific Life Technologies Enterprise Holding Limited	England
Thermo Fisher Scientific Life Technologies Investment I LLC	Delaware
Thermo Fisher Scientific Life Technologies Investment II LLC	Delaware
Thermo Fisher Scientific Life Technologies Investment UK I Limited	England
Thermo Fisher Scientific Life Technologies Investment UK II Limited	England

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Life Technologies Israel Investment I Limited	England
Thermo Fisher Scientific Life Technologies Israel Investment II Limited	England
Thermo Fisher Scientific Life Technologies Luxembourg Holding LLC	Delaware
Thermo Fisher Scientific Life Technologies Luxembourg S.à r.l	Luxembourg
Thermo Fisher Scientific Life UK Holdings 2 LP	England
Thermo Fisher Scientific Life UK Holdings LP	England
Thermo Fisher Scientific LSI Financing (Barbados) 2 SRL	Barbados
Thermo Fisher Scientific LSI Financing (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific LSI Financing (Barbados) 4 SRL	Barbados
Thermo Fisher Scientific LSI Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific LSI Financing (BR) 3 SRL	Barbados
Thermo Fisher Scientific LSI Financing (Malta) Limited	Malta
Thermo Fisher Scientific LSI LLC	Delaware
Thermo Fisher Scientific LSI Luxembourg S.à r.l.	Luxembourg
Thermo Fisher Scientific LTI Holdings LLC	Delaware
Thermo Fisher Scientific LTL LLC	Delaware
Thermo Fisher Scientific Luxembourg Enterprise Holdings S.à r.l.	Luxembourg
Thermo Fisher Scientific Luxembourg German Holdings S.a.r.l.	Luxembourg
Thermo Fisher Scientific Luxembourg Life Technologies UK Holding S.à r.l	Luxembourg
Thermo Fisher Scientific Luxembourg Sweden Holdings I S.à r.l	Luxembourg
Thermo Fisher Scientific Luxembourg Sweden Holdings II S.à r.l.	Luxembourg
Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l.	Luxembourg
Thermo Fisher Scientific Luxembourg Venture Holdings II S.a.r.l.	Luxembourg
Thermo Fisher Scientific Malaysia Sdn. Bhd.	Malaysia
Thermo Fisher Scientific Malta Financing Limited	Malta
Thermo Fisher Scientific Matrix Holding Limited	England
Thermo Fisher Scientific Messtechnik GmbH	Germany
Thermo Fisher Scientific Middle East Holdings Inc.	Delaware
Thermo Fisher Scientific Milano Srl	Italy
Thermo Fisher Scientific MLP LLC	Delaware
Thermo Fisher Scientific MRP 1 LLC	Delaware
Thermo Fisher Scientific New Zealand Holdings	New Zealand

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific New Zealand Limited	New Zealand
Thermo Fisher Scientific NHK Limited	Hong Kong
Thermo Fisher Scientific Norway Holdings AS	Norway
Thermo Fisher Scientific Norway Senior Holding AS	Norway
Thermo Fisher Scientific Norway US Investments LLC	Delaware
Thermo Fisher Scientific Odyssey Financing (Barbados) SRL	Barbados
Thermo Fisher Scientific Odyssey Holding LLC	Delaware
Thermo Fisher Scientific Odyssey Holdings Limited	England
Thermo Fisher Scientific One Limited	England
Thermo Fisher Scientific Operating Company LLC	Delaware
Thermo Fisher Scientific Oy	Finland
Thermo Fisher Scientific Pakistan (Private) Limited	Pakistan
Thermo Fisher Scientific Panama I Cayman Ltd	Cayman Islands
Thermo Fisher Scientific Patheon Luxembourg S.à r.l	Luxembourg
Thermo Fisher Scientific Peprotech Holding LLC	Delaware
Thermo Fisher Scientific Peru S.R.L.	Peru
Thermo Fisher Scientific PN LLC	Delaware
Thermo Fisher Scientific PN2 (Luxembourg) S.à.r.l	Luxembourg
Thermo Fisher Scientific PN3 LLC	Delaware
Thermo Fisher Scientific PNM Limited Liability Partnership	England
Thermo Fisher Scientific PNM S.a.r.l	Luxembourg
Thermo Fisher Scientific Powder (Barbados) 3 SRL	Barbados
Thermo Fisher Scientific Powder (Barbados) I SRL	Barbados
Thermo Fisher Scientific Powder (Malta) Limited	Malta
Thermo Fisher Scientific Powder Finance LLC	Delaware
Thermo Fisher Scientific Powder Financing 2 LLC	Delaware
Thermo Fisher Scientific Powder Holdings 4 LLC	Delaware
Thermo Fisher Scientific Powder Holdings 5 LLC	Delaware
Thermo Fisher Scientific Powder Holdings I	Cayman Islands
Thermo Fisher Scientific Powder Holdings I (Malta) Limited	Malta
Thermo Fisher Scientific Powder Holdings II (Malta) Limited	Malta
Thermo Fisher Scientific Powder Holdings III (Malta) Limited	Malta

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Powder Holdings IV (Malta) Limited	Malta
Thermo Fisher Scientific Powder Holdings V (Malta) Limited	Malta
Thermo Fisher Scientific Powder LLC	Delaware
Thermo Fisher Scientific Powder Luxembourg S.a.r.l.	Luxembourg
Thermo Fisher Scientific Powder SRL	Barbados
Thermo Fisher Scientific Powder UK Holdings Limited	England
Thermo Fisher Scientific Powder UK Senior Holdings Limited	England
Thermo Fisher Scientific Powder US Holdings Limited	England
Thermo Fisher Scientific Powder US Holdings LLC	Delaware
Thermo Fisher Scientific Powder US Limited	England
Thermo Fisher Scientific Powder US Senior Holdings LLC	Delaware
Thermo Fisher Scientific PPD (OLI) LLC	Delaware
Thermo Fisher Scientific PPD Development Holdings Limited	England
Thermo Fisher Scientific PR Limited	England
Thermo Fisher Scientific PRB S.a.r.l.	Luxembourg
Thermo Fisher Scientific PSG Corporation	Delaware
Thermo Fisher Scientific Pte. Ltd.	Singapore
Thermo Fisher Scientific Re Ltd.	Bermuda
Thermo Fisher Scientific Remel Luxembourg S.a.r.l.	Luxembourg
Thermo Fisher Scientific Senior Financing LLC	Delaware
Thermo Fisher Scientific Senior Holdings Australia LLC	Delaware
Thermo Fisher Scientific Senior Holdings LP	Canada
Thermo Fisher Scientific Singapore Holdings LLC	Delaware
Thermo Fisher Scientific SL	Spain
Thermo Fisher Scientific SLV Holding LLC	Delaware
Thermo Fisher Scientific Solutions LLC	Korea
Thermo Fisher Scientific South Africa Proprietary Ltd	South Africa
Thermo Fisher Scientific SpA	Italy
Thermo Fisher Scientific Spectra S.a.r.l.	Luxembourg
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg I S.à r.l.	Luxembourg
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l.	Luxembourg
Thermo Fisher Scientific Sweden 2 LLC	Delaware

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Fisher Scientific Sweden Holdings LLC	Delaware
Thermo Fisher Scientific Sweden Holdings S.a.r.l	Luxembourg
Thermo Fisher Scientific Switzerland B.V.	Netherlands
Thermo Fisher Scientific Taiwan Co., Ltd.	Taiwan
Thermo Fisher Scientific TDI 2 S.a.r.l.	Luxembourg
Thermo Fisher Scientific TDI S.a.r.l.	Luxembourg
Thermo Fisher Scientific TR Limited	Hong Kong
Thermo Fisher Scientific TX LLC	Texas
Thermo Fisher Scientific UK Holding Company Financing Limited	England
Thermo Fisher Scientific US 1 LLC	Delaware
Thermo Fisher Scientific Vector Holdings 2 LLC	Delaware
Thermo Fisher Scientific Vector Holdings LLC	Delaware
Thermo Fisher Scientific Vector Holdings UAB	Lithuania
Thermo Fisher Scientific Vector Senior Holdings I UAB	Lithuania
Thermo Fisher Scientific Vector Senior Holdings II UAB	Lithuania
Thermo Fisher Scientific West Palm Holdings LLC	Delaware
Thermo Fisher Scientific WIC 2 LLC	Delaware
Thermo Fisher Scientific WIC LLC	Delaware
Thermo Fisher Scientific Wissenschaftliche Geräte GmbH	Austria
Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l.	Luxembourg
Thermo Fisher Scientific Worldwide Investments LLC	Delaware
Thermo Fisher Senior Canada Holdings LLC	Delaware
Thermo Fisher TDI Holding LLC	Delaware
Thermo FLC LP	Delaware
Thermo Foundation, Inc.	Massachusetts
Thermo Gamma-Metrics Holdings Pty Ltd.	Australia
Thermo Gamma-Metrics LLC	Delaware
Thermo Gamma-Metrics Pty Ltd	Australia
Thermo Holding European Operations LLC	Delaware
Thermo Hypersil-Keystone LLC	Delaware
Thermo Instrument Controls de Mexico, S.A. de C.V.	Mexico

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo KeveX X-Ray LLC	Delaware
Thermo Keytek LLC	Delaware
Thermo LabSystems Inc.	Massachusetts
Thermo Life Science International Trading (Tianjin) Co., Ltd.	China
Thermo Life Sciences AB	Sweden
Thermo Luxembourg Holding S.a.r.l. [Domesticated in the State of Delaware under the name of Thermo Luxembourg Holding LLC]	Luxembourg
Thermo Luxembourg S.a.r.l.	Luxembourg
Thermo Luxembourg U.S. S.a.r.l.	Luxembourg
Thermo Measuretech Canada Inc.	Canada
Thermo MF Physics LLC	Delaware
Thermo Neslab LLC	New Hampshire
Thermo Onix Limited	England
Thermo Optek Limited	England
Thermo Orion Inc.	Massachusetts
Thermo Patheon Holdings LLC	Delaware
Thermo Portable Holdings LLC	Delaware
Thermo Power Corporation	Massachusetts
Thermo Process Instruments GP, LLC	Delaware
Thermo Process Instruments, L.P.	Texas
Thermo Ramsey Italia S.r.l.	Italy
Thermo Ramsey LLC	Massachusetts
Thermo Ramsey S.A.	Spain
Thermo Re, Ltd.	Bermuda
Thermo Scientific Microbiology Pte Ltd.	Singapore
Thermo Scientific Microbiology Sdn Bhd	Malaysia
Thermo Scientific Portable Analytical Instruments Inc.	Delaware
Thermo Scientific Services, Inc.	California
Thermo Securities Corporation	Delaware
Thermo Sentron Canada Inc.	Canada
Thermo Services (Hungary) Kft	Hungary

NAME	STATE OR JURISDICTION OF ORGANIZATION
Thermo Services Philippines Corp.	Philippines
Thermo Suomi Holding B.V.	Netherlands
Thermo TLH (UK) Limited	England
Thermo TLH L.P.	Delaware
Thermo TLH Luxembourg S.a.r.l.	Luxembourg
Thermo Trace Pty Ltd.	Australia
Thermo USC I LLC	Delaware
Thermo-Fisher Biochemical Product (Beijing) Co., Ltd.	China
ThermoFisher Scientific Regional Headquarters Company	Saudi Arabia
ThermoLase LLC	Delaware
TK Partnership (aka Silent Partnership)	Japan
TMOI Inc.	Delaware
TPI Real Estate Holdings LLC	Delaware
Trek Diagnostic Systems Limited	England
Trek Diagnostic Systems LLC	Delaware
Trex Medical Corporation	Delaware
TSP Holdings I LLC	Delaware
TWX, LLC	Massachusetts
United Diagnostics, Inc.	Delaware
USB Corporation	Ohio
Vestrum Health Inc.	Canada
Vestrum Health, LLC	Delaware
VG Systems Limited	England
Westover Scientific, Inc.	Washington
Wildcat Acquisition Holdings (UK) Limited	England

**Subsidiary Issuer of Guaranteed Securities**

Thermo Fisher Scientific Inc. (the “Registrant”) is the guarantor of the senior secured registered notes listed below issued by Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the Registrant.

**Thermo Fisher Scientific (Finance I) B.V.**

- Floating Rate Senior Notes due 2027
- 0.800% Senior Notes due 2030
- 1.125% Senior Notes due 2033
- 3.628% Senior Notes due 2035
- 1.625% Senior Notes due 2041
- 2.000% Senior Notes due 2051

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-285159) and Form S-8 (Nos. 333-188846, 333-220231, 333-261548, 333-272173, and 333-275438) of Thermo Fisher Scientific Inc. of our report dated February 26, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

February 26, 2026

## THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),  
AS ADOPTED PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc N. Casper, certify that:

1. I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 26, 2026

/s/ Marc N. Casper

---

Marc N. Casper  
Chairman, President and Chief Executive Officer

## THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),  
AS ADOPTED PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Williamson, certify that:

1. I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 26, 2026

/s/ Stephen Williamson

---

Stephen Williamson  
Senior Vice President and Chief Financial Officer

**THERMO FISHER SCIENTIFIC INC.**

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the "Company") for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Marc N. Casper, Chairman, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 26, 2026

/s/ Marc N. Casper

Marc N. Casper  
Chairman, President and Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

**THERMO FISHER SCIENTIFIC INC.**

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the "Company") for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 26, 2026

/s/ Stephen Williamson

Stephen Williamson  
Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.